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Endometrial cancer is a cancer arising from the endometrium, the inner lining of the 
uterus. It is the most common gynecological cancer in developed countries, and the 5th 
most common cancer in women.1 In the Netherlands, each year over 1 900 women are 
diagnosed with endometrial cancer and 490 women die from this cancer.2 The majority 
of endometrial cancers develop after menopause, with the highest incidence between 65 
and 75 years.2,3 The incidence of endometrial cancer has grown over the last decade which 
can largely be ascribed to ageing of the population, increased life expectancy, increasing 
rates of obesity, and decreasing rate of hysterectomy for benign causes.2,4-6 Due to early 
clinical symptoms of postmenopausal vaginal bleeding, most endometrial cancers (~70%) 
are detected in an early stage when the tumor is confined to the uterus.7 A minority of 
endometrial cancers (2-5%) develop in women with Lynch syndrome, mainly before 
menopause.8-10 Lynch syndrome is an hereditary disease with germline mutations in DNA 
mismatch repair genes and a 40-60% lifetime risk of colorectal and endometrial cancer.11-13
Pathology
Histological classification
Endometrial cancers can be histologically classified according to the World Health Organization 
(Table 1).7 Endometrioid adenocarcinoma is the most common subtype, accounting for 75-
80% of the cases, that usually develop in a background of hyperplasia of the endometrium 
(Figure 1A).7,14 Most endometrioid endometrial cancers are well differentiated with preserved 
glandular architecture and lack of intervening stroma. The less common non-endometrioid 
subtypes, include serous and clear cell carcinomas, are often found in a background of 
atrophic endometrium, and can constitute ~20% of endometrial cancer diagnoses (Figure 
1B-C).7,14,15 Serous carcinoma can be distinctive by their architecture (hobnail appearance) 
and nuclear features (clumped chromatin, prominent nucleoli and mitotic activity).16,17 Clear 
cell carcinomas can also be characterized by hobnail cells and a high mitotic activity, but also 
clear cells and hyalinized stroma.16,17 Endometrial cancers are classified as mixed carcinoma if 
two histological subtypes with at least one non-endometrioid subtype is present in more than 
10% of the lesion.7,15 Mixed serous and endometrioid carcinomas and mixed clear cell and 
endometrioid carcinomas comprising more than 25% of the serous or clear cell component, 
respectively, are generally classified as serous or clear cell carcinomas. Carcinosarcomas, a 
mixture of epithelial and mesenchymal cells, are regarded as carcinomas with a mesenchymal 
component.7 The significant difference in patient outcome between the histological 
subtypes stresses the importance of accurate histological assessment. Several studies 
have reported moderate to good reproducibility of subtype diagnosis by pathologists.18-20
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FIGO grade
Endometrioid and mucinous endometrial cancers, but also other rare subtypes, are graded 
using a 3-tiered International Federation of Obstetricians and Gynecologists (FIGO) system 
based on architecture and cytologic atypia.7 The architectural grading is as follows: grade 1 
has ≤5% solid growth pattern, grade 2 has between 6-50% solid growth pattern and grade 3 
has >50% solid growth pattern. Marked nuclear atypia could increase the architectural grade 
1 to grade 2 or architectural grade 2 to grade 3. The non-endometrioid subtype is classified as 
grade 3, irrespective of growth pattern and cytologic atypia. The reproducibility of this grading 
system between pathologists was shown to be fair to moderate.21-24 Two-tiered systems have 
been proposed to decrease interobserver variability, and has superior prognostic power.21-24 
Although, these binary systems are currently not used in clinical practice, grades 1-2 and 
grade 3 are often informally dichotomized into low grade and high grade, respectively.
Table 1. Histological subtypes of (epithelial) endometrial cancer.
Histological types (epithelial) Frequency
Endometrioid adenocarcinoma 75-80%
Non-endometrioid adenocarcinoma 20-25%
  Serous adenocarcinoma                   5-10%  
  Mixed cell adenocarcinoma 3-5%
  Clear cell adenocarcinoma 1-5%
  Mucinous adenocarcinoma 1-2%
  Undifferentiated carcinoma 1-2%
  Squamous cell carcinoma <1%
  Transitional cell carcinoma <1%
  Small cell carcinoma                   <1%
  Others                     <1%
Figure 1. Histological classification of endometrial cancers. Common histological subtypes of epithelial endometrial 
cancer include endometrioid (A), serous (B) and clear cell (C). Scale bar represents 50  µM.
FIGO stage
The extent of tumor growth is divided into four stages using a surgical-pathological staging 
system from 1988.25 A new version of the FIGO staging system was introduced in 2009 as more 
information became available with regard to risk factors associated with natural behavior of 
endometrial cancer and survival (Table 2).26 Included risk factors are depth of myometrial 
invasion, extension into the cervical canal, pelvic node metastases, aortic node metastases, 
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Chapter 1
Accurate pathological assessment of depth of myometrial invasion and cervical stromal 
involvement is crucial for FIGO staging. Stage IA tumors are those confined to the uterine 
corpus with less than 50% myometrial invasion, whereas stage IB tumors are those with greater 
than 50% myometrial invasion. Determination of myometrial invasion may be challenging 
due to different patterns of invasion.27,28 Patterns of invasion that have been described include 
e.g. broad front invasion and invasion of irregular groups of glands with or without a stromal 
response. To diagnose stage II tumors, pathologists need to assess cervical stromal involvement 
in the absence of extra-uterine disease, which is easily recognized in most cases.7,29 Difficulties 
can be to distinguish between cervical glandular or stromal involvement, and delimiting the 
uterine corpus from the cervix.
Table 2. FIGO 2009 staging system for endometrial cancer
Stage I Tumor confined to the corpus uteri
  IA No or less than half myometrial invasion
  IB Invasion equal to or more than half of the myometrium 
Stage II Tumor invades the cervical stroma, but does not extend beyond the uterus
Stage III Local and/or regional spread of tumor
  IIIA Tumor invades the serosa of the corpus uteri and/or adnexas
  IIIB Vaginal and/or parametrial involvement
  IIIC1 Positive pelvic lymph nodes
  IIIC2 Positive para-aortic lymph nodes with or without positive pelvic lymph nodes
Stage IV Tumor invades bladder and/or bowel mucosa and/or distant metastases
  IVA Tumor invades bladder and/or bowel mucosa
  IVB Distant metastases, incl. intra-abdominal metastases and/or inguinal lymph nodes
Lymphovascular space invasion
Although, lymphovascular space invasion is not part of the FIGO staging system, it is an 
important prognostic factor in endometrial carcinoma.30-34 A definition and optimal 
determination of this factor is still under investigation, especially regarding the clinical 
relevance of quantification. Lymphovascular space invasion can be defined as tumor cells 
present in a space lined by endothelial cells outside the immediate invasive border. Tumor spill, 
retraction artifacts or mimics (e.g. certain myometrial invasion growth patterns) may hamper 
correct assessment of lymphovascular space invasion.35 Immunohistochemistry of markers 
for lymphatic channels (D2-40) and endothelial cells (CD31, CD34) may aid to recognize 
true lymphovascular space invasion.36 In addition, quantification of lymphovascular space 
invasion may improve accurate evaluation. Substantial (diffuse or multifocal) lymphovascular 
space invasion strongly correlates with prognosis.37-39
Therapy
Surgery
Preoperative histopathological assessment is required to diagnose endometrial cancer and to 
guide treatment decisions.14 Hysterectomy, usually in combination with bilateral salpingo-
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oophorectomy, is the cornerstone of treatment. The procedure has been traditionally 
performed by laparotomy, but nowadays the laparoscopic procedure is preferred because of 
its reduced operative morbidity and hospital stay.40 The role of a staging lymphadenectomy is 
still controversial. Two randomized trials did not show any benefit for survival or relapse-free 
survival,  and the advantage of staging in grade 3 cancers remains to be elucidated.41,42 In the 
Netherlands, complete surgical staging is considered for high-grade endometrioid cancers 
and recommended for serous and clear cell cancers.43 An international randomized trial 
will address the role of lymphadenectomy in early stage, grade 3 cancers in determining the 
indication for adjuvant treatment.
Adjuvant therapy
The indication of adjuvant treatment is based on the patient’s risk of disease recurrence using 
clinicopathological risk factors such as age, stage, and histological subtype.44 The combination 
of clinicopathological factors is used to stratify a patient’s risk of disease recurrence into 
three risk groups: low- (45-50% of all endometrial cancer patients), intermediate- (30-
35%), and high-risk (15-20%).45 In the Netherlands, PostOperative Radiation Therapy in 
Endometrial Cancer (PORTEC) criteria are used to define risk groups (Table 3), however, 
similar other definitions have been published, most recently those of an international 
consensus conference.14,46,47 There is no indication for adjuvant radiation therapy for patients 
with low-risk features, as risk for recurrent disease is low. The PORTEC-1 trial, but also the 
Gynecology Oncology Group (GOG)-99 trial and A Study in the Treatment of Endometrial 
Cancer (ASTEC) trial, compared external beam radiotherapy with no additional treatment 
for patients with stage I endometrial cancer (Table 4).46-48 Both the PORTEC-1 and GOG-99 
trials defined a high-intermediate risk group that demonstrated a significant reduction in 
locoregional recurrence (4% vs. 14% and 1.6% vs. 7.4%) after external beam radiotherapy. In 
the PORTEC-1 trial, high-intermediate risk patients were defined as having two out of three 
of the following risk factors: age above sixty years, deep myometrial invasion and/or grade 
3. In the subsequent PORTEC-2 trial, it was demonstrated that vaginal brachytherapy was 
equally effective in reduction of vaginal recurrence as external beam radiotherapy, with fewer 
gastro-intestinal toxic effects in women with high-intermediate risk disease (Table 4).49
Table 3. Definition of clinicopathological risk groups to guide adjuvant therapy.
FIGO 2009 
Stage IA Stage IB Higher stages
Grade
Grade 1     <60 years >60 years    
Grade 2     <60 years >60 years    
Grade 3   >60 years        
  Low-risk endometrioid endometrial cancer  
  High-intermediate risk endometrioid endometrial cancer  
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The optimal adjuvant therapy for endometrial cancer patients with high-risk features is still 
controversial due to lack of evidence of efficacy of adjuvant therapy (Table 4). External beam 
radiotherapy and vaginal brachytherapy provide optimal local control, however, distant 
metastases contribute to the inferior outcome of high-risk endometrial cancer patients. A 
meta-analysis of three randomized studies in which adjuvant radiotherapy was compared to 
chemotherapy demonstrated a small (~4%) survival benefit for chemotherapy.50-53 There are 
indications that the combination of adjuvant external beam radiotherapy with chemotherapy 
improves the progression-free survival compared with either alone, but not for patients with 
non-endometrioid cancers (NSGO/EORTC/lliade-III).54 The two-years outcomes of the GOG-
249 randomized trial showed no evidence that progression-free survival with the combination 
of 3 cycles of adjuvant radiation therapy and chemotherapy with vaginal brachytherapy was 
better than pelvic radiation therapy alone.55 The outcome of PORTEC-3 and GOG-258 trials, 
both evaluating the role of chemotherapy in combination with external beam radiotherapy 
will provide more evidence for the optimal therapy for high-risk endometrial cancer patients. 
Although the efficacy of adjuvant therapy for patients with high-risk features remains an 
area of controversy, external beam radiotherapy is currently recommended, and adjuvant 
platinum-based chemotherapy can be considered for stage III or IV, and non-endometrioid 
cancers.
Follow-up and recurrent disease
Risk of recurrence of endometrial cancer is related to the clinicopathological risk assessment. 
The recurrence rate is estimated to be 5-10%, 15-20% and >30% for patients with low-, 
intermediate- and high-risk features, respectively.56-58 The use of adjuvant radiotherapy 
decreases vaginal and pelvic recurrences, but has no impact on distant metastasis or overall 
survival.59 After treatment, all endometrial cancer patients undergo three to five years 
surveillance for early recurrence detection. The majority of recurrences are diagnosed within 
three years.60-62 The salvage rate for early-stage endometrial cancer are high. Isolated vaginal 
recurrence occurs most commonly in patients who did not receive adjuvant radiotherapy. 
Radiotherapy is a curative treatment for vaginal recurrences. The frequent sites of recurrence 
in the intermediate- and high-risk endometrial cancer patients are pelvic and para-aortic 
nodal recurrences, peritoneal and lung metastases. These recurrences are treated with surgery, 
radiotherapy, hormonal therapy, chemotherapy, or combined modalities.61,62
Clinicopathological classification
Endometrial cancer was traditionally classified into two broad subtypes, type 1 and type 
2, based on epidemiology, histopathology and clinical behavior by Bokhman in 1983.63 
Primarily, the histologic subtypes and molecular alterations were not part of the dualistic 







develop from a background of endometrial hyperplasia. Risk factors for these cancers include 
unopposed estrogen exposure, obesity, nulliparity, late menopause and anovulation. Type 1 
cancers generally show a indolent behavior and have in general a good prognosis (85% 5-years 
survival). Type 2 endometrial cancers, on the other hand, are often non-endometrioid, high-
grade, arise in a background of atrophic endometrium, and occur in elderly women. These 
cancers are unrelated to estrogen exposure and are generally associated with an aggressive 
clinical course and poor prognosis (60% 5-years survival).
Subsequent molecular studies supported the dichotomous classification.65-68 Type 1 
carcinomas are associated with estrogen receptor (ER) and progesterone receptor (PR) 
expression, mutations in the PI3K-AKT (PTEN, KRAS, PIK3CA) and Wnt (CTNNB1) 
signaling pathways, and mutations in the chromatin remodeling gene ARID1a. In addition, 
type 1 carcinomas frequently show microsatellite instability either due to MLH1 promoter 
hypermethylation (sporadic) or a germline mutation in DNA mismatch repair genes (MLH1, 
PMS2, MSH2, MSH6, Lynch-associated). In contrast, type 2 carcinomas exhibit loss of 
ER and PR protein expression, recurrent TP53 mutations, and HER2 gene amplification. 
However, this classification is too simplistic since not all endometrial carcinomas fit into these 
two pathways; e.g. some tumors show overlapping molecular features of both type 1 and -2 
carcinomas.
Genomic classification
In 2013, The Cancer Genome Atlas has reported an integrated genomic, transcriptomic and 
proteomic characterization of endometrial cancers.69 This analysis allowed reclassification 
of endometrial cancer into four molecular subgroups: POLE ultramutated, microsatellite 
instability hypermutated, copy-number low, and copy-number high (Table 5). POLE-mutant 
endometrial cancers, mainly endometrioid subtype, are characterized by hotspot mutations in 
exonuclease domain of POLE (subunit of DNA polymerase epsilon) and very high mutation 
rates, increased frequency of C>A transversions, few copy number alterations, mutations in 
PTEN, PIK3R1, PIK3CA, FBXW7, and KRAS, and favorable outcome. Microsatellite unstable 
endometrioid endometrial cancers are characterized by MLH1 promoter hypermethylation, 
high mutation rates, few copy-number alterations and PIK3CA and PTEN mutations. 
The ‘copy-number low’ group comprises microsatellite stable grade 1 and 2 endometrioid 
endometrial cancers with low mutational rates, characterized by frequent CTNNB1 mutations 
and chromosome 1q amplification. The copy-number high group consists primarily of serous 
and one-fourth of high-grade endometrioid endometrial cancers with low mutational rates, 
recurrent TP53, FBXW7, and PPP2R1A mutations and poor outcome. In view of these 
findings, Bokhman’s dualistic model of endometrial cancer has been even further extended 
by the integration of molecular features both for prognostic and therapeutic purposes.
15
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The Cancer Genome Atlas further revealed clusters of endometrial cancers based on 
messenger RNA expression, protein expression, and DNA methylation, which significantly 
correlated with the four molecular subgroups. The gene transcriptional activity was consistent 
with the copy-number alteration. In addition, the loss- and gain-of-function mutations 
correlated well with the protein expression data. The subgroup with microsatellite instability 
was associated with an heavily methylated subtype, whereas the copy-number high subgroup 
showed minimal DNA methylation changes.
The publicly availability of these data have led to subanalyses and further studies by 
independent researchers focusing on their specific topic of interest. Protein expression 
of L1 cell adhesion molecule (L1CAM) has been found as promising prognostic factor.70,71 
L1CAM-positive cancers demonstrated remarkably high hazard ratios for distant recurrences 
in a large series of stage I endometrial cancer patients.71 Further studies have shown that 
L1CAM is an independent predictor of poor survival in endometrial cancer, and is associated 
with advanced stage, high-risk endometrial cancer using RNA expression data of The Cancer 
Genome Atlas.72,73
Table 5. Characteristics of molecular subgroups in endometrial cancer.
POLE MSI CNA low CNA high
TCGA population (%) n=17 (7%) n=65 (28%) n=90 (39%) n=60 (26%)
CNA Very low Low Low (1q gain) High
MSI status MSI-high,  MSS MSI-high MSS MSS
Mutation rate (mut/Mb) Very high (232×10−6) High (18×10−6) Low (2·9×10−6) Low (2·3×10−6)
Frequently mutated POLE (100%) PTEN (88%) PTEN (77%) TP53 (92%)
genes (%) PTEN (94%) PIK3CA (54%) CTNNB1 (52%) FBXW7 (47%)
  FBXW7 (82%)   PIK3CA (53%) PPP2R1A (22%)
  PIK3CA (71%)      
  PIK3R1 (65%)      
  KRAS (53%)      
Clinical outcome Good Intermediate Intermediate Poor
Histological type Endometrioid Endometrioid Endometrioid Endometrioid, Serous
Grade Grades 1–3 Grades 1–3 Grades 1-2 Grade 3
Adapted from The Cancer Genome Atlas (TCGA) and Murali et al.  







Thesis outline  
Over the last decades, advances have been made in the treatment of endometrial cancer. The 
clinicopathological risk stratification for postoperative therapy has considerably reduced 
overtreatment by refining indications and introducing treatment with fewer side effects. 
Despite refinement in the use of postoperative radiation therapy in EC, over- and under- 
treatment remain a clinical problem: seven patients with stage I high-intermediate risk EC 
need to receive vaginal brachytherapy to prevent one recurrence, while 8% of patients develop 
distant metastases, a risk that might have been reduced with tailored adjuvant chemotherapy. 
This may be caused by the limited accuracy of the clinicopathological risk stratification to select 
patients of higher risk of recurrence.45 The lack of reproducibility of pathologists to diagnose 
tumor type and grade may also limit the accuracy of the clinicopathological risk stratification. 
Expert gyneco-pathology review and a two-tiered grading system will lead to more accurate 
and reproducible diagnoses.21-24,74,75 Nonetheless, there is pressing need to understand 
tumor behavior and design tailored treatments to further improve risk stratification. The 
identification of molecular markers predictive of recurrence risk or treatment benefit beyond 
current clinicopathological factors would represent a major advance. The aims of this thesis 
were to gain insight in the molecular alterations of endometrial cancer and to identify 
prognostic markers in endometrial cancer to refine clinicopathological risk assessment and 
direct adjuvant therapy.
Chapter 2 reports on the concordance of molecular tumor alterations between pre-operative 
curettage specimen and the hysterectomy specimen in patients with endometrial cancer. 
Chapter 3 shows the prognostic value of POLE exonuclease domain mutations in early-stage 
endometrial cancer tissues from patients enrolled in the PORTEC-1 and -2 clinical trials 
and in three additional smaller endometrial cancer series. Chapter 4 describes an integrated 
analysis of clinicopathological risk factors, The Cancer Genome Atlas proposed molecular 
subgroups, a multi-gene mutation analysis and established biomarkers such as L1CAM, ER/
PR and lymphovascular space invasion in two large early-stage endometrial cancer trial 
populations. Chapter 5 shows prognostic molecular subgroups and potentially targetable 
alterations in high-risk endometrial cancer. Chapter 6 focuses on the optimal approach for 
mismatch repair deficiency testing in routine clinical pathology for endometrial cancer. 
Chapter 7 reports on the remarkably high frequency of JAK1 mutations in microsatellite 
unstable endometrial cancers and its association with tumor immune evasion. Finally, 
Chapter 8 provides a general discussion of this thesis, focusing on implications for clinical 
practice and future research.
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Objective: Molecular alterations in endometrial cancer have been shown to be prognostically 
significant but have not yet been implemented in the current clinical risk assessment. Few studies 
have investigated the reliability of molecular alterations in pre-operative specimens. Therefore, 
the objective was to determine whether molecular analysis of pre-operative endometrial cancer 
samples accurately reflects those alterations in the subsequent hysterectomy specimens.
Methods: Paired pre-operative and hysterectomy specimens of 48 patients diagnosed with 
endometrial carcinoma, 42 endometrioid (EEC) and 6 non-endometrioid (NEEC) carcinomas, 
were analyzed for immunohistochemical expression of p53, PTEN and β-catenin. Tumor DNA 
was isolated and analyzed for microsatellite instability (MSI), TP53 mutations and somatic hot 
spot mutations in 13 genes.
Results: In EEC patients, loss of PTEN, nuclear β-catenin and p53-mutant expression was found 
in 43%, 7% and 12%, respectively. No nuclear β-catenin was found in 5 of 6 NEEC patients, all 
serous cancers, whereas a p53-mutant expression was present in all serous cases. MSI was found 
in 19.5%, all EEC. Concordance for PTEN, β-catenin, p53 expression and MSI status was found 
in 79%, 92%, 79% and 93.5%, respectively. We detected 65 hot spot mutations in 39/48 (81%) 
tumors. Overall concordance of the GynCarta multigene analysis was 99.8%. 
Conclusions: The results confirm the reliability of immunohistochemical and DNA-based 
techniques in the evaluation of molecular alterations in pre-operative endometrial specimens 
and high concordance rates with the definitive hysterectomy specimens. The resulting molecular 
signature provides initial pre-operative diagnostic information on the status of oncogenic 
pathways, which may contribute to individualized treatment strategies.
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Concordance of molecular tumor alterations between pre-operative and hysterectomy specimens
Introduction 
Endometrial carcinoma is the most frequent malignancy of the female genital tract in developed 
countries. Due to early clinical symptoms of post-menopausal bleeding, most endometrial cancers 
(80%) are detected in an early stage (International Federation of Obstetricians and Gynecologists 
(FIGO) stage l). Hysterectomy and bilateral salpingo-oophorectomy is the cornerstone treatment 
and FIGO staging is assigned based on surgical and pathological findings.1 Using both clinical 
(age) and pathologic factors (FIGO stage, tumor type, grade and LVSI) risk groups have been 
defined to tailor adjuvant treatment to the individual patient’s risk of disease recurrence.2-4
The role of pelvic and para-aortic lymphadenectomy has been the subject of ongoing debate. 
Two randomized trials including predominantly intermediate risk patients found neither benefit 
in overall or disease free survival nor difference in site of recurrence, while lymphadenectomy 
was associated with higher rates of treatment related morbidity.5,6 Current ongoing and planned 
trials are investigating the roles of lymphadenectomy and chemotherapy with or without radiation 
therapy in high-risk endometrial cancer. Reliable pre-operative risk assessment could be highly 
desirable to guide the patients’ further (adjuvant) treatment.
Pre-operative tissue sampling methods used for the evaluation of endometrial pathology are 
conventional dilation & curettage, out-patient micro-curettage endometrial tissue sampling (such 
as Pipelle or Vabra) and hysteroscopy-guided tissue biopsy. The prognostic accuracy of typing 
and grading of endometrial cancer in such pre-operative samples is subject to considerable 
interobserver variation, especially since sometimes the scant biopsy material harbors the risk of 
misclassification and/or assigning a lower tumor grade based on tumor heterogeneity and therefore 
not always optimal.7-9 Defining FIGO stage I and II endometrial carcinomas depends on the depth 
of myometrial invasion and endocervical involvement. Myometrial invasion will not be evident 
in the superficial sample of the pre-operative curettage material. Other methods of pre-operative 
risk assessment using ultrasound, computed tomography or magnetic resonance imaging have 
limited accuracy and high rates of variability.10-12 Reliable pre-operative risk assessment based on 
the individual tumors’ molecular signature would be valuable in tailoring the extent and route of 
surgery, patient counseling and adjuvant treatment to the patients’ risk profile.
Several molecular alterations in pathways involved in endometrial carcinogenesis are independent 
prognostic factors, but are not yet used in the current system for risk assessment.13-15 Recently, our 
group has shown that molecular alterations in the PI3K–AKT, p53 and Wnt/β-catenin signaling 
pathways and microsatellite instability may independently or in combination better predict an 
individual tumor’s risk of early disease spread than the clinicopathologic features alone.14 Most 
studies analyzing these molecular tumor alterations are performed on hysterectomy specimens. It 
is largely unknown whether such molecular alterations can be reliably identified in pre-operative 












types, risk analysis based on pre-operative material has been studied using endoscopic biopsies 
of colorectal cancer,16 core biopsies in breast cancer,17 biopsies of prostate cancer18 and fine needle 
aspirates from non-small-cell lung cancer.19 The main objective of this study was to analyze the 
presence and concordance of putative prognostic molecular alterations in endometrial cancer in 
pre-operative curettage samples and corresponding hysterectomy specimens.
Materials and methods
Patient and tissue selection
Fifty study subjects were randomly selected from the database of LUMC Department of 
Pathology in which both pre-operative curettage and hysterectomy specimens were available. 
We aimed for 50% of patients with superficial myometrial invasion and 50% of patients 
with deep myometrial invasion. The pre-operative sampling methods used for 15 of the 48 
pre-operative samples include conventional dilation & curettage (n=5), out-patient micro-
curettage endometrial tissue sampling (n=9) and hysteroscopy-guided tissue biopsy (n=1). 
Curettage samples of two patients contained insufficient material to perform all analysis, thus 
these were excluded, leaving 48 patients in the study. The study population consisted of 42 
patients diagnosed with endometrioid endometrial cancer (EEC) and 6 patients with non-
endometrioid endometrial cancer (NEEC, 5 serous and 1 clear cells) (Table 1). Formalin fixed 
paraffin-embedded (FFPE) blocks containing representative tumor and curettage material 
were selected with at least a 2 mm tumor fragment, unpaired and given a random number 
during the course of the experiments, so that it was unknown which hysterectomy and curettage 
specimens belonged together.
Immunohistochemical analysis
Immunohistochemistry for p53, β-catenin and PTEN was performed as described previously.14 
Antigen retrieval was achieved by microwave oven procedure in 10 mmol/L citrate buffer, pH 
6.0 for p53 and β-catenin. For PTEN and MLH1 staining, antigen retrieval was performed in 10 
mmol/L Tris–EDTA, pH 9.0. Sections were incubated overnight with primary monoclonal 
antibodies against p53 (clone DO-7, 1:1000; NeoMarkers), β-catenin (cat. 610154; 1:800; BD 
Transduction), PTEN (clone 6.H2.1, 1:800; DAKO) and MLH1 (clone ES05, 1:100; DAKO). 
Sections were incubated and stained for 30 min using a secondary antibody (Poly-HRP-GAM/
R/R; DPV0110HRP; Immunologic). Diaminobenzidine tetrahydrochloride was used as a 
chromogen for p53 and β-catenin and DAB+ (DAKO, K3468) as chromogen for PTEN. The 
slides were counterstained with hematoxylin, dehydrated and mounted. Non-neoplastic 
endometrium and endometrial tumors with proven p53, β-catenin and PTEN were used as 
external negative and positive controls, respectively.
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Slides were evaluated by two independent pathologists (T.B. and V.S.), blinded for pairing 
between curettage and hysterectomy. Discrepancies were discussed and reviewed at a 
multihead microscope and until consensus was reached. p53 was scored “mutant-like” if 
more than 50% of the tumor cells showed strong positive nuclear staining, or when discrete 
geographical patterns showed more than 50% tumor cell positivity, or when no nuclear p53 
staining was evident in the entire tumor.14,20,21 Activated Wnt-signaling was defined as nuclear 
staining of β-catenin. MLH1 nuclear staining was scored as positive or negative, with 
stromal- and/or lymphocytic cells as internal controls. PTEN staining was evaluated in three 
categories as negative, positive and heterogeneous.22 The cases scored heterogeneous were 
reclassified as positive when more than 10% of tumor cells were positive.
DNA analysis
Prior to DNA isolation, tumor DNA from hysterectomy specimens was enriched in the 
FFPE blocks by taking three 0.6 mm tissue punches from the tumor focus using a tissue 
microarrayer (Beecher Instruments), to reach tumor percentage >70%. DNA from curettage 
blocks was isolated depending on the volume of blood. When there was < 50% blood, 2 whole 
sections (10 μM) were used for DNA isolation. When there was >50% blood, in 10 curettage 
specimens, then 10 sections (10 μM) were used to microdissect fragments of tumor, for the 
enrichment of tumor DNA. DNA isolation was performed fully-automated as described 
previously using the Tissue Preparation System (Siemens Healthcare Diagnostics).23
Microsatellite instability (MSI)
The microsatellite status of each tumor was determined using the Promega MSI analysis system 
(version 1.2), as described previously.14 Tumors with instability in two or more of these 
markers were defined as being high-frequency MSI (MSI-H) whereas those with instability at 
one repeat or showing no instability were classified as being stable (MSS).14
TP53 mutation analysis
Sanger sequencing for exons 5–8 of TP53 was performed on those samples that showed a 
‘mutant-like’ p53 immunohistochemical staining pattern. Sanger sequencing was conducted 
following the exact protocol described previously.14,24
Mutation genotyping
The Sequenom MassARRAY system and the GynCarta multigene analysis 2.0 (Sequenom) 
were used to test for 159 hot spot mutations in 13 genes (BRAF, CDKNA2, CTNNB1, 
FBXW7, FGFR2, FGFR3, FOXL2, HRAS, KRAS, NRAS, PIK3CA, PPP2R1A and PTEN) as 
described previously by Spaans et al. (manuscript submitted, Supplementary Table 2). Briefly, 
isolated genomic DNA was amplified using the GynCarta PCR primer pools by multiplex 
PCR. Unincorporated nucleotides were inactivated by shrimp alkaline phosphatase followed 
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by a single base pair extension reaction using iPLEX Pro chemistry. Salts were removed using a 
cation exchange resin. Products were then spotted onto SpectroCHIP II arrays, and mutant 
and wildtype alleles were discriminated via mass spectrometry using the Sequenom 
Compact MassARRAY Analyzer. All tumor DNA samples were additionally analyzed using 
allele specific qPCR as described previously, to validate KRAS hot spot mutations in exon 2 
and PIK3CA hot spot mutations in exons 9 and 20.14,19
Data analysis
Data analysis was performed using Sequenom MassARRAY Typer Analyzer software 4.0.22, 
which identifies mutants by comparing ratios of the wildtype peak to that of all suspected mutants 
and generates a report with specific mutations and the ratios of wildtype and mutation peaks. 
Two investigators manually reviewed mutations (≥ 5% mutant peak) to remove all artifact 
peaks due to salt peaks or other background peaks.
Results
Among the 42 endometrioid (EEC) and 6 non-endometrioid (NEEC) endometrial cancers 
included in this study, 26 tumors (54.2%) were diagnosed as grade 1, 10 (20.8%) as grade 2 and 
12 (25.0%) as grade 3 in the definitive hysterectomy specimen (Table 1). The curettage diagnoses 
were compared to those from the hysterectomy. Among the 48 cases, 45 (93.8%) showed 
concordance in histological subtype and 32 cases (66.7%) showed concordance in grade 
between curettage and hysterectomy specimen (Table 1). In the curettage samples, 14.6% (7/48) 
of the tumors had been assigned a higher tumor grade and 16.7% (8/48) a lower tumor grade 
than those in the hysterectomy diagnoses. The accuracy of assigning tumor grade was higher for 
grade 2 (4 cases; 3 shift to grade 1, 1 shift to grade 3) and grade 3 (4 cases; 1 shifts to grade 1, 3 
shift to grade 2) than for grade 1 (8 cases; 5 shift to grade 2, 3 shift to grade 3).
Table 1. Patient and tumor characteristics and concordance of histopathological features in hysterectomy and 
pre-operative curettage specimens.
  Hysterectomy Curettage Total discordant Concordance
n=48  (%) n=48 (%) cases rate
Age at Diagnosis        
Mean 68.4      
Range 51-84      
Histopathological Type      
Endometrioid 42 (87.5) 41 (85.4)  3  93.8Non-endometrioid 6 (12.5) 7 (14.6)
  Clear cell 5  6    
  Serous 1  1    
Myometrial Invasion        
<50% 25 (52.1) - - ->50% 23 (47.9)
Grade        
1 26 (54.2) 30 (62.5)
16 66.72 10 (20.8) 6 (12.5)
3 12 (25.0) 12 (25.0)
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Immunohistochemical analysis of PTEN, β-catenin and p53 succeeded in paired 
curettage and hysterectomy samples of all patients, while DNA analysis completely failed for 
two curettage samples due to low DNA concentration (0.6 and 1.0 ng/μL) and poor DNA 
quality and therefore excluded from further analysis. The average yield of DNA recovered 
from the 46 hysterectomy and 46 curettage specimens was 12.5 ± 5.8 ng/μL and 7.0 ± 
4.2 ng/μL, respectively (Supplementary Table 1). The DNA quality assessed by qualitative 
multiplex PCR assay showed that most samples contained moderate or good quality DNA 
as seen by the amplification of PCR fragments of different lengths (Supplementary Table 1). 
No significant differences were observed in the yield of DNA and DNA quality obtained 
from the pre-operative curettage and hysterectomy specimens. TP53 sequencing of exons 
5–8 was performed on those samples that showed either mutant or no immunohistochemical 
staining and paired analysis was successful in 18 cases (85.7%; 20 hysterectomy/18 curettage). 
MSI analysis was successful in 40 cases (87.0%; 41 hysterectomy/40 curettage). Furthermore, 
GynCarta multigene analysis was successful in 98.5% of all assays (13 multiplexes for 159 hot 
spot mutations) and paired hot spot mutation analysis of KRAS and PI3KCA was successful 
in 42 cases (89.5%; 45 hysterectomy/ 42 curettage). The reason for failure was either running 
out of material or poor DNA quality due to suboptimal fixation.
Molecular alterations found in the tumor of both hysterectomy and pre-operative specimens 
are depicted in Table 2. In the hysterectomy specimens diagnosed as EEC, 42.9% showed loss 
of PTEN, 7.1% showed nuclear β-catenin staining and 20.0% were microsatellite unstable. 
In contrast, NEEC showed only in 16.6% loss of PTEN, showed no nuclear β-catenin 
staining and were all microsatellite stable. Through analysis of mutations of fourteen 
genes, we could detect at least one mutation in 42 of the 46 hysterectomy specimens. 
The distribution of mutations is shown in Supplementary Table 3. We identified 11.9% TP53 
mutations, 17.5% CTNNB1 (β-catenin), 2.5% FBXW7, 7.5% FGFR2, 22.5% KRAS, 2.5% NRAS, 
37.5% PIK3CA and 60.0% PTEN hot spot mutations in EEC. In NEEC, mutations were found in 
TP53 (83.3%), CTNNB1 (16.6%), PTEN (16.6%) and PPP2R1A (50%). Notably, the only NEEC 
tumor without a p53 mutation was a clear-cell carcinoma with a PTEN and CTNNB1 mutation. 
Mutations in PPP2R1A in combination with TP53 mutations were specific for non-endometrioid 
endometrial tumors whereas FBXW7, FGFR2, KRAS, NRAS, and PIK3CA mutations were 
subtype-specific for endometrioid endometrial tumors. The frequency of PIK3CA exon 9 
mutations was higher in grade 1 endometrioid carcinomas (16.7%) than in grade 2 (10%) or 
grade 3 (0%) tumors. Conversely, mutations in PIK3CA exon 20 were more common in grade 
3 (33.3%) than in grade 2 (30%) or grade 1 (8.3%) endometrioid carcinomas. In addition, a 
slightly higher number of molecular alterations per case were seen in endometrioid tumors 
with deep myometrial invasion compared to tumors with less than 50% myometrial invasion 
(P-value=0.062, parametric t-test, equal variances). Additionally, the depth of myometrial 
invasion was not related to a specific mutated gene or gene mutation.
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Table 2. Concordance of molecular alterations in endometrial hysterectomy and pre-operative specimens using 
immunohistochemistry and DNA analysis.
  Hysterectomy Curettage Total discordant Concordance 
  n (%) n (%) cases Rate
Immunohistochemistry (n=48)      
PTEN        
Positive 29 (60.4) 28 (58.3) 5 89.6Negative 19 (39.6) 20 (41.7)
p53        
Wildtype 38 (79.2) 39 (81.3) 1 97.9Mutant-like 10 (20.8) 9 (18.8)
Nuclear β-catenin       
Absent 45 (93.8) 43 (89.6) 2 95.8Present 3 (6.3) 5 (10.4)
DNA analysis (n=46)       
Microsatellite instability       
MSS 33 (80.5) 36 (90.0) 3 93.5MSI 8 (19.5) 4 (10.0)
BRAF        
Wildtype 46 (100) 46 (100) 0 100Mutant 0 (0) 0 (0)
CDKN2A        
Wildtype 46 (100) 46 (100) 0 100Mutant 0 (0) 0 (0)
CTNNB1        
Wildtype 38 (82.6) 35 (76.1) 5 99.8Mutant 8 (17.4) 11 (23.9)
FBXW7        
Wildtype 45 (97.8) 44 (95.7) 1 99.8Mutant 1 (2.2) 2 (4.3)
FGFR2        
Wildtype 43 (93.5) 43 (93.5) 0 100Mutant 3 (6.5) 3 (6.5)
FGFR3        
Wildtype 46 (100) 46 (100) 0 100Mutant 0 (0) 0 (0)
FOXL2        
Wildtype 46 (100) 46 (100) 0 100Mutant 0 (0) 0 (0)
HRAS        
Wildtype 46 (100) 46 (100) 0 100Mutant 0 (0) 0 (0)
KRAS        
Wildtype 37 (80.4) 37 (80.4) 0 100Mutant 9 (19.6) 9 (19.6)
NRAS        
Wildtype 45 (97.8) 44 (95.7) 1 99.9Mutant 1 (2.2) 2 (4.3)
PIK3CA        
Wildtype 31 (67.4) 29 (63.0) 4 99.8Mutant 15 (32.5) 17 (37.0)
PPP2R1A        
Wildtype 43 (93.5) 41 (89.1) 2 99.8Mutant 3 (6.5) 5 (10.9)
PTEN        
Wildtype 22 (47.8) 21 (45.7)
3 99.9Mutant 24 (52.2) 25 (54.3)
MSS=microsatellite stable; MSI=microsatellite unstable
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Figure 1. Example of discordant immunostainings between hysterectomy and pre-operative curettage specimens. 
For PTEN, the hysterectomy showed loss of expression whereas the paired pre-operative curettage showed 
a positive staining. A p53 ‘mutant-like’ expression was observed in the hysterectomy while focal, weak and 
heterogeneous staining was observed in the paired pre-operative curettage. Nuclear β-catenin staining was 
observerd in the curettage but not in the paired hysterectomy.
Concordance rates between hysterectomy and pre-operative curettage specimens were high 
(88–100%) for molecular alterations using immunohistochemical and DNA analysis. For 
immunohistochemical analysis, loss of PTEN expression showed the lowest concordance 
(89.6%). For nuclear β-catenin staining, discordant cases were those where nuclear staining 
was observed in the curettage but not in the hysterectomy. In all except one curettage, p53 
immunostaining corresponded to the staining observed in the hysterectomy. p53 ‘mutant-
like’ immunostained concordant cases showed concordance of TP53 mutation analyses using 
Sanger sequencing in both the curettage and hysterectomy specimens. In the discordant case, 
in which immunostaining of the curettage was scored wildtype and the hysterectomy showed a 
clonal mutant staining, no mutation was identified in TP53 using Sanger sequencing in either 
curettage or hysterectomy specimen. Sequencing of tumors that showed entirely negative 
staining did not reveal any mutations. Figure 1 shows an example of a discordant PTEN, p53 
and β-catenin immunostaining between hysterectomy and pre-operative curettage specimens.
Concordance for microsatellite status between curettage and hysterectomy specimens was 
93.5%. MSI assay was successfully performed on 40 paired cases, and 9 MSI cases were all 
endometrioid endometrial tumors. In the three discordant cases, the curettage specimen was 
microsatellite stable while the tumor in the hysterectomy was microsatellite instability. MSI 
endometrial cancers are most often sporadic and caused by promoter hypermethylation of 
MLH1. Using immunohistochemistry, loss of MLH1 expression was observed in curettage 
and hysterectomy specimens of all three discordant cases from which one curettage specimen 
showed a heterogeneous staining pattern.
PTENp53β-catenin      H
ysterectom




Finally, overall concordance for GynCarta multigene analysis between curettage and 
corresponding hysterectomy specimens was 99.8% (16 discordant cases / (159 mutation * 
46 paired curettage and hysterectomy specimens minus failed reactions)). Thirteen of the 
discordant cases showed a mutation in the pre-operative curettage specimen while the 
mutation was not found in the paired hysterectomy specimen (Figure 2). KRAS and PIK3CA 
mutations were validated for all samples using allele specific qPCR. Upon validation, 
concordance of 99.7% was observed between GynCarta multigene analysis and allele specific 
qPCR. A KRAS G13D mutation was not detected in one paired hysterectomy and curettage 
specimen using GynCarta multigene analysis. Furthermore, one curettage showed a PIK3CA 
E545K mutation which was only detected with GynCarta multigene analysis (Supplementary 
Table 4).
      Curettage
         CTNNB1    FBXW7    FGFR2    KRAS    NRAS    PIK3CA  PPP2R1A    PTEN








CTNNB1 WT 34 4                            
  MUT 1 7                            
FBXW7 WT     44 1                        
  MUT       1                        
FGFR2 WT         43                      
  MUT           3                    
KRAS WT             37                  
  MUT               9                
NRAS WT                 44 1            
  MUT                   1            
PIK3CA WT                     28 3        
  MUT                     1 14        
PPP2R1A WT                         41 2    
  MUT                           3    
PTEN WT                             19 2
  MUT                             1 24
Figure 2. Concordance of molecular alterations in endometrial hysterectomy and pre-operative specimens 
using GynCarta multigene analysis. Concordant cases between the paired hysterectomy and curettage specimen 
wildtype (WT) and mutant (MUT) cases are indicated in green and discordant cases in red. No mutations in 
BRAF, CDKNA2, FGFR3, FOXL2 and HRAS were found in paired curettage and hysterectomy-specimens. 
The   concordance was calculated as discordant cases 16/ ((total samples 46 * 159 assays)−137 failed reactions)=0.998.
Discussion
This study shows that molecular alterations detected in pre-operative curettage samples 
reliably predict the alterations found in the subsequent hysterectomy specimens. We showed 
concordance rates ranging from 88% for immunohistochemical techniques to 99% for DNA 
techniques in paired samples of 48 patients with endometrial cancer. Various studies have 
shown an inconsistency of tumor typing and histological grading between pre-operative 
and hysterectomy specimens.25-27 In accordance with these previous reports, we found that 
especially pre-operative tumor grade 1 does not accurately predict final histological results. 
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Pre-operative assignment of a lower grade is not an unusual finding due to grading of more 
superficially located parts of the tumor, but may lead to underestimating the risk of 
disease recurrence. Early recognition of high-risk status would be desirable for accurate 
patient counseling and determining further treatment, tailoring the extent of surgery and/
or adjuvant therapies to the individual patient’s risk profile. The present study showed 
very high concordance rates for DNA-based techniques: 99.8% for GynCarta multigene 
analysis, 93.5% for microsatellite analysis and 100% for TP53 sequencing. Immunostaining 
showed more discrepancies, however it still resulted in an acceptable concordance for PTEN 
(89.6%), β-catenin (95.8%) and p53 (97.9%). These data indicate that molecular alterations 
found in pre-operative tissue samples correspond better to the subsequent hysterectomy 
specimens than the classic histopathologic features. Finally, specific molecular alterations may 
help to predict the tumor’s propensity for early invasion and disease spread.
So far, most studies of potential prognostic biomarkers on endometrial curettage materials 
have been limited to immunostaining approaches, and the results have rarely been 
correlated with the hysterectomy specimens.15,28-30 Concordance-studies have been 
inconsistent regarding the reliability of p53 scoring, with a concordance ranging from 86 to 
96%.28,29 We found a concordance of 97.9% and the different observations in other studies are 
likely explained by differences in scoring method for evaluating p53 expression. Concordance 
of other potential prognostic biomarkers such as stathmin and p16 has also been tested 
previously, resulting in a discordance of approximately 30%.15,30 Taken together, the results 
of these and our studies indicate that immunohistochemical evaluation of candidate 
prognostic factors in pre-operative specimens only moderately predicts the expression 
pattern in a hysterectomy specimen. Clinical implementation of immunohistochemistry 
based prognostic factors should therefore be approached with caution.
The majority of discrepancies in immunostaining in our study could be explained by 
heterogeneous topographical staining within one tumor. Nuclear staining of β-catenin is 
frequently found at the surface of endometrial cancers, which could explain why in some 
cases nuclear staining of β-catenin was found in the curettage but not in the hysterectomy 
specimen. In particular, squamous differentiated cells and morules exhibit nuclear staining 
of β-catenin.31 PTEN is known to display substantial topographic heterogeneity as well in 
tumors.22 Scant and fragmented tumor material obtained by curettage may give a distorted 
staining pattern not reflective of the whole tumor seen in hysterectomy specimen. These 
findings exemplify limitations for the use of immunohistochemistry to predict the expression 
in the tumor on pre-operative material. However, immunohistochemistry is probably the 
best method to assess functional PTEN loss in endometrial cancer, since loss of PTEN has been 
attributed to a variety of causes including gene mutations, gene methylation, PTEN post-
transcriptional regulation and actions of microRNAs.32 Pallares et al. have shown that only 
the PTEN 6H2.1 antibody exhibited a good correlation with the presence of molecular 
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alterations in PTEN in endometrial tumors.33 Nonetheless, we found twelve cases with PTEN 
mutations, substitutions and frameshifts that showed normal PTEN expression. Possibly 
the absence of loss of heterozygosity explains the discrepancy in these cases. Additionally, 
6 of 8 cases with CTNNB1 mutations did not show a nuclear β-catenin staining. This 
difference can be explained by alternative Wnt-signaling activating events independent of 
mutations in β-catenin.31 Together these findings suggest that PTEN and β-catenin status 
is best assessed by combining immunohistochemistry with mutation status in endometrial 
specimen.
The limitation of DNA-based assays is presented by a failure rate which in this study was the 
highest for the microsatellite assay (13%). The failure to identify microsatellite instability in 
curettage specimens is explained by running out of material and by decreased sensitivity of 
the assay with relatively low concentrations of tumor DNA in these samples. When loss of MLH1 
immunostaining is used as a surrogate marker for MSI, the combination of MLH1 staining 
with the MSI data results in 100% concordance. Therefore, reliable MSI analysis on curettage 
samples can be achieved when combined with MLH1 staining. The DNA-based analysis for 
mutation genotyping used in this study showed a high concordance and an acceptable failure 
rate (<10%). A limitation of our study is that we could not specify the type of pre-operative 
sampling for all included patients. However, molecular alterations were successfully identified in 
endometrial pre-operative specimens obtained by hysteroscopy-guided tissue biopsy, out-patient 
micro-curettage and the classical dilation & curettage sampling. The pre-operative samples 
with poor DNA quality (21.7%) were not related to the volume of blood or to one specific 
type of pre-operative sampling. Recently, Perez-Sanchez et al. showed a limited success (81%) 
of molecular diagnosis using quantitative reverse transcriptase-polymerase chain reaction 
on RNA from uterine aspirates samples for diagnosis of endometrial cancer.34 However, a 
combination of the molecular and histological diagnosis could diagnose 17% more uterine 
aspirates in comparison to histological diagnosis alone. Furthermore, Kinde et al. recently 
compared somatic mutations found in pre-operative liquid-based pap smears to subsequent 
endometrial and ovarian tumors.35 Similar, to the present study, they were able to identify 
the same mutations in the DNA from pre-operative specimens as in the subsequent 
endometrial tumors, stressing the high potential of DNA-based analysis. The findings of our 
study and published literature regarding the concordance of molecular alterations between 
hysterectomy specimens and pre-operative specimens are shown in Supplementary Table 5.
Future studies are required to investigate whether the addition of a molecular profile results in a 
better risk assessment as compared to clinicopathological parameters alone. The implementation 
of molecular diagnostics on endometrial pre-operative specimens has major challenges such as 
turnaround time, costs per patient, logistics and analytical test validity.36 For clinical decision-
making, data from molecular diagnostics should ideally be available within a few days of 
sampling. Similarly to next generation sequencing, a turnaround time under 14 days is 
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expected for sample preparation, protein and DNA analysis and data analysis.36 However, it will 
be a challenge to collect tumor tissue at individual hospitals for molecular testing within set 
time limits. Regulations, standard protocols, trained personnel, laboratory accreditation and 
validation including external quality assessments should improve the adoption of molecular 
diagnostics. Future studies investigating the feasibility of applying this molecular approach in 
the workup of patients with endometrial cancer will be required to address these issues.
In conclusion, this molecular profiling concordance-study using 48 endometrial cancers 
with their corresponding curettage specimens provides evidence that pre-operative 
curettage samples can reliably predict the molecular alterations of the endometrial cancers as 
found in the definitive hysterectomy specimens. These findings may impact future studies 
that determine the prognostic value of hysterectomy-based molecular profiling, as the 
results can safely be translated towards the pre-operative tissue samples. We have shown 
that the concordance of DNA-based techniques is superior to the concordance of classic 
histology and immunohistochemical approaches. Whether these molecular alterations can 
have superior prognostic and predictive power than the classical clinicopathological 
risk features still remains to be determined and will require analysis of large study cohorts, 
preferably from randomized controlled trials.
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Supplementary files
Supplementary Table 1. DNA quality of endometrial hysterectomy and pre-operative specimens and success rate 
of DNA analysis.
  Hysterectomy Curettage
n=46 (%) n=46 (%)
DNA concentration (ng/µl)  
mean 12.5 7.0
range 0.3-22.5 0.9-20.3
DNA quality    
                                         poor                 0  bp 3 (6.5) 10 (21.7)
                                       moderate        150 bp 6 (13.0) 6 (13.0)
                       255 bp 4 (6.5) 2 (6.5)
                                         good              343 bp 29 (63.0) 14 (30.4)
                           511 bp 4 (6.5) 14 (30.4)
     
Total n=46 Hysterectomy Curettage
Microsatellite instability assay 89.1 87.0
GynCarta 98.7 91.8
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Supplementary Table 3. Mutations detected in hysterectomy and pre-operative curettage specimens.
  Hysterectomy Curettage     Hysterectomy Curettage 
  n n     n n
CTNNB1       PPP2R1A    
D32H 3 3   P179L 2 2
G43E 0 1   R183W 1 1
S33C 1 1   S256F 0 1
S33Y 0 1   R258H 0 1
S33F 2 1   PTEN    
S37C 1 1   E7Star 1 1
S37F 1 3   R130fs*4 4 4
S45F 0 1   R130P 1 1
FBXW7       R130* 3 3
R479Q 0 1   R130G 4 4
R505C 1 1   R173C 2 1
FGFR2       R173H 1 1
S252W 2 2   R233* 3 3
KRAS       R234W 0 1
G12C 2 2   V290fs*1 1 2
G12D 3 3   L318fs*2 2 2
G12A 1 1   T321fs*23 1 1
G12V 2 2   N323fs*21 1 1
G13S 1 1        
NRAS            
G12S 1 1        
G12D 0 1        
PIK3CA            
R88Q 3 4        
E542K 0 1        
E545A 1 1        
E545G 0 1        
E545K 1 1        
Q546K 2 2        
Q546R 1 1        
Y1021 3 2        
M1042I 1 1        
H1047R 3 3        
Supplementary Table 5. Comparison of the current study with published literature regarding the concordance of 
molecular alterations between hysterectomy specimens and pre-operative specimens.
Study n Pre-operative specimen Method Marker Concordance
Protein analysis          
Oreskovic et al.29 136 Fractional curettage IHC p53 96%
Oreskovic et al.29 136 Fractional curettage IHC ER 99%
Oreskovic et al.29 136 Fractional curettage IHC PR 95%
Oreskovic et al.29 136 Fractional curettage IHC Ki67 95%
Engelsen et al.15 140 Curettage IHC p53 86%
Engelsen et al.15 200 Curettage IHC p16 73%
Trovik et al.30 477 Curettage IHC Stathmin 67%
Stelloo et al. (current) 48 Curettage IHC p53 97.9%
Stelloo et al. (current) 48 Curettage IHC PTEN 89.6%
Stelloo et al. (current) 48 Curettage IHC β-catenin 95.8%
DNA analysis          
Pradhan et al.37 111 Curettage DNA image cytometry DNA ploidy 72.7%
Kinde et al.35 24 Pap smears Sequencing 12 genes 100%
Stelloo et al. (current) 46 Curettage MSI assay 5 markers 93.5%
Stelloo et al. (current) 46 Curettage Multigene assay 13 genes 99.8%
38
Chapter 2
Supplementary Table 4. Concordance between GynCarta multigene analysis and allele specific qPCR in the 
hysterectomy (HYST) and pre-operative curettage specimens (CUR). Concordance was determined to validate the 
results for 7 KRAS and 3 PIK3CA mutations. Failed reactions were excluded as comparison was not possible (6 for 
PIK3CA and 5 for KRAS; 53/920 in total). This led to a concordance of (3/(920-53))=0.997.
KRAS   GynCarta multigene analysis 
    G12S G12R G12C G12D G12A G12V G13D Wildtype











G12S HYST 0                              
  CUR   0                            
G12R HYST     0                          
  CUR       0                        
G12C HYST         2                      
  CUR           2                    
G12D HYST             2                  
  CUR               2                
G12A HYST                 1              
  CUR                   1            
G12V HYST                     2          
  CUR                       2        
G13D HYST                         1     1
  CUR                           1   1
Wildtype HYST                             36  
  CUR                               33
Failed HYST                             1  
    CUR                               4
                   
PIK3CA   GynCarta multigene analysis    
    H1047R E542K E545K Wildtype    











H1047R HYST 3                     
  CUR   3                   
E542K HYST     0                 
  CUR       0               
E545K HYST         1             
  CUR           1           
Wildtype HYST             40         
  CUR       1       38       
Failed HYST             2         
  CUR               4       
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Background: Current risk stratification in endometrial cancer (EC) results in frequent over- 
and underuse of adjuvant therapy, and may be improved by novel biomarkers. We examined 
whether POLE proofreading mutations, recently reported in about 7% of ECs, predict 
prognosis.
Methods: We performed targeted POLE sequencing in ECs from the PORTEC-1 and -2 trials 
(n=788), and analyzed clinical outcome according to POLE status. We combined these results 
with those from three additional series (n=628) by meta-analysis to generate multivariable-
adjusted, pooled hazard ratios (HRs) for recurrence-free survival (RFS) and cancer-specific 
survival (CSS) of POLE-mutant ECs. All statistical tests were two-sided.
Results: POLE mutations were detected in 48 of 788 (6.1%) ECs from PORTEC-1 and -2 and 
were associated with high tumor grade (P<0.001). Women with POLE-mutant ECs had fewer 
recurrences (6.2% vs. 14.1%) and EC deaths (2.3% vs. 9.7%), though, in the total PORTEC 
cohort, differences in RFS and CSS were not statistically significant (multivariable-adjusted 
HR=0.43, 95% CI=0.13 to 1.37, P=0.15; HR=0.19, 95% CI=0.03 to 1.44, P=0.11 respectively). 
However, of 109 grade 3 tumors, 0 of 15 POLE-mutant ECs recurred, compared with 29 
of 94 (30.9%) POLE wild-type cancers; reflected in statistically significantly greater RFS 
(multivariable-adjusted HR=0.11, 95% CI=0.001 to 0.84, P=0.03). In the additional series, 
there were no EC-related events in any of 33 POLE-mutant ECs, resulting in a multivariable-
adjusted, pooled HR of 0.33 for RFS (95% CI=0.12 to 0.91, P=0.03) and 0.26 for CSS (95% 
CI=0.06 to 1.08, P=0.06).
Conclusion: POLE proofreading mutations predict favorable EC prognosis, independently of 
other clinicopathological variables, with the greatest effect seen in high-grade tumors. This 
novel biomarker may help to reduce overtreatment in EC.
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Introduction
Endometrial cancer (EC) is the commonest gynecological malignancy in the Western world, 
and is rising in incidence because of increasing obesity and ageing of the population.1 Most cases 
(80%) are detected at an early stage (FIGO stage I)2 because of early symptoms. The standard 
management of EC consists of hysterectomy and bilateral salpingo-oophorectomy with or 
without postoperative vaginal brachytherapy (VBT) or pelvic external beam radiotherapy 
(EBRT) depending on recurrence risk.3,4 Women with grade 3 cancers or advanced disease are 
increasingly treated with adjuvant chemotherapy,5,6 the role of which will be further defined 
by ongoing studies. Current risk stratification is based on both clinical (age) and pathologic 
factors (FIGO stage, tumor type, grade, and lymphovascular space invasion [LVSI]). 
Despite refinement in the use of postoperative treatment in EC over the last two decades, 
over- and underusage of adjuvant therapy remains a clinical problem. Approximately seven 
patients with stage I EC with risk factors need to receive VBT to prevent one recurrence, 
while 8% to 10% patients develop distant metastases that may have been prevented with 
adjuvant chemotherapy.3-6 Consequently, the identification of molecular markers predictive 
of recurrence risk or treatment benefit beyond current clinicopathological factors would 
represent a major advance.7 While studies have investigated the prognostic significance of 
several molecular alterations involved in endometrial carcinogenesis, including microsatellite 
instability (MSI), PIK3CA and TP53 mutation,8,9 to date none have been incorporated into 
routine clinical practice.
We recently showed that germline variants in the exonuclease domain of the DNA polymerases 
POLE and POLD1 predispose to cancer, including EC, by impairing polymerase proofreading 
and greatly increasing the rate of base substitution mutations.10 We subsequently demonstrated 
that somatic POLE proofreading mutations are found in about 7% of sporadic ECs, where they 
strongly associate with high tumor grade.11 Similar findings have been reported in parallel by 
The Cancer Genome Atlas (TCGA), which also demonstrated that while POLE mutations were 
only found in endometrioid tumors, they were not inversely associated with TP53 mutation.12 
These pathogenic POLE proofreading mutations, about 90% of which cluster in exons 9 and 
13, localize to amino acids within, or close to, conserved motifs essential for proofreading 
function.11,12 In keeping with this, POLE proofreading-mutant ECs are ultramutated, with a 
base substitution mutation frequency among the highest in human tumors.13
Different forms of genomic instability in cancers are known to be associated with 
clinicopathological features, including prognosis.14-16 Favorable outcome of women with 
POLE-mutant ECs has been suggested,12 but only reached statistical significance when 
limited to analysis of grade 3 tumors in a recent report,17 and current evidence is insufficient 
to inform practice.18 In this study, we have analyzed associations between POLE proofreading 







trials (PORTEC-1 and -2)3,4 of early-stage (FIGO stage I), (high-) intermediate risk EC, with 




Details of the PORTEC-1 and PORTEC-2 studies have been published previously (see the 
Supplementary Materials).3,4 PORTEC-1 compared pelvic EBRT with no additional treatment 
(NAT) in 715 women with intermediate risk, stage I EC recruited between June 1990 and December 
1997.3 PORTEC-2 randomly assigned 427 women with high-intermediate risk stage I/IIA EC 
between May 2002 and September 2006 to either EBRT or VBT following surgery.4 The median 
(range) duration of follow-up was 159.6 (33.6–222) months in PORTEC-1 and 89 (18–122) months 
in PORTEC-2. The PORTEC study protocols were approved by the Dutch Cancer Society and 
by the medical ethics committees at participating centers. All patients provided written informed 
consent to study participation and treatment. 
Additional EC Series
The Leuven (n=187)9, Zurich/Basel (n=267)19, and TCGA (n=373)12 series have also been 
reported previously (Supplementary Materials). The Leuven and TCGA cohorts were 
collected prospectively, while Zurich/Basel cases were identified retrospectively. These sets 
included both endometrioid and nonendometrioid ECs (EECs and NEECs), and also included 
patients with stage III/IV disease (21.8–31.2%). Central pathology review was mandated 
in both TCGA and the Zurich/Basel cohorts, while the Leuven cases were reviewed by a 
single academic pathologist. Patients in the Leuven and Zurich/Basel cohorts were managed 
according to standard protocols, while treatment in the TCGA series was at the discretion of 
the attending physician: median (range) follow-up in each was 29 (1–184) months, 46 (1–173) 
months, and 28.7 (0.6–185.6) months, respectively. Follow-up data varied between series. RFS 
data were available for the Leuven and TCGA series, but not the Zurich/Basel set, while CSS 
data were available for the Leuven and the Zurich/Basel series, but absent from the TCGA 
study. Collection and analysis of the Leuven and Zurich/Basel series were approved by the 
scientific ethics committee from all centers (UZ Leuven Medical ethics committee and KEK-
ZH-NR: 2010-0358, respectively). Ethical approval for anonymized tumor molecular analysis 
was granted by Oxfordshire Research Ethics Committee B (Approval No. 05\Q1605\66).
Demographic and Clinicopathological Variables
Baseline demographic and clinicopathological variables were treated as either categorical 
(e.g., grade, stage, EEC vs. NEEC) or continuous (age) as appropriate. All analyses were based 
on data from central pathology review.
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Molecular Analysis
Tumor DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) blocks from 434 
(60.1%) and 398 (93.2%) ECs from the PORTEC-1 and -2 studies, respectively. There were no 
statistically significant differences between the biomarker and the total study populations in 
demographic/ clinicopathological characteristics, treatment or survival. DNA was extracted 
from 187 fresh-frozen ECs in the Leuven set, 373 fresh-frozen ECs in the TCGA set, and 
260 FFPE ECs in the Zurich/Basel set (Supplementary Methods). The Leuven, Zurich/
Basel, and TCGA biomarker cohorts were similar to the total series population in each case 
(Supplementary Methods).
Sanger sequencing of POLE exons 9 and 13 (Supplementary Table 1) was successful in over 
94% of cases. For TCGA, we extracted POLE mutation data from publicly available whole-
exome sequencing data (https://tcga-data.nci.nih.gov/tcga/).12 We defined pathogenic POLE 
proofreading mutations as variants absent from public germline sequence databases (http://
evsgs.washington.edu/EVS/; http://www.1000genomes.org/) and previously confirmed as 
somatic variants associated with tumor ultramutation,11,12,20,21 with the exception of one novel 
variant predicted to perturb protein function by SIFT (http://sift.jcvi.org) and Mutation 
Assessor (http://mutationassessor.org). All variants were confirmed in at least duplicate 
independent polymerase chain reaction and sequencing reactions.
Statistical Analysis
Analyses performed and reported in this biomarker study are listed in Supplementary Table 2 
in accordance with published guidelines.22,23 For analysis of the association of POLE mutation 
with outcome, our primary endpoint was recurrence-free survival (RFS), with secondary 
endpoints of cancer-specific survival (CSS), and overall survival (OS). In the PORTEC 
studies, RFS was defined as the time from random assignment to relapse, with censoring at 
last contact or death in case of no recurrence. CSS was measured as the time from random 
assignment to death from EC, with censoring at date of last contact or noncancer death. OS 
was measured as the time from random assignment to death from any cause, with censoring 
at date of last contact in patients still alive. The same criteria were used in the additional 
series, with the exception that survival measurements were from time of diagnosis. Survival 
curves were plotted using the Kaplan-Meier method and compared by the log-rank test. We 
used Cox proportional hazards models to calculate hazard ratios (HRs) for RFS, CSS, and 
OS of POLE-mutant ECs relative to POLE wild-type tumors by univariable analyses and, 
following adjustment for baseline characteristics and prognostic factors (age, tumor type, 
grade, LVSI, depth of myometrial invasion, and treatment), by multivariable analyses (see 
Supplementary Methods and Supplementary Tables 3–6). Proportionality of hazards in Cox 
models was confirmed by visual inspection of complementary log plots or by interaction 
terms of covariables and (log)time. In view of the similar patient populations, the limited 







mutations, the PORTEC studies were combined for most analyses. For Cox regression 
analysis of the PORTEC grade 3 subset and the Leuven, Zurich/Basel, and TCGA series, 
we applied Firth’s correction,24 owing to the absence of events in the POLE-mutant groups. 
For multivariable analysis of the additional series, we included disease stage as a covariable; 
although myometrial invasion, LVSI, and treatment were not included because of lack of 
data, we confirmed that omission of these variables from the PORTEC multivariable analyses 
did not alter estimates of RFS or CSS with POLE mutation (P=0.93 and P=0.87 respectively) 
(see Supplementary Methods). Statistical analyses were performed using SPSS (SPSS Inc., 
Chicago, IL), Stata (StataCorp, College Station, TX) and R (http://www.r-project.org/). All 
P-values were two-sided. A P-value under 0.05 was considered statistically significant.
Results
Patient Characteristics and POLE Proofreading Mutations in PORTEC Studies
Demographic and clinicopathological characteristics of the PORTEC study participants in 
whom tumor POLE sequencing was successful are shown in Table 1. The majority (about 
98%) of cancers in both studies were EECs. POLE exon 9 and 13 proofreading mutations 
were detected in 48 of 788 (6.1%) tumors from the combined PORTEC studies (Table 1), 
with similar distribution across study arms.11,12 With the exception of two tumors harboring a 
germline polymorphism of uncertain pathogenicity (rs150032060; c.1282G>A, p.Ala428Thr), 
detected in tumor-free myometrium in both cases and excluded from subsequent analyses, all 
mutations were recurrent substitutions at somatic mutational hotspot codons (Supplementary 
Table 7) known to cause ultramutation.11,12 Apart from one neuroendocrine tumor, all POLE 
mutations occurred in endometrioid ECs. Analysis of 48 available preoperative curettings 
identified POLE mutations in all five cases in which they were detected in the subsequent 
hysterectomy, resulting in 100% concordance. Compared with POLE wild-type ECs, POLE-
mutant tumors occurred in younger women (median age 63.5 vs. 68.5 years, P<0.001, t test), 
and were more commonly grade 3 (31.3% vs. 12.7%, P<0.001, χ2 test), though LVSI and deep 
(>50%) myometrial invasion were less frequent (0% vs. 9.5%, P=0.03, and 58.2% vs. 71.9%, 
P=0.045, respectively, χ2 test) (Table 1).
Clinical Outcome by POLE Proofreading Mutation in PORTEC Studies
We first examined the association of POLE proofreading mutation with EC recurrence. Three 
of 48 (6.2%) women with POLE-mutant tumors developed local or distant recurrence during 
study follow-up, compared with 104 of the other 740 (14.1%) patients (Figure 1A, Table 2). All 
three recurrences in the POLE-mutant cohort were distant metastases without locoregional 
relapse and occurred in women with grade 1 EECs and deep myometrial invasion, managed 
by observation, EBRT, and VBT, respectively. The univariable HR for recurrence-free survival 
(RFS) with tumor POLE proofreading mutation was 0.41 (95% CI=0.13 to 1.28, P=0.13), 
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POLE wild-type     740              579             228               36  740               603    277               73
POLE-mutant        48               40               7                 4    48                 41    20                 7
Figure 1. Cumulative probability of recurrence (A) and cancer-specific survival (B) according to POLE proofreading 
mutation in the combined PORTEC studies. P-values are obtained by two-sided log-rank test.
A          B
with little change following adjustment for known prognostic variables by Cox regression 
(HR=0.43, 95% CI=0.13 to 1.37, P=0.15) (Figure 1A, Table 2; Supplementary Tables 3 and 
5). As many local EC recurrences are salvageable with therapy, we next examined whether 
cancer-specific survival (CSS) varied according to tumor POLE mutation. In women with 
POLE-mutant EC, there was one (2.3%) EC death during follow-up, compared with 72 (9.7%) 
in the rest of the study population. The unadjusted HR for CSS was 0.20 (95% CI=0.03 to 1.46, 
P=0.11), with minimal alteration following multivariable analysis (HR=0.19, 95% CI=0.03 to 
1.44, P=0.11) (Figure 1B, Table 2; Supplementary Tables 4 and 6). Overall survival of women 
with POLE-mutant ECs was not statistically significantly greater than that of other patients by 
univariable or multivariable analysis (10-year OS=76.2% vs. 70.4%) (Table 2).
Table 2. Clinical outcome in PORTEC studies according to POLE proofreading mutation determined by univariable 
and multivariable analysis.
      Univariable analysis Multivariable analysis*
Outcome Events/total (%) 10-year, % HR (95% CI) P† HR (95% CI) P†
Recurrence            
POLE wild-type 104/740 (14.1) 15.2 0.41 (0.13-1.28) 0.130 0.43 (0.13-1.37) 0.150
POLE mutant‡ 3/48 (6.2) 5.5        
Cancer-specific survival
POLE wild-type 72/740 (9.7) 89.7 0.20 (0.03-1.46) 0.110 0.19 (0.03-1.44) 0.110
POLE mutant‡ 1/48 (2.3) 97.7        
Overall survival           
POLE wild-type 248/740 (33.5) 70.4 0.69 (0.38-1.22) 0.200 1.06 (0.59-1.92) 0.850
POLE mutant‡ 12/48 (25.0) 76.2        
 * Multivariable Cox models include POLE mutation, age, nonendometrioid histology, tumor grade, and 
lymphovascular invasion. CI=confidence interval; HR=hazard ratio. †Calculated using Cox proportional hazards 
test. All statistical tests were two-sided. ‡POLE exon 9 or 13 proofreading mutation. 
The strong association of POLE mutations with high tumor grade (11) caused us to hypothesize 
that their apparent prognostic effect would be most evident in this group, who are commonly 
considered for treatment intensification. Of 109 patients with grade 3 tumors, there were no 
recurrences or cancer deaths in the 15 (13.7%) POLE-mutant case, compared with 29 (30.9%) 
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relapses and 25 (26.6%) EC deaths in the remaining 94 women (Figure 2, A and B), reflected 
in statistically significantly improved RFS in univariable analysis (HR=0.09, 95% CI=0.001 
to 0.66, P=0.01) and, following adjustment for other prognostic variables in multivariable 
analysis (HR=0.11, 95% CI=0.001 to 0.84, P=0.03) (Table 3; Supplementary Tables 8 and 
9). These results were essentially unchanged after limiting RFS analysis to the 97 grade 3 
endometrioid ECs (univariable HR=0.11, 95% CI=0.001 to 0.78, P=0.02; multivariable-
adjusted HR=0.12, 95% CI=0.001 to 0.87, P=0.03) (Supplementary Table 8). Notably, POLE 
proofreading mutation was a stronger predictor of recurrence and EC death than all other 
prognostic variables examined in these analyses (Supplementary Tables 8 and 9). 
Number at risk
POLE wild-type   94                  63              28               2                  94 66                33   8
POLE-mutant      15                  11              4               0                 15 12                5   0
Figure 2. Cumulative probability of recurrence (A) and cancer-specific survival (B) according to POLE proofreading 
mutation in patients with grade 3 tumors in the combined PORTEC studies. P-values are obtained by two-sided 
log-rank test. 
Pooled Analysis With Additional EC Series
While the PORTEC analyses demonstrated a tendency for POLE proofreading-mutant ECs of 
all grades to improved outcome, the generally good prognosis of patients limited our ability 
to confirm this beyond the grade 3 subgroup. We therefore sought to support our results by 
analysis of two EC series from Leuven and Zurich/Basel, together with the published TCGA 
set, collectively comprising an additional 628 patients. POLE proofreading mutations were 
detected in 33 (5.3%) case patients in the additional series (Supplementary Table 7). As in 
the PORTEC studies, POLE-mutant tumors were more frequently high-grade (54.5% vs. 
32.4%, P=0.013, χ2 test) and were generally of endometrioid histology, though three POLE-
mutant mixed endometrioid/ serous and one serous cancer were detected in the Leuven series 
(Supplementary Tables 10–12).
In the two series with RFS data—Leuven and TCGA—no POLE-mutant EC recurred with 
median follow-up of 28 months, compared with 31.6% and 19.0% of other tumors, respectively 
(Supplementary Figures 1A and 2, Supplementary Tables 13 and 14). Similarly, for the two series 







in which CSS was documented—Leuven and Zurich/Basel (median follow-up 46 months)—
there were no EC deaths in women with POLE-mutant tumors, compared with 18.6% and 10.8% 
of the remaining patients (Supplementary Figures 1B and 3, Supplementary Tables 13 and 
15). As anticipated given their sizes, no individual series demonstrated statistically significant 
differences in the RFS/CSS of POLE-mutant ECs by either univariable or multivariable 
analyses (Supplementary Tables 13–15). We therefore combined multivariable-adjusted HRs 
from each series with those from the PORTEC studies by meta-analysis to generate pooled 
estimates for RFS and CSS according to POLE proofreading mutation (Figure 3, A and B). 
POLE-mutant ECs were associated with statistically significantly greater RFS compared with 
other tumors (HR=0.33, 95% CI=0.12 to 0.91, P=0.03), with no evidence of heterogeneity 
among studies (P=0.66), though the difference in CSS was not statistically significant using a 
two-tailed test (HR=0.26, 95% CI=0.06 to 1.08, P=0.06). Interestingly, the only POLE-mutant 
tumors that recurred were early-stage, grade I ECs from the PORTEC cohorts (Supplementary 
Table 16). To date, most POLE proofreading mutations have been detected in EECs,11,12,17 
although POLE-mutant NEECs have been reported.11,25,26 Given the difficulty in histotyping 
high-grade ECs, we considered the possibility that the four POLE-mutant tumors reported as 
NEECs in the Leuven series may have been misclassified, thus biasing our results because of 
the poor prognosis of NEEC. We therefore confirmed that the estimate of RFS was essentially 
unchanged by repeating the meta-analysis after excluding POLE wild-type NEECs from all 
cohorts (HR=0.34, 95% CI=0.12 to 0.93, P=0.04) (Supplementary Tables 5, 6, 13, and 14).
Table 3. Clinical outcome of patients with grade 3 tumors in PORTEC studies according to POLE proofreading 
mutation by univariable and multivariable analysis.
      Univariable analysis Multivariable analysis*
  Events/total (%) 10-year (%) HR (95% CI) P† HR (95% CI) P†
Recurrence          
POLE wild-type 29/94 30.8 0.09  (0.001-
0.66) 0.010 0.11 (0.001–0.84)  0.028POLE mutant‡ 0/15 0
Cancer specific survival        
POLE wild-type 25/94 73.4 0.11 (0.001-0.78) 0.020 0.14 (0.001-1.01) 0.051POLE mutant‡ 0/15 100
Overall survival        
POLE wild-type 46/94 60 0.49 (0.18-1.36)  0.170 0.78 (0.27-2.21) 0.630POLE mutant‡ 4/15 73.3
* Multivariable Cox models include POLE mutation, age, non-endometrioid histology and lymphovascular 
invasion. †Calculated using Cox proportional hazards two-sided test with Firth’s correction for analysis of 
recurrence and cancer-specific survival (due to absence of events in the POLE-mutant groups). ‡POLE exon 9 or 
13 proofreading mutation.
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0.01                0.1                   1                    10
              HR
0.01                0.1                   1                    10
              HR
 Study                                                                                              HR (95% CI), P                 % weight
 PORTEC      0.43 (0.13 to 1.37), P=0.15          74.4
 LEUVEN       0.18 (0.01 to 3.11), P=0.24         12.9
 TCGA       0.12 (0.01 to 2.11), P=0.15         12.7 
 OVERALL       0.33 (0.12 to 0.91), P=0.03       100.0
 Study                                                                                               HR (95% CI), P                 % weight
 PORTEC      0.19 (0.03 to 1.44), P=0.11          53.5
   
 LEUVEN                   0.66 (0.04 to 11.40), P=0.78  24.7
 Zurich/Basel     0.21 (0.01 to 4.26), P=0.31         21.9
 
 





Figure 3. Pooled HRs for recurrence-free survival (A) and cancer-specific survival (B) of POLE proofreading-mutant 
endometrial cancer derived from the PORTEC studies and additional series. Results from multivariable analyses were 
combined by meta-analysis using Mantel-Haenszel weights to generate pooled, adjusted HRs and 95% confidence 
intervals. All statistical tests were two-sided. CI=confidence interval; HR=hazard ratio; TCGA=The Cancer Genome 
Atlas.
Discussion
By analyzing tumors from nearly 800 women in two large, randomly assigned controlled 
trials and pooling data with three independent series comprising over 600 additional patients, 
we have demonstrated that POLE proofreading-mutant ECs of all grades display excellent 
prognosis, independent of other known prognostic factors. POLE-mutant tumors have a 
risk of recurrence approximately one third that of other ECs, and a relative risk of cancer 
death that appears even lower, though the latter finding was not statistically significant in 
our analysis. This is despite a strong association of POLE proofreading mutations with high 
tumor grade—a characteristic that predicts a high risk of metastases in early EC.27 Indeed, 







grade 3 tumors in the rest of this subgroup, consistent with a recent report, which combined 
high-grade ECs from the TCGA series with an additional, small retrospective series.17 The 
role of adjuvant chemotherapy in patients with high-risk grade 3 tumors is currently under 
investigation, and as systemic therapy was not used in PORTEC-1 or -2 these data suggest that 
patients with POLE proofreading-mutant EC may be unlikely to benefit from such treatment. 
Similarly, the absence of locoregional recurrence of POLE-mutant ECs was observed across 
all arms of the PORTEC studies, including the NAT arm of PORTEC-1. While further studies 
are required before firm conclusions can be drawn on the implications of POLE proofreading 
mutations for postoperative treatment in EC, our results suggest that minimization of adjuvant 
therapy for POLE-mutant ECs localized to the uterus may be worthy of investigation. They 
also suggest POLE proofreading mutation should be considered for inclusion in cancer gene 
panels used in EC, as it may improve prognostication, particularly for grade 3 tumors.
While highlighting the strengths of using high-quality clinical trial sample banks for biomarker 
research,18 our study has limitations. The challenge of confirming even a strong effect of a 
marker with modest (<10%) frequency in a population with relatively favorable prognosis 
meant that we used additional EC series to confirm the improved RFS of POLE-mutant ECs. 
While acknowledging the limitations of sets containing a mixture of histological subtypes and 
stages, with limited follow-up and lacking comprehensive treatment data18 the similar results 
from each following multivariable analysis suggests that our results are unlikely to be because 
of chance or confounding by inclusion of NEECs in our analyses. However, as highlighted 
above, it will be important to confirm the favorable prognosis of POLE-mutant ECs in further 
independent series, and particularly in tumors of advanced stages. It should also be noted that 
as a single biomarker survey of POLE hotspot exons in ECs of predominantly endometrioid 
histology, we are presently unable to determine the effect of the about 10% of pathogenic 
variants outside exons 9 and 13,11,12 or whether the effect of POLE mutation varies according 
to tumor molecular subtypes. Both questions are likely to be addressed by future studies.
POLE proofreading-mutant cancers are a molecularly distinct group of tumors with a striking 
mutation burden and distinctive mutation signature.11-13 Whether these characteristics 
contribute to their favorable prognosis awaits confirmation. Study of mutator polymerases 
in yeast has confirmed the existence of a mutational threshold, which, if exceeded, results in 
decreased viability because of lethal mutations in essential genes prior to cell division.28 It will 
be of interest to determine whether the dramatic increase in mutation rate in S. cerevisiae 
caused by the corresponding substitution to human POLE p.Pro286Arg29 approaches this 
error threshold. Similarly, analysis of the burden of deleterious mutations accumulated in 
POLE proofreading-mutant cancers may provide insights into their behavior.30
Over the last two years, we and others have shown that somatic mutations in the proofreading 
domain of POLE occur in several human tumors.10-12,20,31 We now demonstrate that, despite 
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a strong association with high grade, POLE proofreading-mutant ECs have a favorable 
prognosis. While the frequency of POLE mutation in EC is modest, it is worth noting that it 
is broadly similar to that of many novel molecular aberrations recently discovered by TCGA 
and other sequencing efforts. As most common cancer variants are currently not actionable, 
similar analyses of these modest-frequency (5% to 10%) molecular subgroups are likely to 
be essential if we are to realize the ambition of personalized cancer medicine during the next 
decade.
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Full details of the PORTEC-1 and PORTEC-2 clinical trials are provided in the original 
publications.1,2 Inclusion criteria for PORTEC-1 were histologically proven endometrial 
adenocarcinoma (including adenocarcinoma with squamous features, adenosquamous 
carcinoma, papillary serous carcinoma, and clear-cell carcinoma), of intermediate risk, 
defined as postoperative FIGO stage I, grade 1 with deep (>50%) myometrial invasion, grade 
2 with any depth of invasion, or grade 3 with superficial (<50%) invasion. 662/714 (92.7%) 
of tumors were endometrioid endometrial cancers (EECs). Tumor subtype and grade were 
confirmed by central pathology review in 567 (79.4%) cases. 
Eligibility criteria for PORTEC-2 were endometrial adenocarcinoma of high-intermediate 
risk, defined as: (i) age greater than 60 years and stage IC grade 1 or 2 disease, or stage IB grade 
3 disease; or (ii) patients of any age with stage IIA disease (apart from grade 3 with greater 
than 50% myometrial invasion). Patients whose cancers had serous or clear cell histology 
were excluded. Central pathology review was performed in 86% cases, following which 12 
tumors were reclassified as of non-endometrioid histology. 
Leuven series
Details of the Leuven prospective series have been previously reported.3 Pathological analysis 
and grading were performed by a single, experienced gynecological pathologist according 
to the WHO classification of Tumors of Female Reproductive Organs. Clinical information 







lymphadenectomy in cases of grade 1-2 tumors with diameter > 2 cm or 50% myometrial 
invasion, or grade 3 EECs and NEECs. Patients were followed up every 3 months for the first 
2 years, every 6 months from 2-5 years and yearly afterwards. Follow-up data including in 
details of RFS, CSS and OS were extracted from electronic patient files.
Zurich/Basel series
Details of the Basel/Zurich series have been previously reported.4-6 Tumor blocks were collected 
retrospectively from patients treated in academic centers and outpatient clinics. Staging 
was according to the AJCC TNM system (7th edition), and classified by two independent 
histopathologists with the aid of IHC. Patients with localized disease were treated by TAH-
BSO (with or without pelvic and para-aortic lymphadenectomy). Adjuvant intra-vaginal 
radiation therapy was given postoperatively in cases of myometrial invasion or grade 3 tumor. 
Follow-up information was obtained from the participating centers and from the Cancer 
Registries of Basel and Zurich. 
TCGA series 
Details of the TCGA EC series have been previously reported.7 Patients were recruited 
from participating centres, and tumors staged according to the AJCC system. Whole exome 
sequencing was performed on 248 cases. Treatment and follow up were at the discretion of 
the treating clinician; of the overall population, 19% received adjuvant RT, 10% adjuvant 
chemotherapy, and 14% adjuvant chemoradiotherapy; in 51% of cases, the postoperative 
treatment delivered was not known.
DNA extraction
In the PORTEC studies, DNA was extracted from 0.6mm tissue punches taken from areas 
containing ≥70% tumor in FFPE blocks, with exception of 14 cases with tumor size of 
<0.6mm, or insufficient fraction of tumor cells, where DNA was extracted following manual 
microdissection by standard methods. Similar methodology was used to extract tumor DNA 
in the Zurich/Basel series, while in Leuven series, DNA was extracted from fresh-frozen 
tissue using DNeasy Blood & Tissue Kit (Qiagen), following confirmation of adequate tumor 
cellularity using H&E slides on FFPE material.
PCR and sequencing reactions
PCR primers for sequencing of POLE exons 9 and 13 are shown in Table S1. PCR was 
performed using 10ng of template DNA with Qiagen multiplex PCR kit with Q solution in a 
15μL reaction volume, with primers at 0.4μM final concentration and proportions of other 
reagents according to the manufacturer’s recommendations. Reaction conditions were as 
follows; 95°C denaturation for 15 minutes; 94°C melt for 45 seconds, 55°C annealing for 90 
seconds and 72°C extension for 45 seconds repeated for 38 cycles; and final 72°C extension for 
10 minutes. PCR products were confirmed by gel electrophoresis and cleaned up with Exosap-
57
Prognostic significance of POLE proofreading mutations
IT (Affymetrix) as per manufacturer’s instructions. BDT (Life technologies) sequencing was 
performed according to manufacturer’s recommendations using the forward primer for 
sequencing of POLE exon 9 and reverse primer for POLE exon 13. 
PORTEC. PCR screening of POLE exons 9 and 13 was successful in 412/434 (94.9%) and 
376/398 (95.4%) cases respectively from the PORTEC-1 and -2 studies. There was no 
significant difference between the biomarker study and overall populations in the proportion 
of cases with grade 3 tumors (13.7% vs. 13.3%, P=0.84) or disease stage (P=0.07). 
Leuven. Of 187 fresh frozen samples analyzed in the Leuven set, PCR screening was successful 
in 183 (97.9%) cases. Of these, 13 (7.1%) were excluded due to non-endometrial histology 
(n=7, 3.8%), missing data (n=2, 1.1%), and insufficient follow up (n=4, 2.2%). There was no 
significant difference between the biomarker and overall populations in the proportion of 
cases with grade 3 tumors (54.3% vs. 55.2%, P=0.92) or stage III/IV disease (30.4% vs. 31.2%, 
P=0.91). 
TCGA. Data were downloaded from cBioportal (http://www.cbioportal.org/public-portal/). 
Of 248 cases with whole-exome sequence data, 19 were excluded due to absence of outcome 
data (n=17, 6.9%) or lack of tumor grading (n=2, 0.8%). There was no significant difference 
between the analyzed and overall populations in the proportion of cases with grade 3 tumors 
(39.1% vs. 37.1%, P=0.71) or stage III/IV disease (23.0% vs. 21.0%, P=0.66). 
Zurich/Basel. Of 267 cases from the Zurich/Basel set in whom outcome data and tumor DNA 
were available, PCR screening was successful in 260 cases (97.4%). 31 (11.9%) cases were 
excluded from multivariable analysis due to absence of data on tumor grade (n=30, 11.5%) or 
grade and stage (n=1, 0.4%). There was no significant difference between the biomarker and 
overall populations in the proportion of cases with grade 3 tumors (18.0% vs. 14.4%, P=0.24) 
or stage III/IV disease (18.6% vs. 18.5%, P=1.0). 
Statistical Analyses
All informative subjects were used for statistical analyses, and subjects in whom data were 
absent were excluded. Baseline clinicopathological and molecular variables were compared 
using Fisher’s exact or Chi-square test for categorical variables, and Student’s t-test for 
continuous variables. Analyses performed in this biomarker study are listed in Table S2 in 
accordance with published guidelines. All statistical tests were two-sided. 
For analysis of clinical outcome, we used multivariable Cox proportional hazards models 
to minimize confounding from prognostic factor imbalance between POLE proofreading-
mutant and wild-type groups in all datasets. For the PORTEC studies, 784 patients had 







guidelines,8,9 for the PORTEC analyses, we first examined the effect of addition of POLE 
proofreading mutation to a Cox model containing all standard prognostic factors for which 
data were available  (Table S3, S4). For the final Cox models reported, variables associated 
with recurrence at a significance level of P<0.1 by univariable analysis (age, non-endometrioid 
histology, grade and lymphovascular invasion) were included in the initial model. With the 
exception of non-endometrioid histology, all four variables retained independent significance 
at P<0.1 following the addition of POLE EDM status to the model and were used for the final 
analyses (Tables S5, S6). For the grade 3 subgroup in PORTEC, and the non-PORTEC series, 
we used the Firth correction10,11 owing to the absence of events in the POLE proofreading-
mutant cohorts. Although we were unable to include myometrial invasion, LVSI and treatment 
in multivariable analyses of the additional series, we confirmed that their omission from the 
‘standardized’ PORTEC Cox models containing all prognostic variables (Tables S3,S4) did not 
significantly alter the estimates of the effect of POLE mutation on either RFS (HR=0.39, 95% 
CI 0.12-1.23 vs. HR=0.46, 95% CI 0.14-1.47, P=0.88) or CSS (HR=0.18, 95% CI 0.03-1.29 vs. 
HR=0.20, 95% CI 0.03-1.46, P=0.93).12 For these analyses, confidence intervals and P-values 
were calculated by the Wald method using the Coxphf function in R (http://www.r-project.
org/). Multivariable-adjusted hazard ratios were pooled by meta-analysis using the metan 
command in Stata. 
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Supplementary Table 1. POLE exon 9 and 13 sequencing PCR primer details.
Target (residues) Primer name Primer sequence Primer used for sequencing
Exon 9 POLE-Ex9Fw 5’- tgcttattttgtccccacag-3’ Forward(268-303) POLE-Ex9Rv 5’- tacttcccagaagccacctg-3’
Exon 13 POLE-Ex13Fw 5’- tctgttctcattctccttccag-3’ Reverse(410-445) POLE-Ex13Rv 5’- cgggatgtggcttacgtg-3’
Supplementary Table 2. Analyses performed and reported in this study.
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Supplementary Table 3. Cox regression model for recurrence-free survival in PORTEC-1 and -2 demonstrating 
effect of addition of POLE proofreading mutation to model of standard prognostic variables.
Variable HR (95% CI) P*
Base model    
   NEEC vs. EEC 1.82 (0.76–4.33) 0.18
   Tumor grade    
      Grade 2 vs. grade 1 2.30 (1.42–3.71) 0.001
      Grade 3 vs. grade 1 3.41 (2.11–5.52) <0.0001
   Myometrial invasion (>50% vs. <50%) 1.48 (0.92–2.37) 0.11
   LVSI (present vs. absent) 2.28 (1.40–3.69) 0.001
   Age (continuous) 1.04 (1.01–1.06) 0.004
   Treatment    
      EBRT vs. NAT 0.61 (0.39–0.95) 0.03
      VBT vs. NAT 0.84 (0.50–1.40) 0.50
Base model with addition of POLE mutation  
   POLE mutation† 0.46 (0.14–1.47) 0.19
*P-value calculated by two-sided Cox proportional hazards test. †POLE proofreading exonuclease domain 
mutations detected from sequencing exons 9 and 13 only (contain  ~80% pathogenic variants)
EEC=endometrioid endometrial cancer, NEEC=non-endometrioid endometrial cancer. LVSI=lymphovascular 
space invasion, EBRT=external beam radiotherapy, VBT=vaginal brachytherapy, NAT= no additional treatment.
Supplementary Table 4. Cox regression model for cancer-specific survival in PORTEC-1 and -2 demonstrating effect 
of addition of POLE proofreading mutation to model of standard prognostic variables.
Variable HR (95% CI) P*
Base model    
   NEEC vs. EEC 1.70 (0.65–4.44) 0.28
   Tumor grade    
      Grade 2 vs. grade 1 2.43 (1.34–4.40) 0.003
      Grade 3 vs. grade 1 5.43 (3.11–9.49) <0.001
   Myometrial invasion (>50% vs. <50%) 1.80 (1.01–3.19) 0.045
   LVSI (present vs. absent) 1.93 (1.08–3.45) 0.03
   Age (continuous) 1.04 (1.01–1.07) 0.02
   Treatment   0.90
      EBRT vs. NAT 1.14 (0.65–1.20) 0.65
      VBT vs. NAT 1.14 (0.59–2.28) 0.70
Base model with addition of POLE mutation  
   POLE mutation† 0.2 (0.03–1.46) 0.11
*P-value calculated by two-sided Cox proportional hazards test. †POLE proofreading exonuclease domain 
mutations detected from sequencing exons 9 and 13 only (contain  ~80% pathogenic variants)
EEC=endometrioid endometrial cancer, NEEC=non-endometrioid endometrial cancer. LVSI= lymphovascular 
space invasion, EBRT= external beam radiotherapy, VBT =vaginal brachytherapy, NAT= no additional treatment.
Supplementary Table 5. Final multivariable Cox models for recurrence-free survival including POLE proofreading 
mutation using all PORTEC cases and limited to endometrioid ECs only.
Variable HR (95% CI) P*
All tumors (n=788)    
   Tumor grade    
      Grade 2 vs. grade 1 2.52 (1.55–4.08) <0.001
      Grade 3 vs. grade 1 3.47 (2.20–5.47) <0.001
   LVSI (present vs. absent) 2.16 (1.32–3.54) 0.002
   Age (continuous) 1.04 (1.01–1.06) 0.003
   POLE mutation 0.43 (0.13–1.37) 0.15
EECs only (n=770)  
   POLE mutation† 0.44 (0.14–1.42) 0.17
*P-value calculated by two-sided Cox proportional hazards test. †POLE proofreading exonuclease domain 
mutations detected from sequencing exons 9 and 13 only (contain  ~80% pathogenic variants)
EEC=endometrioid endometrial cancer, LVSI=lymphovascular space invasion.
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Supplementary Table 6. Final multivariable Cox models for cancer-specific survival including POLE proofreading 
mutation using all PORTEC cases and limited to endometrioid ECs only.
Variable HR (95% CI) P*
All tumors (n=788)    
   Tumor grade    
      Grade 2 vs. grade 1 2.69 (1.47–4.91) <0.001
      Grade 3 vs. grade 1 5.03 (2.97–8.51) <0.001
   LVSI (present vs. absent) 2.10 (1.16–3.78) 0.01
   Age (continuous) 1.04 (1.01–1.08) 0.006
   POLE mutation 0.19 (0.03–1.44) 0.11
EECs only (n=770)    
   POLE mutation† 0.21 (0.03–1.50) 0.12
*P-value calculated by two-sided Cox proportional hazards test. †POLE proofreading exonuclease domain 
mutations detected from sequencing exons 9 and 13 only (contain  ~80% pathogenic variants)
EEC=endometrioid endometrial cancer, LVSI=lymphovascular space invasion.
Supplementary Table 7. POLE proofreading mutations detected in PORTEC-1/2 and additional series.







c.857C>G p.Pro286Arg 31 (3.9) 5 (2.9) 5 (2.2) 8 (3.5)
c.890C>T p.Ser297Phe 2 (0.3) 0 0 1 (0.4)
c.890C>A p.Ser297Tyr 1 (0.1)      
 c.895A>G* p.Met299Va* 0 1 (0.6) 0 0
c.1231G>C/  
c.1231G>T p.Val411Leu 14 (1.8) 3 (1.8) 1 (0.4) 5 (2.2)
c.1270C>A p.Leu424Ile 0 0 0 1 (0.4)
c.1270C>G p.Leu424Val 0 0 0 1 (0.4)
c.1331T>A p.Met444Lys 0 0 0 1 (0.4)
Other (non-exon 9/13) NA NA NA 1 (0.4)
Total 48 (6.1) 9 (5.3) 6 (2.6) 18 (7.9)
*Variant not previously reported affecting residue absolutely conserved in Pol ε orthologues close to hotspot codon 
297 and predicted to be deleterious by mutation assessor (score 2.35) and SIFT (score 0.00). “Other” indicates non-
exon 9/13 variants associated with ultramutation in TCGA analysis. 
Supplementary Table 8. Multivariable Cox model for recurrence-free survival of PORTEC grade 3 tumor subgroup 
including POLE proofreading mutation and standard prognostic variables.
Variable HR (95% CI) P*
All grade 3 tumors (n=109)    
   NEEC vs. EEC 1.96 (0.68–4.81) 0.20
   LVSI (present vs. absent) 1.13 (0.25–2.87) 0.82
   Myometrial invasion (>50% vs. <50%) 1.86 (0.89–3.95) 0.10
   Age (continuous) 1.01 (0.96–1.05) 0.83
   POLE mutation 0.11 (0.001–0.84) 0.03
Grade 3 EECs only (n=97)    
   POLE mutation† 0.12 (0.001–0.87) 0.03
*P-value calculated by two-sided Cox proportional hazards test with Firth correction. †POLE proofreading 
exonuclease domain mutations detected from sequencing exons 9 and 13 only (contain  ~80% pathogenic variants). 








Supplementary Table 9. Multivariable Cox model for cancer-specific survival of PORTEC grade 3 tumor subgroup 
including POLE proofreading mutation and standard prognostic variables. 
Variable HR (95% CI) P*
All grade 3 tumors (n=109)    
   NEEC vs. EEC 1.84 (0.56–4.86) 0.28
   LVSI (present vs. absent) 1.01 (0.27–2.82) 0.98
   Myometrial invasion (>50% vs. <50%) 1.65 (0.75–3.66) 0.21
   Age (continuous) 1.02 (0.97–1.08) 0.42
   POLE mutation 0.14 (0.001–1.01) 0.05
Grade 3 EECs only (n=97)    
   POLE mutation† 0.15 (0.001–1.10) 0.07
*P-value calculated by two-sided Cox proportional hazards test with Firth correction. †POLE proofreading 
exonuclease domain mutations detected from sequencing exons 9 and 13 only (contain  ~80% pathogenic variants). 
NEEC=non-endometrioid endometrial cancer, EEC=endometrioid endometrial cancer, LVSI=lymphovascular 
space invasion.
Supplementary Table 10. Demographic and clinicopathological characteristics of Leuven series according to POLE 
proofreading mutation.
  POLE wild-type POLE mutant* P† 
n=161 (94.7%) n=9 (5.3%)
Age, years      
Median (range) 70 (36–93) 57 (45–81) 0.06
Tumor type      
EEC 103 (64.0) 5 (55.6) 0.75NEEC 58 (36.0) 4 (44.4)
FIGO stage      
I 92 (57.1) 6 (66.7)
0.50II 18 (11.2) 1 (11.1)III 30 (18.6) 0
IV 21 (13.0) 2 (22.2)
Grade      
1 41 (25.5) 2 (22.2)
0.732 32 (19.9) 1 (11.1)
3 88 (54.7) 6 (66.7)
*POLE proofreading exonuclease domain mutations detected from sequencing exons 9 and 13 only contain ~90% 
pathogenic variants). †P-values represent comparison of POLE wild-type and POLE proofreading mutant groups 
calculated by unpaired t-test (age), Fisher’s exact test (tumor type), or χ2 test (other). All statistical tests were two-
sided. EEC=endometrioid endometrial cancer, NEEC=non-endometrioid endometrial cancer.
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Supplementary Table 11. Demographic and clinicopathological characteristics of TCGA series according to POLE 
proofreading mutation.
  POLE wild-type POLE mutant* P†  n=211 (92.1%) n=18 (7.9%)
Age, years      
Median (range) 63 (34-90) 57 (33-87) 0.06
Tumor type      
EEC 170 (80.6) 18 (100) 0.049NEEC 41 (19.4) 0
FIGO stage      
I 156 (73.9) 13 (72.2)
0.74II 11 (5.2) 1 (5.6)III 34 (16.1) 4 (22.2)
IV 10 (4.7) 0
Grade      
1 65 (30.8) 6 (33.3)
0.612 69 (32.4) 4 (22.2)
3 77 (36.5) 8 (44.5)
*POLE proofreading exonuclease domain mutations detected from whole exome sequencing. †P-values represent 
comparison of POLE wild-type and POLE proofreading mutant groups calculated by unpaired t-test (age), Fisher’s 
exact test (tumor type), or χ2 test (other).  All statistical tests were two-sided. EEC=endometrioid endometrial 
cancer, NEEC=non-endometrioid endometrial cancer.
Supplementary Table 12. Demographic and clinicopathological characteristics of Zurich/ Basel series according to 
POLE proofreading mutation.
  POLE wild-type POLE mutant* P†
  n=223 (97.4%) n=6 (2.6%)  
Age, years      
Median (range) 66 (33-88) 57 (52-89) 0.42
Tumor type      
EEC 215 (96.4) 6 (100) 1.0NEEC 8 (3.6) 0
FIGO stage      
I 143 (64.1) 5 (83.3)
0.17II 31 (13.9) 0III 42 (18.8) 0
IV 7 (3.1) 1 (16.7)
Grade      
1 147 (65.9) 2 (33.3)
0.0042 48 (21.5) 0
3 28 (12.6) 4 (66.7)
*POLE proofreading exonuclease domain mutations detected from sequencing exons 9 and 13 only (contain 
~90% pathogenic variants). †P-values represent comparison of POLE wild-type and POLE proofreading mutant 
groups calculated by unpaired t-test (age), Fisher’s exact test (tumor type), or χ2 test (other). EEC=endometrioid 







Supplementary Table 13. Patient outcome according to POLE proofreading mutation in Leuven series.
    Univariable analysis Multivariable analysis*
  Events/total (%) HR 95% CI) P* HR (95% CI) P*
Recurrence          
     POLE wild-type 51/161 (31.6) 0.14 (0.008-2.34) 0.17 0.18 (0.01-3.11) 0.24     POLE mutant 0/9 (0.0)
Cancer specific survival        
     POLE wild-type 30/161 (18.6) 0.24 (0.01–3.10) 0.20 0.66 (0.04-11.39) 0.78     POLE mutant 0/9 (0.0)
Overall survival          
     POLE wild-type 36/161 (22.4) 0.21  (0.01–3.60) 0.28 0.53 (0.03-8.96) 0.66     POLE mutant 0/9 (0.0)
* Calculated using Cox proportional hazards two-sided test. Cox models use all informative cases irrespective of 
histology. Corresponding results from multivariable analyses following omission of POLE-wild-type NEECs from 
models are: RFS – HR=0.18, 95%CI 0.01-3.25, P=0.25; CSS – HR=1.07, 95%CI 0.52-21.95, P=0.97 (multivariable 
analysis of OS not done for EEC subset).
Supplementary Table 14. Patient outcome according to POLE proofreading mutation in the TCGA series.
    Univariable analysis Multivariable analysis
  Events/total (%) HR (95% CI) P* HR (95% CI) P*
Recurrence        
     POLE wild-type 40/211 (19.0) 0.164 (0.0083-2.35) 0.20 0.12 (0.0070-2.11) 0.15     POLE mutant 0/18 (0.0)
Cancer specific survival        
     POLE wild-type NR NR NR  NR  NR     POLE mutant NR
Overall survival        
     POLE wild-type 21/211 (9.9) 0.29 (0.016-5.15) 0.43 0.34 (0.018-6.48)  0.48     POLE mutant 0/18 (0.0)
* Calculated using Cox proportional hazards two-sided test. Cox models use all informative cases irrespective of 
histology. Corresponding results from multivariable analyses following omission of POLE-wild-type NEECs from 
models are: RFS – HR=0.18, 95%CI 0.01-3.08, P=0.24 (multivariable analysis of OS not done for EEC subset). 
NR – not reported.
Supplementary Table 15. Patient outcome according to POLE proofreading mutation in the Zurich/Basel series.
 
  Univariable analysis Multivariable analysis
Events/total (%) HR (95% CI) P* HR (95% CI) P*
Recurrence        
     POLE wild-type NR NA NA NA NA     POLE mutant NR
Cancer specific survival        
     POLE wild-type 24/223 (10.8) 0.73 (0.04-12.70) 0.82 0.21 (0.01-4.26) 0.31     POLE mutant 0/6 (0.0)
Overall survival        
     POLE wild-type 57/223 (25.6) 0.87 (0.17-4.48) 0.86 0.42 (0.08-2.27) 0.31     POLE mutant 0/16 (0.0)
* Calculated using Cox proportional hazards two-sided test with Firth correction. Cox models use all informative 
cases irrespective of histology. Corresponding results from multivariable analyses following omission of POLE-
wild-type NEECs from models are: CSS – HR=0.23, 95%CI 0.01-4.63, P=0.34. NR – not reported. NA – not 
available.
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Supplementary Table 16. Comparison of POLE proofreading-mutant endometrioid endometrial cancers by grade in 
PORTEC studies and additional series.
  POLE proofreading mutant* EECs
  Grade 1/2 Grade 3 P†
  n=48 (%) n=29 (%)  
FIGO stage      
I 44 (91.7) 22 (75.9) 0.14
II 2 (4.1) 2 (6.9)  
III 1 (2.1) 3 (10.3)  
IV 1 (2.1) 2 (6.9)  
Depth of  invasion      
<50% 17 (35.4) 15 (51.7) 0.15
>50% 28 (58.3) 12 (41.4)‡  
Not known 3 (6.3) 2 (6.9)  
LVSI      
No 42 (87.4) 18 (62.1) 0.06
Yes 3 (6.3) 6 (20.7)  
Not known 3 (6.3) 5 (17.2)  
Recurrence      
No 45 (93.8) 29 (100) –
Yes 3 (6.3) 0  
*POLE proofreading exonuclease domain mutations detected from sequencing exons 9 and 13 only in PORTEC, 
Leuven and Zurich/Basel series (contain  ~90% pathogenic variants), and whole exome sequencing in TCGA 
series. †P-values represent comparison of informative grade 3 and grade 1/2 ECs by or χ2 test (stage) and Fisher’s 
exact test (invasion, LVSI). All statistical tests were two-sided. ‡ May underestimate the true frequency of deep 
myometrial invasion in high-grade POLE-mutant tumors due to exclusion of grade 3 ECs with >50% myometrial 
invasion from PORTEC studies. In POLE-mutant ECs from the unselected additional series deep myometrial 
invasion was more common in grade 3 than in grade 1/2 tumors (75% vs. 25%, P=0.04, Fisher’s exact test). 
LVSI=lymphovascular space invasion.
Supplementary Figure 1. Outcome according to POLE proofreading mutation in Leuven series. Probability of 
differential recurrence-free survival (A) and cancer-specific survival (B) according to POLE proofreading mutation 
status are shown. P-values are obtained by log-rank test. All statistical tests were two-sided. 
 A                 B
Number at risk
POLE wild-type   161                25                        2           161                         32            2
POLE-mutant       9                            3                              0              9                  3                            0
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Supplementary Figure 2. Recurrence-free survival according to POLE proofreading mutation in TCGA series. Two-
sided P-value obtained by log-rank test. 
Supplementary Figure 3. Cancer-specific survival according to POLE proofreading mutation in Zurich/Basel series. 
Two-sided P-value obtained by log-rank test.
 
Number at risk
POLE wild-type   221                   26                          2           
POLE-mutant       18                               5                                0           
 
Number at risk
POLE wild-type   223                            81                9
POLE-mutant       6                     2                                0
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Purpose: Recommendations for adjuvant treatment for women with early-stage endometrial 
carcinoma (EC) are based on clinicopathological features. Comprehensive genomic 
characterization defined four subgroups: p53-mutant, microsatellite instability (MSI), POLE-
mutant and no specific molecular profile (NSMP). We aimed to confirm the prognostic 
capacity of these subgroups in large randomized trial populations, investigate potential 
other prognostic classifiers, and integrate these into an integrated molecular risk assessment 
guiding adjuvant therapy.
Experimental design: Analysis of MSI, hotspot mutations in 14 genes including POLE, 
protein expression of p53, ARID1a, β-catenin, L1CAM, PTEN, ER, and PR was undertaken 
on 947 available early-stage endometrioid ECs from the PORTEC-1 and -2 trials, mostly 
high-intermediate risk (n=614). Prognostic value was determined using univariable and 
multivariable Cox proportional hazard models. Areas under the curve of different risk 
stratification models were compared.
Results: Molecular analyses were feasible in >96% of the patients and confirmed the four 
molecular subgroups: p53-mutant (9%), MSI (26%), POLE-mutant (6%), and NSMP (59%). 
Integration of prognostic molecular alterations with established clinicopathological factors 
resulted in a stronger model with improved risk prognostication. Approximately 15% of high-
intermediate risk patients had unfavorable features (substantial LVSI, p53-mutant, and/or 
>10% L1CAM), 50% favorable features (POLE-mutant, NSMP being microsatellite stable and 
CTNNB1-wild type), and 35% intermediate features (MSI or CTNNB1-mutant).
Conclusions: Integrating clinicopathological and molecular factors improves the risk 
assessment of patients with early-stage EC. Assessment of this integrated risk profile is feasible 
in daily practice, and holds promise to reduce both over- and undertreatment.
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Introduction
Endometrial cancer (EC) is the most common gynecological cancer in developed countries.1 
Over 50% of women with EC present with early-stage, low-risk disease, and are treated with 
surgery alone.2 Adjuvant therapy recommendations are based on the individual patient’s 
risk of disease recurrence using clinicopathological factors such as age, stage, histological 
subtype, tumor grade, and lymphovascular space invasion (LVSI).3 EC patients are generally 
stratified in three risk groups; however, various definitions exist.4-6 The PORTEC-1 and -2 
(PostOperative Radiation Therapy for EC) clinical trials have contributed evidence that 
adjuvant radiotherapy can be safely omitted in patients with low-intermediate risk features, 
and that EC patients with high-intermediate risk features can effectively be treated with 
vaginal brachytherapy.4,7 Despite this clinicopathological risk stratification considerable over- 
and undertreatment remains: seven patients with stage I high-intermediate risk EC need 
to receive vaginal brachytherapy to prevent one recurrence, while 8% of patients develop 
distant metastases that may have been prevented or delayed with adjuvant chemotherapy. We 
hypothesized that the clinicopathological risk assessment might be improved by integration 
of molecular biomarkers predictive of individual tumor behavior.
 
Many studies addressing the prognostic significance of molecular alterations in EC have 
focused on one or two biomarkers.8,9 Integrated genomic characterization by The Cancer 
Genome Atlas (TCGA) defined four distinct EC subgroups with possible prognostic value.10 
Using methods broadly available in clinical practice these four subgroups can be easily 
determined by their surrogate markers: p53, microsatellite instability (MSI), and POLE 
resulting in a practically and clinically useful molecular classification tool.11,12 In relatively 
small series of unselected ECs, the combination of both the clinicopathological and molecular 
classification improved the clinicopathological risk assessment.12 At present it is unclear how 
other potential molecular prognosticators, such as mutations in CTNNB1, PIK3CA and 
L1CAM overexpression should be integrated in the suggested TCGA subgroups.
 
The aims of this study were to confirm and validate the prognostic significance of the 
proposed molecular classification tool in early-stage endometrioid ECs (EECs), mainly high-
intermediate risk, from two large randomized trials (PORTEC-1 and -2) with mature long-
term follow-up data and to investigate whether incorporation of other molecular alterations 








Patients and study design
For both PORTEC-1 and -2 trials central pathology review was undertaken, during which 
formalin-fixed paraffin-embedded (FFPE) tumor material was collected. All tumor samples 
with confirmed endometrioid histology were included in the current analysis. The design 
and clinical results of both randomized trials have been published previously.4,7 In brief, 
PORTEC-1 (1990-1997) included 714 patients with stage I EC, grade 1 or 2 with deep 
myometrial invasion, or grade 2 or 3 with superficial invasion. PORTEC-2 (2000-2006) 
included 427 EC patients with high-intermediate risk features: stage I, age >60 years, grade 
1-2 with deep invasion or grade 3 with superficial invasion and stage IIA disease (except grade 
3 with deep invasion). The PORTEC study protocols were approved by the Dutch Cancer 
Society and the medical ethics committees at participating centers. All patients provided 
informed consent. Data on patient and tumor characteristics, including results of pathology 
review and outcome, were obtained from the trial databases. The presence of substantial LVSI, 
diffuse or multifocal LVSI around the tumor, was evaluated and previously reported.13 The 
REMARK criteria were followed, wherever possible, throughout this study.14
Procedures
For immunohistochemical analyses, all slides were evaluated by two investigators and a 
gyneco-pathologist, blinded for patient characteristics and outcome. Evaluations were done 
independently with discrepancies resolved at simultaneous viewing. For DNA analyses, 
tumor DNA was isolated as previously reported.11
p53 expression, MSI, and POLE exonuclease domain mutation status were assessed, as described 
previously, to identify the four molecular EC subgroups.11 In short, immunohistochemical 
expression of p53 (clone DO-7, 1:2000; Neomarkers) was scored positive if >50% of the tumor 
cells showed a strong positive nuclear staining, or when discrete geographical patterns showed 
>50% tumor cell positivity. Tumors in which no p53 staining of the tumor was observed and 
cases with only DNA present (n=119) were sequenced for exon 5-8 TP53 mutations.15 The 
MSI status was determined using the Promega MSI analysis system (version 1.2). Tumors 
with instability in at least two markers were defined as being MSI whereas those showing no 
instability were classified as being stable (MSS). Tumors in which instability at one repeat 
was observed or MSI status could not be determined due to poor DNA quality (n=121) were 
stained manually for the mismatch repair proteins MLH1 (clone ES05, 1:100; DAKO), MSH2 
(clone FE11, 1:200, DAKO), MSH6 (clone EPR3945, 1:800, Genetex), and PMS2 (clone EP51, 
1:75, DAKO).11 Both methodologies, MSI assay and mismatch repair protein expression, are 
highly sensitive methods for the identification of a defective DNA mismatch repair system.16 
Tumors were then considered MSI if tumor cells showed loss of nuclear staining of at least 
one of the mismatch repair proteins, and MSS if tumor cells showed nuclear positivity for 
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all mismatch repair proteins. POLE exonuclease domain hotspot mutations (named POLE 
mutations throughout this paper) were detected by Sanger sequencing of exon 9 and 13. 
KASPar competitive allele specific PCR (LGC Genomics) assays were used to screen for 
POLE variants at codons 286, 297 and 411 in tumors with poor DNA quality (n=98, primer 
sequences are available upon request). Part of these results were previously published.17
To assess mutations in other frequently altered genes in EC, we used the Sequenom MassARRAY 
system and the GynCarta multigene analysis 2.0 (Sequenom) to test for 159 hotspot mutations 
in BRAF, CDKNA2, CTNNB1, FBXW7, FGFR2, FGFR3, FOXL2, HRAS, KRAS, NRAS, 
PIK3CA, PPP2R1A, PTEN as described previously.15 Further immunohistochemical analyses 
were performed for estrogen receptor (ER), progesterone receptor (PR; clone PGR636, 1:200; 
DAKO), PTEN (clone 6H2.1, 1:200; DAKO), β-catenin (clone 14, 1:1600; BD transduction), 
and ARID1a (clone PSG-3, 1:800; Santa Cruz) expression. Immunohistochemical procedures 
were as described previously except for ER expression analysis (clone EP1, DAKO, 1:100, 
Tris-EDTA pH 9.0, 3,3’-diaminobenzidine+).11,15 ER and PR were scored positive when at 
least >10% of tumor cells showed nuclear expression. PTEN, β-catenin, and ARID1a staining 
were evaluated as described previously.11,15 In short, PTEN staining was evaluated in three 
categories as negative, positive and heterogeneous. Activated Wnt-signaling was defined as 
nuclear staining of ß-catenin. ARID1a was scored as negative, weak positive or strong positive 
nuclear staining or as ‘clonal loss’. Previously published results of immunohistochemical 
L1CAM expression (clone 14.10, 1:500; Covance Inc.) on the same patients in this study were 
integrated for analysis.18 Tumors with >10% positive tumor cells were considered L1CAM 
positive.
Statistical analysis 
Associations between clinicopathological features and molecular alterations were tested using 
Chi-square statistics or Fishers exact test in case of categorical and t test or analysis of variance 
(ANOVA) for continuous variables. Time-to-event analyses were calculated from the date of 
randomization to date of recurrence (vaginal and/or pelvic for locoregional recurrence, and 
distant metastases for distant recurrence) or to date of endometrial cancer death (disease 
specific survival) or to date of death (overall survival) or to date of any recurrence or death 
(recurrence-free survival); patients who were alive and without recurrence were censored at 
the date of last follow-up. Survival curves were calculated using the Kaplan–Meier method 
with log-rank test. Cox proportional hazards models were used to evaluate the prognostic 
value of each factor. Factors with P-values <0.10 were included in a multivariable Cox model 
with a stepwise method to include in the final model. In the last step, significant factors from 
the forward selection model (P-values <0.05) were included in a final Cox model together 
with established clinicopathological prognostic factors: age as continuous variable, grade (1-2 
vs. 3), LVSI (substantial vs. none or mild), and adjuvant treatment (vaginal brachytherapy, 







stratification models was quantified using the area under the receiver operating curve with 
95% confidence intervals (CIs). All reported p-values were based on two–sided tests with 
P-values <0.05 considered statistically significant (IBM SPSS 20.0).
Results
In total, 947 (83% of randomized patients) EECs from PORTEC-1 and -2 were available 
(Figure 1). Analysis of classifying alterations (p53, MSI, POLE) was successful in 809/836 
(97%) cases for which sufficient material was available. For 111 PORTEC-cases only FFPE 
slides were available for DNA isolation, which provided 52 (47%) additional successfully 
analyzed cases. Patient, tumor and treatment characteristics did not differ between included, 
excluded and failed cases (Supplementary Table S1). The median follow-up was 131 months 
(range 0.2-219.2 months).
The four molecular subgroups displayed marked differences in clinicopathological 
characteristics, alterations in potential other classifiers, and clinical outcome (Table 1, 
Figure 2, Supplementary Table S2). In total, 834 EECs could be classified in one of the four 
subgroups: 74 (9%) p53-mutant, 219 (26%) MSI, 49 (6%) POLE-mutant, and 492 (59%) 
NSMP. Twenty-seven (3%) tumors were found to have more than one classifying alteration 
(p53, MSI or POLE). p53-mutant tumors were significantly associated with grade 3, loss of 
hormone receptors, >10% L1CAM expression, PPP2R1a, and FBXW7 mutations. MSI tumors 
presented more frequently with substantial LVSI, and abnormal ARID1a expression. POLE 
mutations occurred more frequently in younger women, grade 3, and often co-occurred with 
PTEN mutations. In contrast, the NSMP tumors were more frequently grade 1, and CTNNB1 
mutant. The prognosis was unfavorable in the p53-mutant group, intermediate in the MSI and 
NSMP group, and the POLE-mutant group had a favorable prognosis with no local and only 
 
Classified in molecular subgroups (n=834)
Excluded
• 30 (3%) NEECs
• 164 (14%) EECs no material available
Available FFPE material (n=947, EECs)
• 836 FFPE blocks, 111 FFPE slides Failed analysis of molecular classifier(s)
• 27 (3%) FFPE blocks
• 59 (53%) FFPE slides (DNA only)*
Successful analysis of molecular classifiers
• 809 FFPE blocks, 52 FFPE slides (n=861)
Multiple classifying alterations (n=27)
Trial population (n=1141)
• PORTEC-1: 714 patients randomized
• PORTEC-2: 427 patients randomized
Figure 1. Flow chart of sample analyses. *The majority of cases with incomplete analysis were PORTEC-1 cases from 
which only FFPE tumor slides were available EEC= endometrioid endometrial cancer; NEEC=non-endometrioid 
endometrial cancer.
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two distant recurrences (Figure 2). In addition, women with a POLE- and p53-mutant tumor 
developed no recurrences (0/7), whereas some of the women with MSI tumors with POLE 
(2/6) or p53 mutation (2/13), or both (1/1) developed recurrences (Supplementary Table S3). 
Within the four subgroups, distant recurrence and endometrial cancer-related death rates 
were similar.
Table 1. Clinicopathological characteristics and alterations in potential other molecular classifiers according to the 
four molecular subgroups in early-stage endometrial cancer (n=834).








NSMP          
n=492 (59.0%) P-value
Age, years            
Mean (range) 68 (41-90) 69 (51-86) 69 (43-89) 62 (46-81) 68 (41-90) 0.000
< 60 138 (16.5) 7 (9.5) 35 (16.0) 19 (38.8) 77 (15.7)
0.00160-70 360 (43.2) 32 (43.2) 89 (40.6) 18 (36.7) 221 (44.9)
> 70 336 (40.3) 35 (47.3) 95 (42.4) 12 (24.5) 194 (39.4)
Grade            
1-2 724 (86.8) 48 (64.9) 135 (83.6) 33 (73.4) 457 (92.9) 0.0003 110 (13.2) 26 (35.1) 36 (16.4) 13 (26.6) 35 (7.1)
Myometrial invasion           
<50% 251 (30.1) 35 (47.3) 71 (32.4) 25 (51.0) 120 (24.4) 0.000>50% 583 (69.9) 39 (52.7) 148 (67.6) 24 (49.0) 372 (75.6)
LVSI*            
Absent/Focal 784 (95.5) 70 (94.6) 194 (91.1) 47 (100) 473 (97.1) 0.002Substantial 37 (4.5) 4 (5.4) 19 (8.9) 0 14 (2.9)
Risk group            
Low 242 (29.0) 22 (29.7) 62 (28.3) 24 (49.0) 134 (27.2)
0.013High-intermediate 546 (65.5) 44 (59.5) 143 (65.3) 23 (46.9) 336 (68.3)
High 46 (5.5) 8 (10.8) 14 (6.4) 2 (4.1) 22 (4.5)
Treatment            
NAT 241 (28.9) 17 (23.0) 63 (28.8) 16 (32.7) 145 (29.5)
0.688EBRT 409 (49.0) 38 (51.3) 113 (51.6) 25 (51.0) 233 (47.4)
VBT 184 (22.1) 19 (25.7) 43 (19.6) 8 (16.3) 114 (23.1)
Mutations**          
CDKN2A 2 (0.2) 0 0 0 2 (0.4) 0.707
CTNNB1 157 (19.5) 5 (7.0) 19 (9.0) 8 (17.0) 125 (26.3) 0.000
FBXW7 40 (5.0) 8 (11.3) 13 (6.1) 1 (2.1) 18 (3.8) 0.032
FGFR2 80 (9.9) 2 (2.8) 20 (9.4) 0 58 (12.2) 0.007
KRAS 139 (17.3) 7 (9.9) 43 (20.3) 3 (6.4) 86 (18.1) 0.042
NRAS 25 (3.1) 1 (1.4) 8 (3.8) 0 16 (3.4) 0.456
PIK3CA 261 (32.4) 17 (23.9) 70 (33.0) 24 (51.1) 150 (31.6) 0.019
PPP2R1a 39 (4.8) 12 (16.9) 6 (2.8) 1 (2.1) 20 (4.2) 0.000
PTEN 349 (43.4) 15 (21.1) 106 (50.0) 34 (72.3) 194 (40.8) 0.000
Altered protein expression***          
>10% L1CAM 44 (5.6) 27 (39.7) 5 (2.4) 1 (2.6) 16 (3.4) 0.000
<10% ER 38 (5.0) 16 (24.2) 5 (2.5) 4 (10.5) 13 (2.8) 0.000
<10% PR 81 (10.6) 25 (39.1) 19 (9.4) 9 (23.7) 28 (6.1) 0.000
loss/clonal ARID1a 329 (45.4) 17 (27) 123 (63.7) 13 (35.1) 176 (40.8) 0.000
loss/hetero. PTEN 395 (51.5) 28 (43.1) 130 (64.4) 19 (48.7) 218 (47.3) 0.000
nuclear β-catenin 184 (23.6) 7 (10.6) 34 (16.3) 3 (7.7) 140 (30.1) 0.000
* Degree of LVSI unknown for 13  (1.6%) cases. ** Mutation analysis failed for 29  (3.5%) cases. ***Immunohistochemical 
analysis failed, or no available FFPE slides for 111 (13%) ARID1a, 56 (6.7%) β-catenin, 73 (9%) ER, 68 (8%) PTEN, 73 
(9%) PR. LVSI=lymphovascular space invasion, NAT=no additional treatment, EBRT=external beam radiotherapy, 







C                 D
A                 B
Figure 2. Survival analyses of molecular subgroups in early-stage endometrial cancer (n=834). A) Rate of locoregional 
recurrences, B) rate of distant recurrences, C) disease specific survival, and D) overall survival.
The prognostic value of the molecular subgroups and additional molecular alterations was 
evaluated in univariable analysis and multivariable analysis with the clinicopathological 
factors (age, grade, depth of myometrial invasion, LVSI) and treatment, both in the whole 
population (Supplementary Table S4) and in an analysis restricted to cases with high-
intermediate risk features (Table 2-univariable analysis, Table 3-multivariable analysis). In 
both analyses, p53-mutant and substantial LVSI were the strongest prognostic factors for 
locoregional-, distant recurrence, and overall survival, while >10% L1CAM expression was 
prognostic for distant recurrence and overall survival. After excluding cases with favorable 
(POLE-mutant) and unfavorable factors (substantial LVSI, p53-mutant and >10% L1CAM), a 
final analysis found MSI prognostic for distant recurrence and overall survival, and CTNNB1 
exon 3 mutation status prognostic for distant recurrence (Table 3, Supplementary Table S4). 
Univariable prognostic factors, FGFR2 mutation and loss of hormone receptor expression, 
lost its significance in multivariable analysis in the presence of other (un)favorable prognostic 
factors. Univariable analysis in 242 ECs with low-risk features showed a higher rate of 
locoregional and distant recurrences and lower overall survival in the eight patients with 
>10% L1CAM, and a trend for p53-mutant patients (Supplementary Table S5).
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Table 2. Univariable analysis of clinicopathological characteristics, molecular subgroups, and potential other 
molecular classifiers in high-intermediate risk early-stage endometrial cancer (n=546).
    Locoregional Recurrence Distant Recurrence Overall Survival
      42 events     50 events     182 events  
  Total n HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Age (cont.) 546 1.035 0.988-1.085 0.145 1.015 0.972-1.060 0.508 1.085 1.062-1.110 0.000
Grade                    
1-2 492 1     1     1    
3 54 1.784 0.751-4.239 0.190 3.038 1.552-5.945 0.001 1.741 1.149-2.639 0.009
Myometrial invasion                  
<50 62 1     1     1    
>50 484 0.539 0.239-1.216 0.137 0.304 0.161-0.574 0.000 0.586 0.392-0.877 0.009
LVSI                    
Absent/mild 507 1     1     1    
Substantial 28 3.733 1.567-8.891 0.003 4.895 2.368-10.121 0.000 2.791 1.668-4.432 0.000
Given treatment                    
NAT 113 1     1     1    
EBRT 276 0.311 0.150-0.642 0.002 0.873 0.425-1.796 0.713 0.833 0.595-1.167 0.289
VBT 157 0.546 0.257-1.157 0.114 1.108 0.511-2.401 0.796 0.745 0.480-1.157 0.190
Molecular subgroup                  
NSMP 336 1     1     1    
p53 44 6.787 3.069-15.012 0.000 11.083 5.629-21.821 0.000 4.861 3.098-7.073 0.000
MSI 143 2.476 1.182-4.776 0.015 2.220 1.180-4.447 0.025 1.853 1.329-2.584 0.000
POLE 23 - - 0.970 0.869 0.116-6.532 0.891 0.907 0.367-2.237 0.832
CTNNB1                    
No mutation 433 1     1     1    
Mutation 101 0.575 0.225-1.467 0.247 0.934 0.453-1.929 0.854 0.669 0.438-1.023 0.063
FBXW7                    
No mutation 512 1     1      1    
Mutation 22 0.666 0.091-4.848 0.688 0.530 0.073-3.847 0.531 1.569 0.827-2.977 0.168
FGFR2                    
No mutation 468 1     1      1    
Mutation 66 0.746 0.256-2.095 0.578 0.296 0.072-1.219 0.092 0.556 0.316-0.979 0.042
KRAS                    
No mutation 453 1     1      1    
Mutation 81 0.998 0.419-2.379 0.997 1.322 0.639-2.734 0.452 1.035 0.686-1.561 0.871
NRAS                    
No mutation 519 1     1      1    
Mutation 15 - - 0.430 - - 0.398 0.635 0.231-1.690 0.354
PIK3CA                    
No mutation 358 1     1      1    
Mutation 176 0.572 0.272-1.201 0.140 0.814 0.436-1.516 0.516 0.921 0.668-1.271 0.618
PPP2R1A                    
No mutation 504 1     1      1    
Mutation 30 1.599 0.492-5.203 0.435 2.128 0.842-5.375 0.110 1.640 0.932-2.888 0.086
PTEN                    
No mutation 305  1     1       1    
Mutation 229 0.908 0.484-1.702 0.763 0.517 0.277-0.965 0.038 0.797 0.588-1.080 0.144
L1CAM                    
<10% 496  1      1      1    
>10% 30 3.283 1.283-8.404 0.013 7.718 3.993-14.917 0.000 3.763 2.379-5.953 0.000
ER                    
>10% 499 1       1      1    
<10% 21 3.547 1.259-9.993 0.017 6.194 2.882-13.310 0.000 2.139 1.183-3.865 0.012
PR                    
>10% 465  1      1     1     
<10% 51 2.828 1.297-6.165 0.009 5.684 3.042-10.622 0.000 2.096 1.379-3.188 0.001
ARID1a                    
Positive 249  1     1       1    
Loss/clonal 228 0.792 0.423-1.483 0.467 0.827 0.455-1.503 0.533 0.878 0.643-1.200 0.415
PTEN                    
Positive 232  1      1      1    
Loss/hetero. 283 0.979 0.529-1.812 0.946 0.988 0.553-1.765 0.967 1.043 0.769-1.414 0.788
β-catenin                    
Membrane 399 1       1      1    








Table 3. Multivariable analysis on the prognostic role of the clinicopathological characteristics, molecular subgroups, 
and potential other molecular classifiers in high- intermediate risk (HIR) endometrial cancers (EC) (n=546) and in a 
subset of HIR EC without substantial LVSI, >10% L1CAM, p53 and POLE mutation (n=443).
All cases of HIR EC (n=546)
  Locoregional Recurrence Distant Recurrence Overall Survival
    41 events     46 events     170 events  
  HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Age (Cont.) 1.032 0.984-1.081 0.197 1.016 0.972-1.062 0.469 1.076 1.051-1.101 0.000
Grade                  
1-2 1     1     1    
3 0.203 0.021-1.946 0.167 0.162 0.029-0.904 0.038 0.262 0.057-1.204 0.085
Myometrial invasion                
<50% 1     1     1    
>50% 0.201 0.024-1.678 0.138 0.126 0.026-0.624 0.011 0.254 0.058-1.101 0.067
LVSI                  
Absent/mild 1     1     1    
Substantial 3.190 1.301-7.821 0.011 4.303 1.833-10.09 0.001 2.637 1.542-4.509 0.000
Treatment                  
NAT 1     1     1    
EBRT 0.277 0.133-0.574 0.001 1.154 0.498-2.677 0.738 0.897 0.623-1.292 0.559
VBT 0.466 0.212-1.027 0.058 1.134 0.465-2.769 0.782 0.707 0.445-1.123 0.142
Molecular subgroup                
NSMP 1     1     1    
p53 7.340 3.168-17.00 0.000 5.766 2.400-13.85 0.000 3.777 2.364-6.037 0.000
MSI 2.319 1.105-4.866 0.026 2.154 1.022-4.540 0.044 1.879 1.307-2.700 0.001
POLE - - 0.973 0.883 0.113-6.890 0.906 1.105 0.394-3.101 0.850
L1CAM                  
<10%       1     1    
>10%       4.303 1.833-10.09 0.001 2.462 1.453-4.170 0.001
HIR EC without substantial LVSI, >10% L1CAM, p53 and POLE mutation (n=443)
  Locoregional Recurrence Distant Recurrence Overall Survival
    27 events     23 events     127 events  
  HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Age (Cont.) 1.063 1.000-1.130 0.052 1.007 0.944-1.074 0.837 1.102 1.070-1.134 0.000
Grade                  
1-2 1     1     1    
3 0.060 0.004-0.842 0.037 0.350 0.033-3.765 0.387 0.409 0.050-3.381 0.407
Myometrial invasion                
<50% 1     1     1    
>50% 0.076 0.009-0.668 0.020 0.099 0.011-0.859 0.036 0.277 0.037-2.070 0.211
Treatment                  
NAT 1     1     1    
EBRT 0.249 0.106-0.585 0.001 0.862 0.329-2.262 0.764 0.806 0.541-1.201 0.289
VBT 0.181 0.054-0.605 0.005 0.511 0.139-1.877 0.312 0.559 0.312-1.003 0.051
Molecular subgroup                 
NSMP 1     1     1    
MSI 1.816 0.815-4.048 0.145 2.520 1.049-6.051 0.039 1.672 1.146-2.438 0.008
CTNNB1                  
No mutation       1          
Mutation       2.959 1.234-7.098 0.015      
Cont.=continuous.
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Figure 3. Molecular integrated risk assessment. A) Flow chart of the molecular integrated risk model. B) Area 
under the curve for the clinical- and molecular-, and molecular integrated risk assessment, with and without 
central pathology review (*P-value<0.05, **P-value<0.01). C) Recurrence-free survival of clinical risk assessment 
in early-stage endometrial cancer (n=834, P-value<0.001). D) Bar chart of the proportion of clinically low-, high-
intermediate-, and high-risk patients based on central pathology review (left) and the proportion of clinically 
high-intermediate risk patients reclassified into favorable, intermediate and unfavorable molecular integrated risk 
groups. E) Recurrence-free survival of molecular integrated risk assessment in early-stage high-intermediate risk 
endometrial cancer (n=546, P-value<0.001). 
Based on the outcomes of multivariable analysis a molecular integrated risk assessment was 
defined that combines clinicopathological and molecular risk factors (Figure 3A). Substantial 
LVSI, p53-mutant and >10% L1CAM tumors were designated unfavorable, while in the 
remaining cases both MSI and CTNNB1 mutant were distinguished from the favorable group 
of POLE-mutant tumors and NSMP tumors being MSS and CTNNB1 wild type (Figure 
3A). Since PORTEC-1 included patients that are currently considered low risk, and central 
pathology review in both trials identified additional low- and high-risk cases, the area under 
the curve (AUC) was estimated for the molecular integrated risk assessment taking these 
different starting points into account (Figure 3B-C). Compared to the original pathology 
reports, central pathology review or molecular classification improved the AUC. However, 
AUCs of the integrated molecular risk assessment showed a substantial improvement, without 
additional improvement when using findings of central pathology review. Approximately 
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features leaving 35% intermediate (Figure 3D-E). In tumors with unfavorable features, 
targetable alterations were found: 65% PI3K/AKT alterations, 9% FBXW7 mutations, 7% 
FGFR2 mutations, 28% L1CAM positivity 78% ER positivity, and 61% PR positivity.
Discussion
In 834 early-stage EECs from two randomized trials (PORTEC-1 and -2) with mature 
long-term follow-up, the prognostic impact of the four molecular subgroups, originally 
proposed by the TCGA, was confirmed.10 Clinically applicable molecular analysis methods 
for surrogate markers were used and proved feasible in >96% of EEC patients. Integration 
of prognostic molecular alterations with established clinicopathological factors results in a 
stronger risk assessment. As a consequence, within the high- intermediate risk population, 
who are currently thought to be relatively homogenous with regard to clinical outcomes, 
approximately 15% patients with a marked unfavorable and 50% with a favorable prognosis 
could be identified.
L1CAM, p53, and LVSI were consistent independent prognostic factors for distant recurrence, 
overall and disease specific survival. p53-mutant tumors exhibit a high degree of genomic 
instability linked to tumor progression, and invasion by upregulation of p53-mutant target 
genes, and TP53 mutation is well known for its prognostic impact in EC.8,10 LVSI, especially 
when quantified as substantial, and L1CAM have similar strong negative prognostic value. 
LVSI strongly increases the risk of tumor spread via lymphatics and capillaries. L1CAM is 
known to enhance motility and migration of tumor cells. Both were recently published in this 
same population as single risk factors13,18 and by Zeimet et al.19, but were now confirmed to 
be independent prognostic factors in an integrated analysis. In contrast, patients with POLE-
mutant or MSS and CTNNB1 wild type tumors displayed a more favorable prognosis. The 
favorable outcome of POLE-mutant ECs with their striking mutation burden may be explained 
by an increased immunogenicity, and became evident in EC recently.20,21 CTNNB1 mutations 
result in activation of Wnt signalling contributing to tumor progression, abnormal expression 
of cell proliferation, and progression genes. Similarly to our results, a previous report showed 
that ECs carrying a CTNNB1 mutation characterize a more aggressive subset within low-
grade early-stage EEC.10,22 The prognostic importance of MSI has been controversial, although 
the strongest association with poor clinical outcome has been observed in early-stage EC 
similar to our observation.23 This report integrates a large number of single prognostic factors 
in the context of clinical trial material resulting in a comprehensive overview.
In this large cohort, only few (3%) tumors had multiple classifying alterations (e.g. POLE and 
MSI). Classification of this small subset would require further analyses, such as mutational 
load and copy-number status. Supek et al. reported that colorectal and stomach tumors 
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with both MSI and POLE mutation had an overall mutational load similar to MSI tumors, 
whereas two out of three MSI/POLE endometrial tumors had a much higher mutational 
load and different mutational signature.24 Furthermore, Shinbrot et al. showed that the 
TP53 gene is frequently affected by POLE mutation induced strand-specific mutations.25 
These data support that mutational load, mutation signature, and pattern may be useful for 
molecular classification of rare tumors that present with combinations of MSI, POLE, or 
TP53 mutations. With the advent of next generation sequencing technologies, these can be 
easily analyzed.
Several molecular alterations, such as hormone receptor expression, CTNNB1 and FGFR2 
mutations, have been previously reported as having prognostic potential in single biomarker 
studies.8,9,13,19,22,26,27 Some univariable factors, FGFR2 mutation and hormone receptor status, 
lost significance in multivariable analysis. This may be due to the fact that FGFR2 mutations 
were equally frequent in MSI and NSMP ECs, and that hormone receptor loss was mainly 
found in p53-mutant and L1CAM positive ECs but was also frequently observed in POLE-
mutant ECs.10,26-28 MSI, p53 and L1CAM proved stronger independent prognosticators in 
this analysis. CTNNB1 mutation status was sufficiently strong to emerge in multivariable 
analysis, stressing its independent prognostic significance. Using this combined approach, 
an improved risk assessment resulted in which POLE, L1CAM, MSI and CTNNB1 are 
integrated with histopathological factors.
Previous studies have shown improved risk stratification obtained by central pathology 
review.29,30 The reviewed pathology in our analyses had the advantage to exclude prototypical 
non-endometrioid cancers. With regard to grading, lack of prognostic relevance of grade 
2 was shown, advocating the use of a two-tiered grading system, as was also proposed by 
others.31-33 The increased AUC of the model based on central pathology review as compared 
to the original inclusion pathology confirms these findings. The molecular integrated risk 
model showed an even higher increase in AUC; however, central pathology review did not 
add any additional value to the molecular integrated risk model. The molecular integrated 
risk model has three major advantages. Firstly, it is based on more objective variables, such 
as mutational status of POLE. Secondly, the molecular integrated risk model identifies 
significantly more patients with favorable features that would otherwise be classified as 
high-intermediate risk with central pathology review alone. Finally, this approach has also 
the advantage to facilitate pre-screening for Lynch syndrome.
Despite the strength of a randomized trial population, mature long-term follow-up, large group 
of early-stage EEC, and straightforward molecular analysis, this study has some limitations. 
Our focused and practical approach provides analyses that can easily be implemented in 
prospective studies and clinical practice. Most common hotspot mutations were analyzed 







been missed. Although, molecular alterations were highly concordant between curettage and 
hysterectomy specimen,15,17,18 intratumor heterogeneity may interfere with prediction of the 
patient’s prognosis and requires further study. LVSI and the classic-histopathology, included 
in the integrated risk model, cannot be evaluated on preoperative specimen, therefore, it is 
recommended not to rely on preoperative specimens. No automated immunohisto-chemical 
protocols were used, while it is likely that robust, standardized automated staining procedures 
are the preferred method in diagnostic pathology. Molecular alterations in our integrated 
risk model have been proven in single biomarker studies; however, this integrated risk model 
needs to be validated or prospectively analyzed. Since the majority of our patient cohort has 
received adjuvant radiotherapy, the decision to omit adjuvant radiotherapy especially in the 
favorable subgroup remains to be elucidated in a prospective study. There is also need to 
further investigate whether certain molecular defined subgroups of EC may be more sensitive 
to radiotherapy. Nevertheless, we believe our data is unique and informative for patient’s 
outcome, and may guide molecular-based trials and therapies for EC.
The proposed molecular integrated risk model outperforms the current clinicopathologic 
approach; therefore, the question arises whether this integrated model can be used for new 
clinical studies and guide treatment decisions. Especially in high-intermediate EC, this risk 
model may substantially reduce overtreatment of favorable cases, and select unfavorable cases 
who might need more intensive treatment. The clinical utility for tailoring adjuvant therapy, 
the feasibility of determining the molecular integrated profile within tight time limits and 
the cost-effectiveness aspects of this approach (e.g. costs of molecular testing vs. saving costs 
of adjuvant radiotherapy) will be prospectively established in a planned prospective trial 
PORTEC-4. Within ~10% of low-risk patients, p53 and L1CAM seem prognostic indicators 
for high recurrence rate and impaired survival, which is in line with Talhouk et al.12 However, 
the small number of events in this subgroup limits these findings. Factors that are associated 
with favorable outcome or predict chemotherapy response in high-risk EC remain to be 
elucidated in future studies.
In conclusion, integration of molecular risk factors with clinicopathological factors in early-
stage EC leads to improved risk stratification with potential clinical utility. This molecular 
integrated risk prediction holds promise to reduce both over- and undertreatment and should 
form the basis for future prospective clinical studies.
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Supplementary Table 1. Clinicopathological characteristics of the PORTEC-1 and -2 trial populations: comparison of 
cases included in the current analysis and those excluded for lack of material (n=164), non-endometrioid histology 
(n=30) or failed molecular analysis (n=86).
  PORTEC-1   PORTEC-2  
  Included Excluded   Included Excluded  
  n=477 n=237 P-value n=384 n=43 P-value
Age, years            
Mean (range) 66 (41-90) 66 (43-88) 0.387 70 (52-89) 70 (46-85) 0.471
< 60 131 (27.5) 69 (29.1)   14 (3.6) 2 (4.7)
0.58560-70 179 (37.5) 92 (38.8) 0.731 190 (49.5) 18 (41.9)
> 70 167 (35.0) 76 (32.1)   180 (46.9) 23 (53.4)
Grade            
1-2 400 (83.9) 201 (84.8) 0.743 345 (89.8) 29 (67.4) 0.000 0.212**3 77 (16.1) 36 (15.2) 39 (10.2) 13 (30.2)
Myometrial invasion            
<50% 198 (41.5) 96 (40.5) 0.798 61 (15.9) 10 (23.3) 0.379>50% 279 (58.5) 141 (59.5) 323 (84.1) 33 (76.7)
LVSI*            
Absent/Focal 452 (95.6) 125 (95.4) 0.945 356 (94.9) 29 (96.7) 0.701Substantial 21 (4.4) 6 (4.6) 19 (5.1) 1 (3.3)
Risk group            
Low 216 (45.3) 106 (44.7)   36 (9.3) 2 (4.7) 0.000 
0.339**High-intermediate 234 (49.1) 112 (47.3) 0.477 327 (85.2) 28 (65.1)High 27 (5.7) 19 (8.0)   21 (5.5) 13 (30.2)
Treatment            
NAT 246 (51.6) 123 (51.9)   2 (0.5) 1 (2.3)
0.727EBRT 231 (48.4) 114 (48.1) 0.934 190 (49.5) 19 (44.2)
VBT 0 0   192 (50.0) 23 (53.5)
LVSI=lymphovascular space invasion, NAT=no additional treatment, EBRT=external beam radiotherapy, VBT=vaginal 
brachytherapy. *Degree of LVSI unknown for 13 included cases, and 119 excluded cases. **Endometrioid EC only.




  p53-mutant MSI POLE-mutant NSMP Total
  n=74 n=219 n=49 n=492 n=834 
PTEN¹ (%) 15 (20) 105 (48) 34 (69) 195 (40) 349 (43)
p.R130G 5 24 3 75 107/790
p.R130fs*4 6 18 19 45 88/801
p.R233* 3 14 0 22 39/799
p.L318fs*2 2 11 0 17 30/796
p.R130* 2 7 0 11 20/790
p.T321fs*3 0 10 0 7 17/786
p.N323fs*2 0 10 0 7 17/791
p.K267fs*9 0 13 0 1 14/827
p.R173C 0 1 8 5 14/805
p.E7* 0 0 8 2 10/802
p.R130P 0 2 0 8 10/800
p.K267fs*31 0 5 0 4 9/798
p.R130L 0 2 0 6 8/800
p.R173H 0 2 3 3 8/801
p.K6fs*4 0 1 1 2 4/801
p.Q214* 0 1 0 3 4/798
p.R234W 0 2 0 2 4/787
p.248fs*5 0 2 0 2 4/801
p.R355* 0 1 0 3 4/803
p.V290fs*1 0 3 0 0 3/800
p.T321fs*23 0 1 0 1 2/797
p.N323fs*21 0 1 0 1 2/826
PIK3CA¹ (%) 17 (23) 69 (32) 24 (49) 151 (31) 261 (32)
p.R88Q 6 24 13 30 73/789
p.H1047R 4 13 0 34 51/800
p.E545K 3 5 0 27 35/800
p.E542K 0 5 2 15 22/809
p.M1043I 0 1 5 11 17/794
p.Y1021C 1 4 4 4 13/825
p.H1047Y 1 9 0 2 12/807
p.Q546K 1 5 0 5 11/804
p.Q546R 0 2 0 9 11/782
p.E545A 1 2 1 6 10/791
p.T1025A 0 2 4 3 9/785
p.H1047L 0 1 0 7 8/800
p.M1043V 0 1 0 4 5/805
p.E545G 0 1 0 3 4/791
p.Q546L 0 0 0 2 2/782
p.Q546P 0 0 0 2 2/782
p.E545D 0 0 0 1 1/793
p.Q546E 0 1 0 0 1/804
CTNNB1¹ (%) 5 (7) 18 (8) 8 (16) 126 (26) 157 (20)
p.S37T 2 1 1 34 38/804
p.S45F 0 0 1 11 12/801
p.S33F 0 1 0 10 11/796
p.T41I 0 2 1 8 11/796
p.D32N 0 2 1 6 9/801
p.S33Y 0 1 1 7 9/796
p.G34R 1 4 0 4 9/828
p.T41A 1 1 0 7 9/814
p.D32Y 0 0 0 8 8/801
p.G34E 0 3 2 3 8/793
p.S45P 0 1 0 6 7/805
p.S37C 1 0 0 5 6/804
p.S33C 0 0 0 5 5/796
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Supplementary Table 2 continued.
  p53-mutant MSI POLE-mutant NSMP Total
  n=74 n=219 n=49 n=492 n=834 
p.D32G 0 0 0 4  4/826
p.S33P 0 1 0 3  4/814
p.T41I 0 2 1 8 11/796
p.D32N 0 2 1 6 9/801
p.S33Y 0 1 1 7 9/796
p.G34R 1 4 0 4 9/828
p.T41A 1 1 0 7 9/814
p.D32Y 0 0 0 8 8/801
p.G34E 0 3 2 3 8/793
p.S45P 0 1 0 6 7/805
p.S37C 1 0 0 5 6/804
p.S33C 0 0 0 5 5/796
p.D32G 0 0 0 4 4/826
p.S33P 0 1 0 3 4/814
p.G34V 0 0 0 3 3/793
p.D32H 0 0 0 2 2/801
p.D32V 0 0 0 2 2/826
p.S33A 0 1 0 1 2/814
p.S37P 0 0 0 2 2/804
p.S45Y 1 0 1 0 2/801
p.S37A 0 0 0 1 1/804
p.S37Y 0 0 0 1 1/804
p.S45C 0 0 0 1 1/801
KRAS¹ (%) 7 (9) 43 (20) 3 (6) 86 (17) 139 (17)
p.G12D 2 14 1 28 45/795
p.G12V 3 10 1 23 37/795
p.G13D 1 13 1 12 27/801
p.G12A 0 4 0 10 14/795
p.G12C 1 1 0 8 10/795
p.G12S 0 0 0 3 3/795
p.G13S 0 0 0 2 2/775
p.Q61H(G) 0 1 0 1 2/791
p.G13C 0 0 0 1 1/775
p.G13R 1 0 0 0 1/775
p.Q61L 0 0 0 0 1/784
FGFR2¹ (%) 2 (3) 19 (9) 0 (0) 59 (12) 80 (10)
p.S252W 1 12 0 34 47/798
p.N549K 1 1 0 15 17/795
p.K659E 0 2 0 7 9/803
p.C382R 0 4 0 2 6/805
p.Y375C 0 2 0 1 3/806
POLE (%) 0 (0) 0 (0) 49 (100) 0 (0) 49 (6)
p.P286R 0 0 32 0 32/834
p.V411L 0 0 14 0 14/834
p.S297F 0 0 3 0 3/834
FBXW7¹ (%) 8 (11) 13 (6) 1 (2) 18 (4) 40 (5)
p.R465H 2 6 0 9 17/825
p.R505C 4 3 0 5 12/799
p.R479Q 2 3 1 1 7/803
p.R465C 1 1 0 3 5/813







Supplementary Table 2 continued.
  p53-mutant MSI POLE-mutant NSMP Total
  n=74 n=219 n=49 n=492 n=834 
PPP2R1A¹ (%) 12 (16) 6 (3) 1 (2) 20 (4) 39 (5)
p.R183W 1 1 0 14 16/783
p.S256F 3 0 0 3 6/778
p.P179L 4 0 0 1 5/807
p.R183Q 0 2 1 2 5/779
p.R258H 0 3 0 1 4/784
p.S256Y 3 0 0 0 3/778
p.P179R 1 0 0 0 1/807
NRAS (%) 1 (1) 8 (4) 0 (0) 16 (3) 25 (3)
p.Q61L 1 3 0 2 6/800
p.Q61R 0 0 0 5 5/800
p.G12D 0 2 0 2 4/828
p.G12S 0 1 0 3 4/806
p.Q61K 0 0 0 2 2/811
p.G12A 0 0 0 1 1/828
p.G12C 0 1 0 0 1/806
p.G12V 0 1 0 0 1/828
p.G13R 0 0 0 1 1/788
CDKN2A (%) 0 (0) 0 (0) 0 (0) 2 (<1) 2 (<1)
p.R80* 0 0 0 1 1/805
p.D108A 0 0 0 1 1/799
BRAF (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
FGFR3 (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
FOXL2 (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
HRAS (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
¹ Some tumors had multiple mutations in one gene. Frequencies presented as n (%), where n represents the number 
of samples showing the mutation. Analyzed hot spot mutations which were not detected are not shown. 
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Supplementary Table 3. Clinicopathological characteristics, additional mutations and protein expression alterations 
in tumors with multiple classifying alterations.
  p53 & MSI p53 & POLE MSI & POLE p53 & MSI & POLE
  n=13 n=7 n=6 n=1
Age, years        
Mean (range) 64 (52-73) 62 (49-76) 70 (61-79) 74 (-)
< 60 3 (23.1) 4 (57.1) 0 0
60-70 6 (46.1) 0 3 (50.0) 0
 70 4 (30.8) 3 (42.9) 3 (50.0) 1
Grade        
1-2 10 (76.9) 5 (71.4) 5 (83.3) 1
3 3 (23.1) 2 (28.6) 1 (16.7) 0
Myometrial invasion        
<50% 6 (46.1) 2 (28.6) 0 0
>50% 7 (53.9) 5 (71.4) 6 (100) 1
LVSI        
Absent 12 (92.3) 7 (100) 4 (66.7) 1
Substantial 1 (7.7) 0 2 (33.3) 0
Risk group        
Low 6 (46.1) 4 (57.1) 0 0
High-intermediate 6 (46.1) 3 (42.9) 5 (83.3) 1
High 1 (7.7) 0 1 (16.7) 0
Treatment        
NAT 3 (23.1) 3 (42.9) 0 1
EBRT 5 (38.4) 4 (57.1) 3 (50.0) 0
VBT 5 (38.4) 0 3 (50.0) 0
Mutations        
CDKN2A 1 (7.7) 0 0 0
FBXW7 3 (23.1) 3 (42.9) 1 (16.7) 0
KRAS 1 (7.7) 0 0 0
PIK3CA 3 (23.1) 4 (57.1) 2 (33.3) 1
PPP2R1a 1 (7.7) 0 1 (16.7) 0
PTEN 5 (38.4) 6 (85.7) 4 (30.8) 1
Altered protein expression      
>10% L1CAM 1 (7.7) 2 (28.6) 1 (16.7) 0
<10% ER 2 (18.2) 2 (33.3) 1 (16.7) 0
<10% PR 3 (27.3) 2 (28.6) 1 (20.0) 0
loss/clonal ARID1a 4 (30.8) 1 (14.3) 3 (50.0) 0
loss/ heterogeneous PTEN 6 (46.1) 3 (42.9) 5 (83.3) 0
nuclear β-catenin 2 (15.4) 1 (14.3) 2 (33.3) 0
Survival        
Alive 10 (76.9) 7 (100) 4 (66.7) 0
Dead 3 (23.1) 0 2 (33.3) 1
Recurrence        
Locoregional 0 0 1 (16.7) 0
Distant 2 (15.4) 0 1 (16.7) 1




Supplementary Table 4. Multivariable analysis on the prognostic role of the clinicopathological characteristics, 
molecular subgroups, and potential other classifiers in all cases of early-stage endometrial cancer (n=834) and in the 
subset of EC without substantial LVSI, >10% L1CAM, p53 and POLE mutation (n=620). 
All cases (n=834)
  Locoregional Recurrence Distant Recurrence Overall Survival
    60 events     65 events     252 events  
  HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Age (Cont.) 1.040 1.007-1.075 0.018 1.010 0.978-1.044 0.536 1.079 1.061-1.097 0.000
Grade                  
1-2 1     1     1    
3 1.852 0.981-3.496 0.057 2.543 1.402-4.613 0.002 1.456 1.030-2.058 0.033
Myometrial invasion                
<50% 1     1     1    
>50% 1.315 0.727-2.381 0.365 1.681 0.913-3.094 0.096 1.077 0.798-1.455 0.627
LVSI                  
Absent/mild 1     1     1    
Substantial 3.224 1.431-7.267 0.005 3.150 1.508-6.581 0.002 2.027 1.235-3.328 0.005
Treatment                  
NAT 1     1     1    
EBRT 0.217 0.117-0.402 0.000 1.437 0.749-2.757 0.276 1.003 0.752-1.339 0.982
VBT 0.404 0.204-0.799 0.009 1.552 0.743-3.242 0.242 0.840 0.569-1.241 0.382
Molecular subgroup               
NSMP 1     1     1    
p53 4.089 2.060-8.116 0.000 4.422 2.221-8.803 0.000 2.475 1.682-3.642 0.000
MSI 1.425 0.797-2.645 0.224 1.622 0.876-3.004 0.124 1.444 1.071-1.948 0.016
POLE - - 0.964 1.060 0.245-4.592 0.938 1.247 0.625-2.488 0.531
L1CAM                  
<10%       1     1    
>10%       3.028 1.540-5.953 0.001 2.098 1.366-3.221 0.001
Cases without substantial LVSI, >10% L1CAM, p53 and POLE mutation (n=620)
  Locoregional Recurrence Distant Recurrence Overall Survival
    36 events     30 events     175 events  
  HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Age (Cont.) 1.057 1.012-1.104 0.013 0.999 0.952-1.048 0.966 1.094 1.071-1.117 0.000
Grade                  
1-2 1     1     1    
3 2.134 0.892-5.106 0.089 6.583 2.751-15.75 0.000 1.609 0.999-2.590 0.051
Myometrial invasion               
<50% 1     1     1    
>50% 1.199 0.549-2.622 0.649 1.539 0.639-3.709 0.336 0.914 0.635-1.315 0.628
Treatment                  
NAT 1     1     1    
EBRT 0.256 0.118-0.555 0.001 1.456 0.610-3.476 0.397 1.050 0.747-1.476 0.777
VBT 0.218 0.071-0.663 0.007 1.065 0.333-3.402 0.916 0.807 0.486-1.339 0.407
Molecular subgroup                
NSMP 1     1     1    
MSI 1.181 0.579-2.409 0.647 2.181 0.997-.4770 0.051 1.431 1.036-1.976 0.030
CTNNB1                  
No mutation       1          
Mutation       2.834 1.284-6.257 0.010      
Cont.=continuous, LVSI=lymphovascular space invasion, NAT=no additional treatment, EBRT=external beam 
radiotherapy, VBT=vaginal brachytherapy
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Supplementary Table 5. Univariable analysis of clinicopathological characteristics, molecular subgroups, and 
potential other classifiers in low-risk early-stage endometrial cancer (n=242).
  Locoregional Recurrence Distant Recurrence Overall Survival
      12 events     10 events     67 events  
  n HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Age (cont.) 242 1.064 1.001-1.131 0.045 1.005 0.935-1.079 0.900 1.087 1.057-1.117 0.000
Grade                    
1-2 227 1     1     1    
3 15 1.511 0.195-11.706 0.693 1.775 0.225-14.015 0.586 1.356 0.544-3.379 0.513
Myometrial invasion              
<50 189 1     1     1    
>50 53 0.305 0.039-2.366 0.256 0.880 0.187-4.143 0.871 0.763 0.416-1.399 0.382
LVSI                    
Absent/mild 234 1     1     1    
Substantial 6 - - 0.705 - - 0.729 - - 0.428
Given treatment                
NAT 112 1     1     1    
EBRT 111 0.098 0.012-0.762 0.026 2.022 0.506-8.084 0.319 1.067 0.651-1.751 0.796
VBT 19 0.681 0.086-5.400 0.716 2.017 0.210-19.404 0.544 1.722 0.592-5.011 0.318
Molecular subgroup               
NSMP 134 1     1     1    
p53 22 0.849 0.106-6.787 0.877 3.939 0.941-16.487 0.061 1.989 0.977-4.048 0.058
MSI 62 0.819 0.217-3.089 0.769 1.154 0.135-9.877 0.896 1.231 0.694-2.182 0.478
POLE 24 - - 0.983 0.439 0.051-3.760 0.453 0.716 0.279-1.836 0.487
CTNNB1                    
No mutation 176 1     1     1    
Mutation 53 1.664 0.501-5.527 0.406 2.579 0.693-9.606 0.158 0.909 0.502-1.646 0.753
FBXW7                    
No mutation 217 1     1     1    
Mutation 12 1.563 0.201-12.131 0.669 - - 0.634 0.443 0.108-1.818 0.259
FGFR2                    
No mutation 217 1     1     1    
Mutation 12 - - 0.589 2.442 0.305-19.539 0.400 1.236 0.445-3.434 0.685
KRAS                    
No mutation 183 1     1     1    
Mutation 46 2.009 0.605-6.672 0.255 3.216 0.863-11.978 0.082 0.746 0.379-1.466 0.395
NRAS                    
No mutation 221 1     1     1    
Mutation 8 - - 0.671 - - 0.718 1.998 0.725-5.506 0.181
PIK3CA                    
No mutation 157 1     1     1    
Mutation 72 0.440 0.096-2.009 0.289 0.271 0.034-2.164 0.218 1.007 0.592-1.713 0.979
PPP2R1A                    
No mutation 223 1     1     1    
Mutation 6 - - 0.713 4.841 0.605-38.721 0.137 0.528 0.073-3.813 0.527
PTEN                    
No mutation 129 1     1     1    
Mutation 100 0.628 0.189-2.087 0.448 0.643 0.161-2.572 0.533 0.751 0.452-1.247 0.268
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Supplementary Table 5 continued.
  Locoregional Recurrence Distant Recurrence Overall Survival
      12 events     10 events     67 events  
  n HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
L1CAM                    
<10% 208 1     1     1    
>10% 8 10.72 2.211-52.000 0.003 10.49 2.107-52.263 0.004 4.167 1.765-9.835 0.001
ER                    
>10% 188 1     1     1    
<10% 11 2.280 0.285-18.254 0.437 6.752 1.360-33.532 0.020 1.270 0.456-3.540 0.648
PR                    
>10% 184 1     1     1    
<10% 20 1.259 0.157-10.071 0.828 3.365 0.679-16.681 0.137 1.897 0.929-3.874 0.079
ARID1a                    
Positive 122 1     1     1    
Loss/clonal 82 0.417 0.087-2.008 0.276 1.508 0.377-6.029 0.562 0.980 0.579-1.659 0.940
PTEN                    
Positive 122 1     1     1    
Loss/hetero. 86 1.818 0.488-6.774 0.373 0.460 0.093-2.281 0.342 1.023 0.604-1.735 0.931
β-catenin                    
Membrane 155 1     1     1    
Nuclear 55 1.380 0.345-5.526 0.649 0.905 0.183-4.485 0.903 0.892 0.489-1.628 0.710
Cont.=continuous, LVSI=lymphovascular space invasion, NAT=no additional treatment, EBRT= external beam 
radiotherapy, VBT=vaginal brachytherapy, hetero.=heterogeneous.
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This study aimed to investigate whether molecular analysis can be used to refine risk assessment, 
direct adjuvant therapy, and identify actionable alterations in high-risk endometrial cancer. 
TransPORTEC, an international consortium related to the PORTEC3 trial, was established 
for translational research in high-risk endometrial cancer. In this explorative study, routine 
molecular analyses were used to detect prognostic subgroups: p53 immunohistochemistry, 
microsatellite instability and POLE proofreading mutation. Furthermore, DNA was analyzed 
for hotspot mutations in 13 additional genes (BRAF, CDKNA2, CTNNB1, FBXW7, FGFR2, 
FGFR3, FOXL2, HRAS, KRAS, NRAS, PIK3CA, PPP2R1A, and PTEN) and protein expression 
of ER, PR, PTEN, and ARID1a was analyzed. Rates of distant metastasis, recurrence-free, and 
overall survival were calculated using the Kaplan–Meier method and log-rank test. In total, 
samples of 116 high-risk endometrial cancer patients were included: 86 endometrioid; 12 
serous; and 18 clear cell. For endometrioid, serous, and clear cell cancers, 5-year recurrence-
free survival rates were 68%, 27%, and 50% (P=0.014) and distant metastasis rates 23%, 64%, 
and 50% (P=0.001), respectively. Four prognostic subgroups were identified: (1) a group 
of p53-mutant tumors; (2) microsatellite unstable tumors; (3) POLE proofreading-mutant 
tumors; and (4) a group with no specific molecular profile (NSMP). In group 3 (POLE-
mutant; n=14) and group 2 (microsatellite unstable; n=19) patients, no distant metastasis 
occurred, compared with 50% distant metastasis rate in group 1 (p53-mutant; n=36) and 39% 
in group 4 (NSMP; P<0.001). Five-year recurrence-free survival was 93% and 95% for group 3 
(POLE-mutant) and group 2 (microsatellite unstable) vs 42% (group 1, p53-mutant) and 52% 
(group 4, NSMP; P<0.001). Targetable FBXW7 and FGFR2 mutations (6%), alterations in the 
PI3K-AKT pathway (60%) and hormone receptor positivity (45%) were frequently found. 
In conclusion, molecular analysis of high-risk endometrial cancer identifies four distinct 
prognostic subgroups, with potential therapeutic implications. High frequencies of targetable 
alterations were identified and may serve as targets for individualized treatment.
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Introduction
Risk classification of endometrial carcinomas is based upon a combination of clinical 
and histopathological factors and is used in guiding adjuvant therapy. High-risk 
factors are (combinations of) advanced age, high-grade, non-endometrioid histology, 
extensive lymphovascular space invasion, and more advanced disease stage. 15–20% 
of patients with endometrial cancer have high-risk disease and an aggressive clinical 
course. There has been widespread uncertainty among clinicians over the best treatment 
approach for this subgroup of patients, including extent of surgery, type and extent of 
radiotherapy, and chemotherapy. Two randomized trials PORTEC3 and GOG249 have 
recently completed an accrual and two trials are going on (GOG258 and the ENGOT-
EN2-DGCC/EORTC55102 trial) to evaluate the role of adjuvant chemotherapy with or 
without pelvic radiation for patients with high-risk endometrial cancer. Significant inter-
observer variability exists, even amongst expert gyneco-pathologists, when subtyping 
and grading endometrial.1-4 In most cases, tumor cell type and grade are diagnosed 
based on hematoxylin and eosin slides according to the WHO histopathological 
criteria.5
 
The use of immunomarkers for distinguishing subtype has increased during 
the past years. Identifying specific molecular alterations which determine tumor 
behavior and metastatic potential is needed to improve risk classification, inform 
treatment decisions, and identify targetable pathways in high-risk endometrial cancers. 
TransPORTEC, an international consortium related to the PORTEC3 trial, was set up 
to conduct such a translational research in high-risk endometrial cancer (www.msbi.
nl/transportec).
Over the past decade, multiple groups have identified common molecular alterations of 
several important genes in endometrial cancer.6-11 These alterations have been fitted in 
the dualistic model of endometrial carcinogenesis discriminating endometrial cancers 
in the more indolent endometrioid cancers (type 1) and the more aggressive non-
endometrioid cancers (type 2). Recently, comprehensive molecular profiling of 373 
endometrial cancers suggested that the traditional dualistic model can be improved upon 
classification of endometrial cancers into four molecular subgroups with a potential 
prognostic significance: DNA polymerase epsilon (POLE) ultramutated, microsatellite 
unstable hypermutated, copy-number low and copy-number high (serous-like and 
mostly TP53 mutant).12 At present such an extensive analysis is impractical and too 
expensive for a routine clinical utilization. However, testing for the surrogate markers 
of these subgroups (e.g., p53 immunohistochemistry, microsatellite instability, and 
POLE proofreading mutation) may be cost effective and would be easy to apply in 
the current clinical practice. In this study, we aimed to investigate whether such 
molecular analyses can be used to detect prognostic subgroups in a series of high-







histological subtype not characterized by The Cancer Genome Atlas. In addition, we 
aimed to determine the frequency of molecularly targetable alterations in high-risk 
endometrial cancers,6,13-16 which is of interest given the poor outcome of high-risk 
endometrial cancers with current management.
Materials and methods
Patient and Tissue Selection
Tumor tissues were selected from partner institutions within the TransPORTEC 
consortium, with the aim of obtaining a large series of high-risk endometrial cancers 
using inclusion criteria of the PORTEC3 study.17 In total, formalin fixed paraffin-
embedded tumor samples from 116 patients that fulfilled these criteria were collected 
from five participating institutions: Leiden University Medical Center, The Netherlands 
(n=14); University Medical Center Groningen, The Netherlands (n=46); University 
College London, United Kingdom (n=8); St Marys Hospital Manchester, United 
Kingdom (n=34); and Gustave Roussy Paris, France (n=14). Paraffin-embedded tissue 
blocks containing representative tumor were selected. Hematoxylin-eosin-stained 
slides were viewed by experienced gynecopathologists (TB and VS) to select an area 
of tumor tissue containing at least 70% tumor cells.
Tissue Microarray Construction
Tissue microarrays were constructed from all samples with sufficient tumor volume 
(n=114) using a tissue microarray Master.18 Tissue microarrays contained 1-mm tumor 
and tumor/stroma cores of each sample, in triplicate, and were randomly distributed. 
Colon, normal endometrial, kidney, liver, ovary, placenta, skin, testis, tonsil, and 
fallopian tube samples were included in the tissue microarrays for orientation purposes 
and as internal positive controls. Immunohistochemistry was performed on whole slide 
and tissue microarray for the first 59 cases to validate the utility of tissue microarray 
for protein expression analysis in endometrial cancer. Comparison of the results showed 
a concordance of >80% for PTEN, ARID1a, p53, ER, and MLH1 (data not shown).
Immunohistochemical Analysis
Immunohistochemistry on tissue microarrays and whole slides (4 μm) was performed 
as described previously.19,20 Details of the procedures and primary antibodies are 
described in Supplementary Table 1. As negative controls, slides were incubated in 
phosphate-buffered saline without primary specific antibodies. Two observers scored 
the tissue microarrays and whole slides independently. The observers were blinded for 
patient characteristics and outcome, and discrepancies were resolved at a multihead 
microscope. p53 was scored positive if 450% of the tumor cells showed a strong 
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positive nuclear staining, or when discrete geographical patterns showed >50% tumor 
cell positivity.21 ‘Indefinite’ cases in which no staining of the tumor was observed were 
sequenced for TP53 mutations. PTEN staining was evaluated in three categories as 
negative, positive, and heterogenous.22 ARID1a was scored as negative, weak positive, or 
strong positive nuclear staining or as ‘clonal loss’.23 In the final analyses, ‘clonal loss’ was 
reclassified as ‘loss of expression’ as this pattern has been indicated to correspond with 
ARID1a mutations.24 The ER, PR, and MLH1 scores for all three tissue microarray 
tumor cores were determined. ER and PR were scored positive when at least one tumor 
core showed any nuclear expression. MLH1 nuclear staining was scored positive or 
negative, if all cores were concordant. ‘Clonal loss’ of MLH1 was scored if one of the 
cores was discordant. Cases were scored ‘failed’ when two of the three cores could not 
be evaluated, because of the absence of the core, tumor, or internal control for staining.
DNA Isolation
Prior to DNA isolation, tumor DNA was enriched in the FFPE blocks by taking three 
0.6-mm tissue cores from the tumor focus by using a tissue microarrayer (Beecher 
Instruments), to reach a tumor percentage >70%. Normal DNA was isolated from 
cores in the adjacent normal myometrium. In five cases, 10 sections (10 μM) were used 
to microdissect fragments of tumor, for the enrichment of tumor DNA. DNA isolation 
was performed fully automated as described previously using the Tissue Preparation 
System (Siemens Healthcare Diagnostics).25
Mutation Analysis
All samples were analyzed by using the Sequenom MassARRAY system and the 
GynCarta Assay version 2.0 (Sequenom) to test for the presence or absence of 159 hotspot 
mutations in 13 genes (BRAF, CDKNA2, CTNNB1, FBXW7, FGFR2, FGFR3, FOXL2, 
HRAS, KRAS, NRAS, PIK3CA, PPP2R1A, and PTEN) as described previously.26 
This gene panel only covers 40% of PTEN mutations found in endometrial cancer and 
therefore loss of PTEN protein expression was analyzed by immunohistochemistry. 
Mutations in POLE exons 9 and 13, which together contain >90% of the pathogenic 
POLE exonuclease domain mutations, were detected by using Sanger sequencing.11 
Sanger sequencing for exon 5-8 of TP53 was performed on those samples that showed 
an ‘indefinite’ p53 immunohistochemical staining pattern as described previously.9
Microsatellite Instability
The microsatellite status of each tumor was determined using the Promega microsatellite 
instability analysis system (version 1.2, Promega), as described previously.9 Tumors 
with instability in two or more of these markers were defined as being high-frequency 
microsatellite unstable, whereas those with instability at one repeat or showing no 







loss of MLH1 protein expression was observed were stained for MSH2, MSH6, and 
PMS2 to confirm loss of one of the mismatch repair proteins (Supplementary Table 1).
Methylation Specific PCR
Tumors with loss of MLH1 protein expression were selected for further testing for 
methylation status of the 5’ regulatory region of MLH1, using methylation-specific PCR, 
with primers that have been previously described.27 Contamination of the carcinoma 
tissue by stromal or inflammatory cells was unavoidable and tumors with a partially 
methylated phenotype were scored as methylated.
Statistics
Rates of distant metastasis, recurrence-free, and overall survival were calculated with 
Kaplan–Meier method and log-rank test starting at the date of diagnosis. For analysis 
of overall survival, all deaths irrespective of cause were considered an event; for 
recurrence-free survival all recurrences (local, regional, and distant) were considered 
as an event. IBM SPSS software version 21.0 was used for all statistical analysis.
Table 1 Patient characteristics.
  n=116 (%)     n=116 (%)
Age     lymphovascular space invasion
Mean, range 66 (21-85)   Absent 40 (34.5)
<60 38 (32.8)   Present 55 (47.4)
60-70 31 (26.7)   Unknown 23 (18.1)
>70 47 (40.5)   Any adjuvant therapy  
FIGO stage 2009     Yes 82 (70.7)
 I 42 (36.2)   No 10 (8.6)
II 21 (18.1)   Unknown 24 (20.7)
III 41 (35.3)   Adjuvant radiotherapy*  
IV 11 (9.5)   EBRT 55 (47.4)
Unknown 1 (0.9)   VBT 1 (0.9)
Tumor type     EBRT + VBT 21 (18.1)
Endometrioid 86 (74.1)   None 15 (12.9)
Serous 12 (10.3)   Unknown 24 (20.7)
Clear cell 18 (15.5)   Adjuvant chemotherapy 
Grade     Yes 16 (13.8)
1 13 (11.2)   No 76 (65.5)
2 5 (4.3)   Unknown 24 (20.7)
3 98 (84.5)      
Depth of invasion       
<50% 23 (19.8)      
>50% 87 (75.0)      
Unknown 6 (5.2)      
EBRT=external beam radiotherapy, 
VBT=vaginal brachytherapy.
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Results
Clinicopathologic Characteristics
Clinicopathological characteristics are shown in Table 1. In total, 18 (16%) clear cell, 12 
(10%) serous, and 86 (74%) endometrioid (33 FIGO stage I grade 3, 18 stage II, 28 
stage III, and 6 stage IV) endometrial cancers were included. Median follow-up was 
months (range 0.3–165.5 months). For endometrioid, serous and clear cell cancers 5-year 
recurrence-free survival rates were 68%, 27%, and 50% (P=0.014), distant metastasis 
rates 23%, 64%, and 50% (P=0.001) and overall survival 67%, 18%, and 39% (P=0.002). 
The corresponding Kaplan–Meier curves are shown in Figure 1. In univariable analysis, 
age (P=0.031) was a prognostic factor for decreased recurrence-free survival, in contrast 
to grade (P=0.988) and deep myometrial invasion (P=0.150). However, it should be taken 
into account that the patients were selected on those high-risk factors. None of the 
clinicopathological factors (age, grade, and myometrial invasion) were prognostic for 
distant metastasis.
Figure 1. Recurrence (A) and distant metastasis (B) free survival of high-risk endometrial cancer patients stratified 
by tumor type. For endometrioid, serous and clear cell cancers 5-year recurrence-free survival rates were 68%, 
27%, and 50% (P=0.014), distant metastasis rates 23, 64, and 50% (P=0.001) and overall survival 67%, 18%, and 
39% (P=0.002).
Molecular Subgroups Within High-Risk Endometrial Cancers
The distribution and frequency of alterations differed substantially across the endometrial 
cancer subtypes, with the highest number of alterations in the endometrioid tumors 
(Supplementary Table 2-4). The co-occurrence of alterations was observed in a higher 
frequency in endometrioid (n=50, 58%) and serous (n=7, 58%) tumors compared with 
clear cell (n=6, 33%) subtypes (P=0.062). Combining the detected alterations resulted in the 
identification of four molecular subgroups; (1) a group of p53-mutant tumors (n=39, 34%); 
(2) microsatellite unstable tumors (n=19, 16%); (3) POLE proofreading-mutant tumors 
(n=14, 12%) and (4) a group with no specific molecular profile (NSMP; n=44, 38%) (Figure 
2). A subset of tumors with endometrioid (n=20, 23%) and clear cell morphology (n=8, 44%) 
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had a p53 mutant-like expression similar to all serous cancers. This group 1 (p53-mutant) 
tumors had relatively few alterations in PPP2R1a, FBXW7, and PI3K-AKT pathway. A 
p53 mutant-like expression was inversely correlated with a microsatellite instability. Only 
one endometrioid cancer showed a p53 mutant-like expression and the microsatellite 
instability with loss of MLH1 protein expression due to promoter hypermethylation. In 
group 3 (POLE-mutant), two endometrioid tumors showed a microsatellite instability 
lacking MLH1 promoter hypermethylation. Furthermore, the group 3 (POLE-mutant) 
tumors were highly associated with PIK3CA hotspot mutations and showed an inverse 
relationship with p53 mutant-like expression. Group 2 (microsatellite unstable) tumors 
consisted of 17 endometrioid and 2 clear cell cancers. All microsatellite unstable tumors 
showed loss of protein expression of one or two mismatch repair proteins (MLH1, MSH2, 
MSH6, and PMS2). DNA promoter hypermethylation of MLH1 was observed in 9 of the 
12 microsatellite unstable tumors with the loss of MLH1 protein expression. In the other 
cases, microsatellite instability could not be attributed to MLH1 promoter methylation 
and microsatellite instability must therefore be the result of alternative mechanisms 
(e.g., Lynch syndrome; Supplementary Table 4). In group 4 (NSMP), we did not detect 
microsatellite instability, p53 mutant-like expression or POLE proofreading mutations. 
These remaining tumors can be characterized mostly by endometrioid and clear cell 
morphology, high frequency of PI3K-AKT alterations, high levels of ER/PR expression and 
CTNNB1 mutations. Additionally, twelve tumors within this subgroup (27%) had none of 
the alterations tested.
Figure 2. Molecular landscape of high-risk endometrial cancer. Routine analysis focusing on frequent 
hotspot mutations and known molecular drivers of endometrial cancer results in the identification of four 
molecular subgroups within high-risk endometrial cancer: (1) p53-mutant, (2) microsatellite unstable, (3) 
POLE proofreading-mutant, and (4) with no specific molecular profile (NSMP). PI3K-AKT pathway 
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Figure 3. Clinical outcome of high-risk endometrial cancer patients stratified by the four molecular subgroups; (1) 
p53-mutant, (2) microsatellite unstable (MSI), (3) POLE proofreading-mutant, and subgroup (4) with no specific 
molecular profile (NSMP). Recurrence-free and distant metastasis-free survival of all high-risk patients (a) and 
endometrioid high-risk patients (b) stratified by the four molecular subgroups. Both in group 3 (POLE-mutant; 
n=14) and group 2 (microsatellite unstable; n=19) endometrial cancer patients no distant metastasis occurred, 
compared with group 1 (p53-mutant; n=36, 5-year distant metastasis 50%) and group 4 patients (NSMP; n=44, 
39%; P<0.001). Five-year recurrence-free survival was 93% and 95% for group 3 (POLE-mutant) and group 2 
(microsatellite unstable) vs. 42% (group 1-p53-mutant) and 52% (group 4-NSMP; P<0.001). Even after exclusion of 
the non-endometrioid cancer patients, group 3 (POLE-mutant) and group 2 (microsatellite unstable) endometrioid 
cancer patients still shows improved recurrence and distant metastasis free survival (P=0.004 and P=0.004).
Correlation of Molecular Subgroups with Clinical Outcome
Next, we analyzed the prognostic significance of the identified molecular subgroups and 
found that the four molecular subgroups were associated with different clinical outcomes. 
Both in group 3 (POLE-mutant; n=14) and group 2 (microsatellite unstable; n=19) 
endometrial cancer patients, no distant metastasis occurred, compared with 5-year rates of 
distant metastasis of 50% and 39%, respectively, among group 1 (p53-mutant) and group 
4 (NSMP; P<0.001). Five-year recurrence-free survival was 93% and 95%, respectively, for 
group 3 (POLE-mutant) and group 2 (microsatellite unstable) cases, vs. 42% and 52% for 
group 1 (p53-mutant) and group 4 (NSMP; P<0.001; Figure 3a). Overall survival at 5 years 
was 93% in group 3 (POLE-mutant) patients, 63% in group 2 (microsatellite unstable; died 
from other causes), 40% in group 1 (p53-mutant) and 61% in group 4 (NSMP). Furthermore, 
POLE-mutant status was associated with a younger age, in contrast to p53-mutant status, 
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which was associated with older age. After exclusion of the non-endometrioid tumors, our 
analysis was still able to discriminate endometrioid patients with good vs. poor prognosis. 
Group 3 (POLE-mutant) and group 2 (microsatellite unstable) cancer patients were both 
associated with a better recurrence and distant metastasis-free survival, as compared with 
group 1 (p53-mutant) and group 4 (NSMP) endometrioid cancer patients (Figure 3b). 
Interestingly, group 1 (p53-mutant) endometrioid tumors and group 4 (NSMP) of high-risk 
endometrial tumors showed no differences in the clinical course.
Targetable Pathways within Molecular Subgroups
The frequencies of targetable alterations for each identified molecular subgroup is shown in 
Table 2. Group 1 (p53-mutant) and group 4 (NSMP) patients seem to have a poor outcome 
under the current treatment. Most cases within these two subgroups had alterations in the PI3K-
AKT pathway (60%) or were hormone receptor-positive (45%) and potentially targetable with 
PI3K-AKT-mTOR inhibitors or hormonal therapies. In 6% of the cases, somatic mutations 
in FBXW7 and FGFR2 were identified, which could potentially be targetable with HDAC 
inhibitors or FGFR inhibitors (e.g. BGI398, AZD4547).
Table 2 Frequency of targetable alterations within the four subgroups; (1) p53-mutant, (2) microsatellite unstable, 
(3) POLE proofreading-mutant and (4) with no specific molecular profile (NSMP).
  Group 1 Group 2 Group 3 Group 4  
   p53 MSI POLE  NSMP Potential drugs
Targetable alteration (%) n=39 n=19 n=14 n=44  
PI3K-AKT pathway                PIK3CA 7 (18) 6 (32) 11 (71) 13 (30)
PTEN* 16 (41) 8 (42) 6 (43) 14 (32) PI3K, AKT, mTOR inhibitors ARID1a* 5 (13) 7 (37) 1 (7) 11 (26)
KRAS 3 (8) 2 (11) 0 4 (9)  
NRAS 1 (3) 0 1 (7) 0  
 Hormone receptor positivity        
ER 23 (59) 14 (74) 9 (64) 33 (74) Hormonal therapy
PR 16 (41) 11 (58) 7 (50) 25 (57)  
Other targetable genes          
FBXW7 3 (8) 1 (5) 1 (7) 1 (2) HDAC inhibitors
FGFR2 0 2 (11) 0 1 (2) FGFR inhibitors
* Alterations based on immunohistochemistry. 
Discussion
This research shows that molecular subclassification of high-risk endometrial cancer can be 
effectively used to identify distinct subsets with prognostic significance. We found highly 
significant and clinically relevant differences in relapse and survival rates between the 
molecular subgroups, which can be used to determine adjuvant therapy in clinical practice. The 
technology required for this molecular classification is suitable for daily clinicopathological 
practice. This practical approach resulted in the confirmation of the four molecular 
subgroups proposed by The Cancer Genome Atlas, and additionally identified potentially 
targetable pathways for high-risk endometrial cancers. These results can be translated into 
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clinical practice by tailoring adjuvant therapy and/or directing targeted treatment in future 
studies. The same molecular analyses have been shown to work successfully on pre-operative 
endometrial biopsy or curettages with high concordance with the hysterectomy specimen.19 
The findings also illustrate that endometrial cancers currently classified as ‘high-risk’ are in 
fact a heterogeneous group of tumors with diverse molecular alterations and variable clinical 
outcome. Our data confirm that even in a selected cohort of high-risk patients serous and 
clear cell histology portends poor prognosis when compared with endometrioid tumors.28 
However, even after exclusion of the non-endometrioid tumors, molecular analysis can 
discriminate patients with a good and poor prognosis.
Importantly, our analyses further support previous studies that showed an association 
of POLE proofreading mutations with younger age and favorable prognosis.11,29,30 It is 
noteworthy that in this cohort, the frequency of POLE proofreading mutation was 12%, 
consistent with its association with high tumor grade10,11,29 and higher than the 6% frequency 
detected in unselected low- and intermediate-risk endometrial cancers.10,11,29,30 In addition, 
we found that microsatellite instability was associated with a reduced risk of recurrence and 
distant metastases. The impact of microsatellite instability on the prognosis of women with 
endometrial cancer is controversial. Some studies reported that microsatellite instability is 
associated with a favorable prognosis,31,32 whereas in other studies a significant worse prognosis 
was found.33,34 Possible explanations for these discrepancies include cohort differences, lack 
of statistical power, and diversity of methodology. Further studies will be required to clarify 
the effects of POLE mutations and microsatellite instability on the biological behavior of 
endometrial tumor cells and the associated mechanisms. Collectively our data suggest that 
POLE proofreading mutations and microsatellite instability may be useful as biomarkers to 
identify patients, mostly with grade 3 and clinically high-risk disease who, in fact, have a good 
prognosis and may not require intensive postoperative radiotherapy or even chemotherapy. 
In addition, our data provide a rationale to develop treatment strategies that take into account 
these genetic alterations.
Within the molecular subgroups we identified potentially targetable pathways alterations. 
This is of particular interest for high-risk endometrial cancer patients with a poorer outcome 
under the current treatment regimens, such as the group 1 (p53-mutant) and group 4 (NSMP) 
cancer patients without p53 mutant-like expression, POLE mutation and/or microsatellite 
instability. Most of the cases in group 4 (NSMP) had alterations in the PI3K-AKT pathway or 
were hormone receptor-positive and potentially targetable with PI3K-AKT-mTOR inhibitors, 
anti-hormone therapies, or combination therapies with dual inhibitors (Table 2). A selected 
group of cancers may be targetable with HDAC inhibitors or FGFR inhibitors based on the 
mutation frequencies of FBXW7 and FGFR2. Previously, higher frequencies of these targetable 
alterations were reported in the comparable p53-mutant/serous-like and microsatellite stable 







rate of detected mutations. However, the identified variants may also include non-pathogenic 
variants. Further studies are required to determine whether new therapies targeting these 
alterations improve the survival.
In the current analysis, we included a relatively large set of clear cell cancers (n=18). In 
our focused molecular analysis these cases were partly included not only within group 1 
(p53-mutant/serous-like) but also in the other three subgroups of endometrioid cancers. 
Overlapping molecular features in clear cell cancers have been noted previously, including 
loss of ARID1a and p53 mutant-like expression.35-37 This questions whether clear cell cancer 
are molecularly distinct or whether these cancers are morphological variants of serous and 
endometrioid cancers harboring the same spectrum of molecular alterations. The data 
presented here are not conclusive yet and a broader unbiased molecular analysis will be 
required to answer this question.
This report on a subgroup of high-risk endometrial cancers was set up as an exploratory study 
and therefore results should be interpreted as such. The retrospective nature, limited sample 
size, differences in adjuvant treatment regimens and follow-up data are obvious limitations. 
Furthermore, with our focused approach analyzing known drivers and hotspot mutations 
we do not provide an unbiased molecular profile, but tested previously identified molecular 
clusters. This focused approach can be viewed as a strength of our study, in that it enhances 
the clinical applicability. However, as a consequence, we did not identify novel molecular 
drivers in a group of tumors without any of the alterations tested.
In conclusion, we showed that relatively straightforward molecular analysis can be used 
to refine the risk assessment of endometrial cancer patients that are currently classified as 
high-risk based on clinicopathological factors. Our results indicate that group 3 (POLE-
mutant) and group 2 (microsatellite unstable) high-risk patients have a favorable prognosis 
and therefore the current risk assessment of these patients may be overestimated, possibly 
resulting in overtreatment. Group 1 tumors that have a p53-mutant like expression and group 
4 tumors with no specific molecular profile are truly high-risk cancers. For truly high-risk 
patients, studies should be directed toward identifying targetable pathways. Our data provide 
a rationale to investigate not only the use of PI3K-AKT pathway inhibitors in this selected 
patient group but also hormonal treatment in those tumors with retained receptor expression 
remains an option. The molecular approach used in this work will be extended and tested 
in the International TransPORTEC Consortium Studies of the large randomized cohort of 
endometrial cancers of patients who participated in the PORTEC3 trial, with the advantages of 
clear, randomized treatment groups and complete follow-up data. This would result in a novel 
approach in which routine molecular analyses are incorporated in the workup of endometrial 
cancer to refine the risk assessment based upon clinical and histopathological factors and 
identify targetable alterations, resulting in the reduction of over- and undertreatment.
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Supplementary files
Supplementary Table 1. Procedures and details of the primary antibodies used for immunohistochemistry.







ARID1a SantaCruz PSG-3 1:800 mouse Tris-EDTA DAB+ whole slide manually
β-catenin BD Transduction 14 1:1600 mouse Citrate DAB whole slide manually
ER DAKO 1D5 1:100 mouse Citrate DAB TMA manually
MLH1 DAKO ES05 1:100 mouse Tris-EDTA DAB+ TMA manually
MSH2 DAKO FE11 1:400 mouse Tris-EDTA DAB+ whole slide automated
MSH6 GeneTex EPR3945 1:100 rabbit Tris-EDTA DAB+ whole slide automated
p53 NeoMarkers DO-7 1:2000 mouse Tris-EDTA DAB whole slide manually
PMS2 DAKO EP51 1:10 rabbit Tris-EDTA DAB+ whole slide automated
PR DAKO  PGR636   1:200  mouse Citrate  DAB TMA    manually
PTEN DAKO 6H2.1  1:200  mouse Tris-EDTA DAB+ whole slide manually
*Procedures as described previously.18,19          
Supplementary Table 2. Hotspot mutation frequency in high-risk endometrial cancers.
  Endometrioid Serous Clear cell Total
  n=86 n=12 n=18 n=116
PIK3CA (%)1 30 (35) 1 (8) 4 (22) 35 (30)
p.R88Q 10 0 1 11/112
p.H1047R 4 0 1 5/113
p.E545K 3 0 1 4/115
p.E542K 3 1 0 4/113
p.T1025A 4 0 0 4/111
p.Q546K 1 0 1 2/114
p.Q546E 2 0 0 2/114
p.M1043V 1 0 0 1/114
p.Q546P 1 0 0 1/114
p.H1047Y 1 0 0 1/113
p.E545G 1 0 0 1/112
p.M1043I(T) 1 0 0 1/111
PTEN(%)1 26 (30) 0  (0) 0  (0) 26 (22)
p.R130fs*4 8 0 0 8/114
p.R130G 6 0 0 6/111
p.R233* 4 0 0 4/113
p.E7* 2 0 0 2/114
p.L318fs*2 2 0 0 2/112
p.K267fs*9 2 0 0 2/112
p.R173C 2 0 0 2/111
p.V290fs*1 1 0 0 1/115
p.N323fs*2 1 0 0 1/114
p.T321fs*23 1 0 0 1/114
p.R130L 1 0 0 1/112
p.R130* 1 0 0 1/111
POLE (%) 13 (15) 0  (0) 1 (6) 14 (12)
p.P286R 8 0 0 8/115
p.V411L 5 0 1 6/115
KRAS (%) 8 (9) 1 (8) 0  (0) 10 (8)
p.G13S 2 0 0 2/114
p.G12D 2 0 0 2/114
p.G12V 1 1 0 2/114
p.G12A 1 0 0 1/114
p.Q61H(A) 1 0 0 1/114
p.G13D 1 0 0 1/112
PPP2R1A (%) 4 (5) 2 (2) 3 (17) 9 (8)
p.R183W 1 0 2 3/113
p.P179L 0 1 1 2/114
p.R258H 1 0 0 1/114
p.R183Q 1 0 0 1/114
p.S256Y 1 0 0 1/113
p.S256F 0 1 0 1/113
CTNNB1 (%) 8 (9) 0  (0) 0  (0) 8 (7)
p.S45Y 1 0 0 1/114
p.S45F 1 0 0 1/114
p.D32G 1 0 0 1/114
p.G34R 1 0 0 1/114
p.G34E 1 0 0 1/114
p.S33C 1 0 0 1/113
p.S33Y 1 0 0 1/113







Supplementary Table 2 continued.
  Endometrioid Serous Clear cell Total
  n=86 n=12 n=18 n=116
FBXW7 (%) 3 (3) 1 (8) 2 (11) 6 (5)
p.R465C 2 1 2 5/114
p.R465H 1 0 0 1/112
FGFR2 (%) 3 (3) 0  (0) 0  (0) 3 (3)
p.C382R 2 0 0 2/114
p.S252W 1 0 0 1/113
NRAS (%) 2 (2) 0  (0) 0  (0) 2 (2)
p.Q61R 1 0 0 1/114
p.G12D 1 0 0 1/114
CDKN2A(%) 1 (1) 0  (0) 0  (0) 1 (1)
p.R80* 1 0 0 1/113
BRAF (%) 0  (0) 0  (0) 0  (0) 0  (0)
FGFR3 (%) 0  (0) 0  (0) 0  (0) 0  (0)
FOXL2 (%) 0  (0) 0  (0) 0  (0) 0  (0)
HRAS (%) 0  (0) 0  (0) 0  (0) 0  (0)
1 One endometrioid endometrial tumor had 2 PIK3CA mutations and five had 2 PTEN mutations in the same 
tumor. n  represents the number of samples showing the mutation. Analyzed hot spot mutations which were not 
detected are not shown.
Supplementary Table 3. Alterations in protein expression in high-risk endometrial cancers.
  Endometrioid Serous Clear cell Total
  n=86 n=12 n=18 n=116
p53        
Wildtype 66 (77) 0 (0) 10 (56) 76 (66)
Mutant-like 20 (23) 12 (100) 8 (44) 40 (34)
ARID1a                      
Negative 21 (25) 0 (0) 3 (17) 24 (21)
Positive 64 (74) 12 (100) 15 (83) 91 (78)
Failed 1 (1) 0 (0) 0 (0) 1 (1)
PTEN        
Negative 29 (34) 2 (17) 1 (6) 32 (28)
Heterogeneous 7 (8) 3 (25) 2 (11) 12 (10)
Positive 50 (57) 7 (58) 15 (83) 72 (62)
MLH1        
Negative 13 (15) 0 (0) 1 (6) 14 (12)
                          Clonal 1 (1) 0 (0) 0 (0) 1 (1)
Positive 72 (84) 12 (100) 17 (94) 101 (87)
ER                     
Negative 24 (28) 3 (25) 10 (55) 37 (32)
                           Positive 61 (71) 9 (75) 7 (39) 77 (67)
Failed 1 (1) 0 (0) 1 (6) 2 (1)
PR        
Negative 35 (41) 9 (75) 13 (72) 57 (49)
Positive  50 (59) 3 (25) 5 (28) 58 (51)
Supplementary Table 4. Microsatellite instability status of high-risk endometrial cancer patients.
  Endometrioid Serous Clear cell Total
Microsatellite status (%) n=86 n=12 n=18 n=116
Microsatellite stable 64 (74) 11 (92) 15 (83) 90 (78)
Sporadic microsatellite instability 10 (12) 0 (0) 0 (0) 10 (9)
Microsatellite instability (no MLH1 methylation) 9 (10) 0 (0) 3 (17) 12 (10)
Failed 3 (3) 1 (8) 0 (0) 4 (3)
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deficiency testing in endometrial cancer
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Background: Mismatch repair (MMR)-deficiency analysis is increasingly recommended for all 
endometrial cancers, as it identifies Lynch syndrome-patients, and is emerging as a prognostic 
classifier to guide adjuvant treatment. The aim of this study was to define the optimal approach 
for MMR-deficiency testing and to clarify discrepancies between microsatellite instability 
(MSI) analysis and immunohistochemical (IHC) analysis of MMR protein expression. 
Patients and Methods: 696 endometrial cancers were analyzed for MSI (pentaplex panel) and 
MMR protein expression (IHC). Agreement between methodologies was calculated using 
Cohen’s Kappa. MLH1 promoter hypermethylation, dinucleotide microsatellite markers and 
somatic MMR and POLE exonuclease domain (EDM) gene variants (using next-generation/
Sanger sequencing) were analyzed in discordant cases.
Results: MSI was found in 180 patients. Complete loss of expression of one or more MMR 
proteins was observed in 196 cases. A PMS2- and MSH6-antibody panel detected all cases 
with loss of MMR protein expression. The results of MSI and MMR protein expression were 
concordant in 655/696 cases (kappa=0.854, P<0.001). Ambiguous cases (n=41, 6%) included: 
subclonal loss of MMR protein expression (n=18), microsatellite stable or MSI-low cases 
with loss of MMR protein expression (n=20), and MSI-low or MSI-high cases with retained 
MMR protein expression (n=3). Most of these cases could be explained by MLH1 promoter 
hypermethylation. Five of seven cases with solitary loss of PMS2 or MSH6 protein expression 
carried somatic gene variants. Two MSI-high cases with retained MMR protein expression 
carried a POLE-EDM variant.
Conclusion: MSI and IHC analysis are highly concordant in endometrial cancer. This holds 
true for cases with subclonal loss of MMR protein expression. Discordant MMR-proficient/
MSI-high cases (<1%), may be explained by POLE-EDM variants.
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Introduction 
A defect in DNA mismatch repair (MMR) leads to the accumulation of mismatches, 
insertions and deletions in repeated sequences - a phenomenon named microsatellite 
instability (MSI). Approximately 20-30% of sporadic endometrial cancers (ECs) display MSI 
as a consequence of somatic promoter hypermethylation and silencing of MLH1.1 Defective 
MMR due to pathogenic germline variants in MMR genes causes Lynch syndrome (LS), a 
tumor predisposition syndrome that accounts for 2% of ECs.2 
Determination of MMR-deficiency in EC may be important for several reasons. First, 
recent studies have suggested that tumor molecular features, including MMR-deficiency, 
may improve prognostication and help guide adjuvant therapy for EC patients.3,4 Second, 
accurate assessment of MMR-deficiency is essential to identify patients with EC caused by LS. 
However in contrast to colorectal cancer, where consensus guidelines for MMR-deficiency 
testing have been published,5 there is no general agreement on screening EC patients for LS.6,7 
Finally, recent studies have shown that MMR-deficiency in colorectal and urothelial cancer 
is predictive of response to immunotherapy,8,9 suggesting that MMR-deficient ECs may also 
benefit from these therapeutics.
MMR-deficiency can be detected by either MSI analysis and/or immunohistochemical (IHC) 
staining, typically for four MMR proteins. The National Cancer Institute microsatellite 
panel was optimized and correlated with IHC analysis (~95%) to detect MMR-deficiency 
in colorectal cancer.10,11 IHC alone has become standard practice in multiple institutions. 
Experience in this setting is that while some tumors show uniform and widespread loss of 
MMR protein expression, cases with subclonal loss of MMR protein expression are also 
observed.11,12 Such cases present with two populations of tumor cells; one with retained 
expression, and another with abrupt and complete regional loss of MMR protein expression.12 
Small studies have shown high agreement between MSI and loss of MMR protein expression 
in EC,13-15 while others have described subclonal loss of MMR protein expression.16-20 However, 
studies identifying the frequency of such staining patterns in large patient series are sparse. 
In this study, we sought to establish the optimum method for MMR-deficiency testing by 
comparison of MSI with IHC analysis in a large series of ECs. We also investigated the 
frequency of subclonal loss of MMR protein expression and the number of potential LS cases. 
Cases showing disagreement between methodologies and those with subclonal loss of MMR 









The population comprised, 854 ECs from the PORTEC-1 and -2 clinical trials based on 
availability of formalin-fixed paraffin-embedded slides and sufficient tumor material for DNA 
isolation.21,22 Further details are summarized in Supplementary Table S1 and Supplementary 
methods.
MSI assay
DNA was isolated as previously described.23 In cases with subclonal loss of MMR protein 
expression, tissue sections were used to microdissect the differentially expressed tumor 
areas. Tumor MSI status was determined as previously reported (Supplementary methods).4 
Tumors initially classified as MSS or MSI-L with concomitant loss of MMR protein expression 
underwent evaluation of three dinucleotide repeat markers,24 and reclassified as MSI-H if 
instability was detected at two dinucleotide markers.
IHC analysis
IHC staining for MLH1, PMS2, MSH2, and MSH6 was performed on all tumors in which MSI 
status was successfully determined (Supplementary methods). The slides were evaluated in 
three categories as retained, loss and subclonal  loss of protein expression with stromal- and/
or lymphocytic cells as internal controls.16 The cases with subclonal loss of protein expression 
were re-evaluated to determine the percentage of tumor cells with loss of MMR expression. 
Methylation-specific PCR for MLH1
Tumors with loss of MLH1 protein expression underwent testing for hypermethylation status 
of the MLH1 5’ regulatory region by methylation-specific PCR, as previously described.25 
Somatic variant screening
Subject to DNA availability and quality, tumors in which the results of MSI analysis and MMR 
protein expression were discordant underwent targeted next generation sequencing (NGS) of 
MMR and POLE genes using the Ion Proton™ System (ThermoFisher, MA, USA) as previously 
described (Supplementary methods).26 Three additional cases were similarly analyzed using 
the Ion AmpliSeq Comprehensive Cancer Panel (ThermoFisher) at The Welcome Trust 
Center for Human Genetics. Frameshift variants in the polycytosine tract in exon 5 of MSH6 
were analyzed using Sanger sequencing.27 
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Combined analysis of MMR protein expression and MSI was possible in 696 (81%) ECs 
(Supplementary Table S1). The frequencies of MSS, MSI-H and MSI-L were 74%, 24% and 2%, 
respectively. Among the 516 tumors assessed as MSS, 496 (96%) showed retained expression 
of all four MMR proteins (Table 1). The remaining twenty MSS cases showed loss of MMR 
protein expression as follows: combined MLH1 and PMS2 loss (n=14), combined MSH2 and 
MSH6 loss (n=3), solitary MSH6 loss (n=3, Figure 1A-D). Of the 11 cases assessed as MSI-L, 
six displayed combined loss of MLH1 and PMS2 expression (complete in four cases, subclonal 
in two cases), two cases showed solitary loss of PMS2, a further two cases had solitary MSH6 
loss and one case retained expression of all four MMR proteins. 
Table 1. Details on the MSI status and MMR protein expression in early-stage EC (n=696).
MMR protein expression  
  MLH1 PMS2 MSH6 MSH2 protein expression Count
MSI status    
MSS 1 1 1 1 Retained 496
MSS 2 2 1 1 Subclonal loss 6
MSS 1 1 2 2 Subclonal loss 2
MSS 0 0 1 1 Loss 8
MSS 1 1 0 1 Loss 3
MSS 1 1 0 0 Loss 1
MSI-L 1 1 1 1 Retained 1
MSI-L 2 2 1 1 Subclonal loss 2
MSI-L 0 0 1 1 Loss 4
MSI-L 1 0 1 1 Loss 2
MSI-L 1 1 0 1 Loss 2
MSI-H 1 1 1 1 Retained 2
MSI-H 2 2 1 1 Subclonal loss 8
MSI-H 0 0 2 1 Loss/Subclonal loss 6
MSI-H 0 0 1 1 Loss 130
MSI-H 1 1 0 0 Loss 10
MSI-H 1 0 1 1 Loss 8
MSI-H 1 1 0 1 Loss 5
Mismatch repair protein expression was scored as following: 0 – Complete loss; 1 – Retained; 2 -Subclonal loss. 
MMR=mismatch repair, MSS=microsatellite stable, MSI-L/H=microsatellite unstable with low- or high-frequency.
The majority of MSI-H cases (130 of 169, 77%) showed complete loss of MLH1 and PMS2 
expression (Table 1). Sporadic MSI due to MLH1 hypermethylation was observed in 97% of 
these 130 MSI-H cases. Eight MSI-H cases showed areas of subclonal loss of MLH1 and PMS2 
(Figure 1E-H), and six cases displayed subclonal loss of MSH6 in addition to complete loss of 
MLH1 and PMS2 protein expression (Figure 1I-L). In ten cases (6%), combined loss of MSH2 
and MSH6 protein expression was observed. The remaining MSI-H tumors showed solitary 
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Figure 1. Representative images of MMR protein expression in EC. MMR protein expression of a MSS case with 
subclonal loss of MLH1 and PMS2 protein expression (A-D, case 13), a MSI-H case with complete loss of MLH1 and 
PMS2 and subclonal loss of MSH6 protein expression (E-H), a MSS case with loss of MSH6 protein expression (I-L, 
case 38). A-E-I) MLH1 protein expression, B-F-J) PMS2 protein expression, C-G-K) MSH2 protein expression and 
D-H-L) MSH6 protein expression. Scale bar represents 50 µM.
Overall, concordance between MSI and IHC analysis was observed in 655 of 696 cases (94%, 
kappa=0.854; 95%CI 0.811-0.897, P<0.001). A PMS2- and MSH6-antibody panel was as 
effective as the four-antibody panel in detecting MMR protein abnormalities. Twenty-seven 
concordant cases without MLH1 promoter hypermethylation were identified as potential 
LS, but the underlying defect was not further tested. Discordant cases (n=41, 6%) included: 
subclonal loss of MMR expression (n=18), MSS or MSI-low cases with loss of MMR expression 
(n=20), and MSI-low or MSI-high cases with retained MMR protein expression (n=3). Details 
on the sample analysis of discordant cases are shown in Supplementary Figure S1.
All cases with subclonal loss of MMR protein expression (n=18) were evaluated in more detail 
by analyzing MSI in mono- and dinucleotide markers, MLH1 promoter hypermethylation and 
somatic MMR- and POLE-exonuclease domain (EDM) variants in microdissected tumor areas 
(Table 2). Among 16 tumors with subclonal MLH1 and PMS2 loss, 14 had areas of differential 
expression that were sufficiently large to permit microdissection. Among these, MSI testing of 
microdissected areas was concordant with IHC analysis in 11 cases; tumor areas with retained 
MMR expression were MSS, whereas areas with loss of MMR expression showed MSI-H. 
A further three tumors showed microsatellite stability of markers in microdissected areas 
regardless of MMR protein expression (case 13-15, Table 2). All fourteen cases were found to 
have somatic promoter hypermethylation of MLH1. One case with subclonal loss of MSH2 
and MSH6 protein expression showed microsatellite stability in the differently expressed areas 
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(case 17, Table 2). Unfortunately, both cases with subclonal loss of MSH2 and MSH6 protein 
expression had limited DNA available, and could not be analyzed in more detail. 
Analysis of microdissected material from the six MSI-H cases with subclonal loss of MSH6 in 
addition tocomplete MLH1 and PMS2 protein loss demonstrated frameshift variants in the 
polycytosine tract of MSH6 in areas with MSH6 loss and stable polycytosine tracts in areas 
with retained MSH6. Five of these cases displayed MLH1 promoter hypermethylation.
We proceeded to perform detailed analysis of the 23 cases with discordant MSI status 
and MMR protein expression by examination of dinucleotide markers, MLH1 promoter 
hypermethylation and/or NGS of the MMR- and POLE genes (Table 3). The two MSI-H cases 
(case 19-20) with retained MMR protein expression had a POLE-EDM variant, p.(V411L), and 
p.(A428T). The POLE-EDM p.(V411L) mutant case also harbored a truncating (p.(R563*)) 
and missense p.(R107W) variant in PMS2. The solitary MSI-L case with retained MMR 
protein expression (case 21) showed stability in dinucleotide markers and no somatic MMR 
or POLE-EDM gene variants. 
One of 12 cases classified as MSS or MSI-L despite combined loss of MLH1 and PMS2 protein 
expression, showed mobility shifts in the dinucleotide markers (case 24, Table 3). Analysis of the 
MLH1 promoter was successful in 11 of these cases, and revealed promoter hypermethylation 
in ten cases, while the single case lacking MLH1 promoter hypermethylation was found to 
harbor a pathogenic POLE-EDM variant, p.(P286R). 
Of the two MSI-L tumors with solitary PMS2 loss (case 34-35, Table 3), only one had 
sufficient DNA quality for further analysis. This confirmed MSI in the dinucleotide markers 
and revealed two likely pathogenic somatic PMS2 variants, a start loss (p.(Met1?)) and a 
frameshift variant (p.(Val302Thrfs*4)).
Four of five cases classified as MSS/MSI-L with solitary MSH6 loss were informative for 
further analysis. All four showed microsatellite stable dinucleotide markers. Three tumors 
carried two (n=1) or one (n=2) pathogenic MSH6 variants, while one tumor carried one 
somatic VUS predicted to affect function by two out of three protein prediction software used 
(Table 3). Case 41 with loss of MSH2 and MSH6 protein expression and a MSS phenotype had 
limited DNA, and was therefore excluded for further analysis.
Discussion
Accurate identification of MMR-deficiency in EC may be important to identify patients with a 







to two small studies, we demonstrated high agreement (94%) between MSI and IHC analysis 
in 696 ECs.13,14 Most discordant cases involved loss of MMR protein expression and a MSS/
MSI-L phenotype and could be explained by MLH1 promoter hypermethylation or MMR 
variants. In addition, subclonal loss of MMR protein expression generally corresponded to 
MLH1 promoter hypermethylation and subclonal MSI within microdissected area of the 
tumor. 
Importantly, the present study demonstrated that <3% of cases displayed subclonal loss of 
MMR protein expression. The fact that MSI and MLH1 promoter hypermethylation were 
commonly found in areas with subclonal loss of MLH1 and PMS2 protein expression 
indicates sporadic intratumor heterogeneity.16,18,19 However, MLH1 germline epimutations 
cannot be totally excluded.2 Subclonal loss of MSH6 expression, either in conjunction with 
or without MSH2 protein expression was also previously observed in EC but the underlying 
molecular mechanisms remain unclear.12,20 In accordance with our findings, subclonal loss of 
MSH6 in cases with complete loss of MLH1 and PMS2 protein expression has been related to 
secondary MSI events in MSH6.20,29 Although numbers are limited, subclonal loss of MMR 
protein expression is not associated with LS.
Our data suggest that cases with subclonal loss of MMR protein expression are best classified 
as MMR-deficient, even though the areas with retained expression are MSS. With regard to 
MMR-deficiency as a prognostic or predictive marker, it remains to be determined whether 
subclonal loss of MMR protein expression has the same biological behavior as tumors with 
MMR-proficiency. In view of the limited numbers of cases with subclonal loss of MMR protein 
expression (~3%), (inter)national collaborations are essential to obtain sufficient cases for 
such an analysis. Pending these future studies, we suggest for uniformity to classify tumors 
with 10% subclonal loss of MMR protein expression, as being MMR-deficient.  
The interpretation of MSI-L cases remains controversial in EC and it is uncertain whether 
such cases are best considered as MSS or MSI. Similar numbers of DNA slippage events were 
observed in MSS and MSI-L ECs.30 To date, no extensive research on the clinical implications 
of MSI-L in ECs has been performed, and the number of MSI-L cases in our study (n=11) 
was too low to permit such an analysis as well. However, most of these showed loss of MMR 
protein expression and would generally be regarded as abnormal by strategies that rely on 
IHC alone. Noteworthy, several studies have also shown MSI-L and MSS in association with 
loss of MMR expression and/or pathogenic germline MMR variants.13,14,31 
Our study shows high agreement between IHC and MSI analysis, but not 100%. Of note, other 
assessments of DNA defects by IHC analysis e.g. HER2 gene amplification only reaches 69-
98% agreement.32 Assessment of MMR protein expression is preferred over MSI analysis for 
the following reasons: lower costs, widely available, and determination of affected MMR gene. 
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Our findings confirm the utility of testing MMR-deficiency using a PMS2- and MSH6-IHC 
approach,33 which can be followed by MLH1- and MSH2-IHC in case loss of PMS2 or MSH6 
was observed. To overcome suboptimal fixation, drawback of IHC analysis, pathologists 
can rely on IHC analysis in pre-operative EC specimen.23 IHC with standard well accepted 
techniques would appear adequate to identify EC patients with LS and to serve as a biomarker 
for trials of EC patients harboring MMR-deficiency.
It is debatable whether not screening for germline MMR variants is a limitation of this study. 
Of note, 5% of all cases in this study can be classified as potential LS (no MLH1 promoter 
hypermethylation). Somatic screening of the discordant cases did show somatic variants 
but not in all cases. However, we cannot exclude the possibility of missed large genomic 
rearrangements within the tested genes, which is a limitation of NGS. Further analysis would 
improve understanding the molecular basis of the discordant cases, however, this study did 
not aim to determine the sensitivity and specificity of the two methodologies to identify 
LS. MSI and IHC analysis are highly concordant therefore germline testing is not needed to 
conclude which approach is best suitable for identifying patients with LS.
In conclusion, MSI and IHC analysis are highly concordant, also in cases with subclonal 
loss of MMR expression, therefore, an IHC approach is sufficient for determining MMR-
deficiency in EC. Pathologists should be aware of the MMR protein expression patterns, 
including subclonal loss, to ensure correct classification in daily diagnostic pathology.
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Supplementary files
Supplementary Methods
Patients and study design
In total, 854 early-stage ECs from the randomized PORTEC-1 and -2 clinical trials based on 
availability of formalin-fixed paraffin-embedded slides and sufficient tumor material for DNA 
isolation were included in this study. Full details and results of both studies have been published 
previously.21,22 PORTEC-1 (1990-1997) included 714 patients with stage I endometrial cancer, 
grade 1 or 2 with deep myometrial invasion, or grade 2 or 3 with superficial invasion. The 
PORTEC-2 study included 427 endometrial cancer patients between 2002 and 2006 with 
high-intermediate risk features: stage I, age >60 years, grade 1-2 with deep invasion or grade 
3 with superficial invasion and stage IIA disease (except grade 3 with deep invasion). The 
PORTEC study protocols were approved by the Dutch Cancer Society and the medical ethics 
committees at participating centers. All patients provided informed consent for collection of 
their data and somatic analysis of tumor alterations. During the clinical trial period, universal 
LS screening was not performed. Patient and tumor characteristics, including results of 
pathology review, were obtained from the trial databases. 
MSI assay
Tumor MSI status was determined as previously reported (Promega MSI analysis system 
(version 1.2)).4 Tumors with instability in at least two of the five mononucleotide repeat 
markers were defined as being microsatellite instability-high (MSI-H), whereas those showing 
no instability were classified as being microsatellite stable (MSS). Tumors in which instability 
was detected at a single repeat were retested together with DNA extracted from unaffected 
myometrium to exclude biallelicity of the marker, and defined as microsatellite instability-low 








IHC staining for MLH1, PMS2, MSH2, and MSH6 was performed on all tumors in which 
MSI status was successfully determined. Antigen retrieval was achieved by microwave oven 
procedure in 10 mmol/L Tris-EDTA buffer, pH 9.0. Sections were incubated overnight with 
primary antibodies against MLH1 (clone ES05, 1:100; DAKO), MSH2 (clone FE11, 1:200, 
DAKO), MSH6 (clone EPR3945, 1:800, Genetex) at room temperature, and PMS2 (clone 
EP51, 1:75, DAKO) at 4°C. Sections were incubated at room temperature with Envision FLEX+ 
Linker (DAKO) for 15 minutes followed by 30 minutes incubation with secondary antibody 
(Poly-HRP-GAM/R/R; DPV0110HRP; ImmunoLogic). 3,3’-diaminobenzidine+ was used as 
a chromogen. The slides were counterstained with hematoxylin, dehydrated and mounted. 
Slides were evaluated by two observers blinded for patient and tumor characteristics, and 
discrepancies were discussed and reviewed at a multihead microscope until consensus was 
reached.
Somatic variant screening
A custom panel was designed with the AmpliSeq™ Designer tool containing MLH1, MSH2, 
MSH6, PMS2, the POLE- and POLD1 exonuclease domains (EDM) and exons 2, 6, 7, 12 
and 13 of MUTYH.26 The panel consisted of 201 amplicons (21378 bp), covering 99.3%, 
99.3%, 100 and 76.8% of the coding regions of MLH1, MSH2, MSH6 and PMS2, respectively. 
Variants were annotated to the following Genbank reference sequences: NM_000249.3 
(MLH1), NM_000251.2 (MSH2), NM_000179.2 (MSH6), NM_000535.5 (PMS2), 
NM_006231.2 (POLE), NM_001256849.1 (POLD1) and NM_001128425.1 (MUTYH). Raw 
data analysis,  alignments, variant calling and data analysis was performed as previously 
described.26
Supplementary Figure 1. Flowchart of sample analyses of cases with discordant MSI status and MMR protein 
expression. Explained cases are further described in the white colored lines and unexplained/failed cases in the grey 
colored lines in Table 2 and Table 3.
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Supplementary Table S1. Clinicopathological characteristics according to the MSI status in early-stage EC (n=696).








Age, years          
Mean (range) 69 (41-88) 68 (41-88) 67 (61-79) 69 (43-88) 0.305
< 60 101 (14.5) 76 (14.7) 0 25 (14.8)  
60-70 300 (43.1) 224 (43.4) 9 (81.8) 67 (39.6) 0.096
> 70 295 (42.4) 216 (41.9) 2 (18.2) 77 (45.6)  
Tumor type          
EEC 679 (97.6) 500 (96.9) 11 (100) 168 (99.4) 0.162NEEC 17 (2.4) 16 (3.1) 0 1 (0.6)*
Grade          
1-2 587 (84.4) 442 (85.7) 7 (63.6) 138 (81.7) 0.0753 109 (15.6) 74 (14.3) 4 (36.4) 31 (18.3)
Myometrial invasion        
<50% 200 (28.7) 143 (27.7) 4 (36.4) 53 (31.4) 0.564>50% 496 (71.3) 373 (72.3) 7 (63.6) 116 (68.6)
Lymph vascular space invasion**      
Absent/Mild 643 (95.8) 493 (98.2)  9 (90.0) 141 (88.7) 0.000Substantial 28 (4.2) 9 (1.8) 1 (10.0) 18 (11.3)
Risk group          
Low 179 (25.7) 135 (26.2) 2 (18.2) 42 (24.8)
0.997High-intermediate 465 (66.8) 343 (66.5) 8 (72.7) 114 (67.4)
High 52 (7.5) 38 (7.3) 1 (0.9) 13 (0.8)
Treatment          
NAT 181 (26.0) 133 (25.8) 2 (18.2) 46 (27.2)  
EBRT 336 (48.3) 248 (48.1) 5 (45.4) 83 (49.1) 0.876
VBT 179 (25.7) 135 (26.1) 4 (36.4) 40 (23.7)  
* The MSI-H NEEC with serous histology showed complete loss of MSH2 and MSH6 expression and harbored 
a pathogenic TP53 mutation . **25 unknown. MSS=microsatellite stable, MSI-L/H= microsatellite unstable with 
low- or high-frequency, EEC=endometrioid endometrial cancer, NEEC= non-endometrioid, NAT=no additional 











Microsatellite instability derived JAK1 frameshift 
mutations are associated with tumor immune 
evasion in endometrioid endometrial cancer
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JAK1 frameshift mutations may promote cancer cell immune evasion by impeding upregulation 
of the antigen presentation pathway in microsatellite unstable endometrial cancers (ECs). 
This study investigated the JAK1 mutation frequency, its functional implication in immune 
evasion and its prognostic significance in microsatellite unstable EC. Microsatellite instability 
and three microsatellite repeats within JAK1 were analyzed in 181 ECs. Sixty-two (34%) ECs 
showed microsatellite instability, of which 22 (35%) had a JAK1 mutation. LMP7, TAP1 and 
HLA class I protein expression and the presence of CD8-positive T-cells were analyzed in 
the microsatellite unstable ECs. JAK1 mutant microsatellite unstable ECs showed impaired 
upregulation of LMP7 (P=0.074) and HLA class I (P<0.001), validated using RNAseq data of 
the TCGA. TAP1 expression and presence of CD8-positive T-cells were not related to JAK1 
mutations. In 198 additional microsatellite unstable ECs, the JAK1 mutation frequency was 
confirmed but no prognostic significance was found. For, JAK1 wildtype (n=135, 72%) and 
mutant (n=52, 28%) ECs, 10-year recurrence free rates were 84% and 77% (P=0.301). These 
observations show that JAK1 mutations are highly frequent in microsatellite unstable EC, not 
associated with survival, but are associated with impaired upregulation of LMP7 and HLA 
class I and may therefore facilitate immune escape.
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Introduction
About 30% of endometrial cancers, predominantly of endometrioid histology, can be 
molecularly characterized by microsatellite instability (MSI). MSI is a hypermutable phenotype 
caused by the loss of DNA mismatch repair (MMR) activity mostly due to sporadic MLH1 
promoter hypermethylation.1 Tumors that exhibit this phenotype have numerous insertions 
and deletions also in coding microsatellites causing frameshift mutations and loss of protein 
function. The coding microsatellite-containing genes frequently affected by MSI are believed 
to be involved in progression of MSI tumors.2 Some target genes, such as BAX, are altered 
in diverse MSI tumor types (e.g. colorectal- and ovarian cancer), whereas others, such as 
JAK1, have a very restricted occurrence in MSI endometrial cancers.3-6 MSI endometrial 
cancers show a remarkably high number of JAK1 frameshift mutations that may have clinical 
implications.4,5 
JAK1 plays a role in the JAK/STAT pathway, which is activated by cytokines such as IFNγ, that 
influence several cellular processes such as cell growth and immune response.7-9 Ren et al. have 
shown that JAK1 mutant gynecological cancer cell lines were defective in interferon gamma 
(IFNγ) induced STAT1 tyrosine phosphorylation and thereby impede upregulation of antigen 
processing machinery components such as LMP2 and TAP1.10 Impaired antigen processing 
and presentation due to hindered expression of LMP and/or TAP proteins are associated with 
lack of HLA class I upregulation and resistance to cytotoxic T-cell mediated lysis.11,12 HLA 
class I expression has been reported as a prognostic marker in endometrial cancer patients13-15 
and upregulation of HLA class I was frequently impaired in MSI endometrial cancers.14,16 
The high rate of JAK1 mutations in MSI endometrial cancer is suggestive of an adaptation 
favoring tumor survival by blocking the JAK/STAT pathway activity, and impeding an 
adequate immune response.    
MSI tumors exhibit a high number of somatic mutations that could facilitate an immune 
response by presentation of neo-antigen-epitopes in the context of HLA class I molecules. 
Programmed death 1 expressed on cytotoxic T-cells is a checkpoint involved in immune 
suppression. Checkpoint inhibitors, as potential mechanism for T-cell activation, recently 
showed promising results in treatment of mismatch repair deficient tumors independent 
of tumor origin.17 However, JAK1 mutations and other mechanisms involved in impeding 
antigen presentation and expression of antigen processing machinery components in MSI 
endometrial cancers may interfere with new treatment regiments for MSI tumors such as the 
programmed death 1 inhibitor pembroluzimab.17,18 
In this study, MSI and JAK1 mutation status were analyzed in a study cohort of 181 tissue 
samples of endometrial cancer patients with the aim to evaluate that the JAK1 locus is 







by analyzing expression of antigen presenting machinery components and the presence of 
cytotoxic T-cells specifically in MSI endometrial cancers. Finally, the effect of JAK1 mutation 
status on survival was evaluated in a large independent cohort of 198 MSI endometrial cancer 
patients with mature long-term follow-up from the PORTEC-1 and -2 clinical trials.19,20 
Methods
Patients
DNA analysis and immunohistochemical staining was performed on a study cohort of 181 
endometrial cancers with endometrioid histology, treated at the University Medical Center 
Groningen between 1985-2004 or at the University Medical Center Leiden between 2000-
2013. Classification and grading was done according to the World Health Organization 
criteria and staging was according to FIGO guidelines (2009). No follow-up data was available 
for this study cohort.
To validate our findings regarding the JAK1 mutation frequency in MSI endometrial 
cancer, an independent cohort of 198 MSI early-stage endometrial cancers derived from the 
randomized PORTEC-1 and -2 clinical trials was used.19,20 To estimate the impact of JAK1 
mutation on survival the same cohort of 198 MSI endometrial cancers was used.21
MSI and JAK1 mutation status 
DNA was isolated as previously described.22 The MSI status of each tumor was determined 
using the Promega MSI analysis system (version 1.2, Promega). Tumors with instability in 
at least two markers were defined as being high-frequency MSI whereas those showing no 
instability or instability in one marker were classified as being stable (MSS). JAK1 frameshift 
mutations (k142fs, p430fs, k860fs) were detected by Sanger sequencing. The following 
primers were used: exon 5-F: 5’-GTCACATCTGGGTCCCCTTTGCCAC-3’, exon 5-R: 
5’-CACAAACTCCAGCTTCTCCTGGGC-3’,  exon 9-F: 5’-GTCGAGGAGGCCTTGTCCTTT 
GTGTC-3’, exon 9-R: 5’-ACACGGGCTCTCTGCACACC-3’, exon 19-F: 5’-GTATCGACTGC 
CTTTCACTCTG-3’, exon 19-R: 5’-CTTACCTCTCCCAAGTCACGG-3’.
Immunohistochemistry
Formalin-fixed paraffin embedded 4-µm tissue sections of MSI endometrial cancers (n=58) 
with sufficient tumor tissue were immunohistochemically stained for expression of LMP7, 
TAP1, HLA class I (HCA2 and HC10) and CD8 (marker of cytotoxic T-cells). Sections were 
deparaffinized in xylene, rehydrated in graded concentration of ethanol and microwave 
antigen retrieval was performed in 10 mM citrate pH 6.0 (LMP7, TAP1), 10 mM Tris/1 mM 
EDTA pH 9.0 (LMP7, TAP1, HCA2, HC10 and CD8) before staining. Endogenous peroxidase 
was blocked by incubation in a 0.3% hydrogen peroxide solution. LMP7 and TAP1 were 
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stained using anti-LMP7 mouse monoclonal 1B3 (Novus Biologicals) and anti-TAP1 rabbit 
polyclonal H300 (Santa Cruz) as primary antibodies by incubation overnight at 4°C (dilution 
1:100 and 1:50 respectively). HLA class I was stained using HCA2 and HC10 as previously 
described.16 Antigen-antibody reactions were visualized using 3.3’-diaminobenzidine (DAB) 
and slides were counterstained with hematoxylin.
Evaluation of immunohistochemistry
Two observers blinded to clinicopathological features, MSI and JAK1 mutation status 
independently evaluated the stained slides. Expression of LMP7 and TAP1 was scored using a 
semiquantative scale as described previously.13,23 This score is based on the percentage of cells 
stained and the intensity of staining. The percentage of cells was scored on a 6 point scale with 
0 for 0%, 1 for 1-5%, 2 for 5-25%, 3 for 25-50%, 4 for 50-75% and 5 for 75-100%. The intensity 
was scored on a 4 point scale with 0 indicating absence of staining and 3 indicating strong 
staining. The expression of LMP7, and TAP1 was categorized in impaired (score 0-2), normal 
(score 3-6) and upregulated (score 7-8) expression. For analysis of HLA class I expression, 
the percentage of tumor cells with membranous HCA2 and HC10 staining was quantified as 
previously described.16 The expression of HLA class I was defined as follows: impaired HLA 
class I expression: less than 5% of tumor cells expressing both HCA2 and HC10, normal 
HLA class I expression; less than 5% of tumor cells expressing either of the markers, and 
upregulated HLA class I expression: 5% or more expressing both markers.
The number of CD8-positive T-cells was calculated using the average number of stained cells 
in 8 fields at 40x magnification. The average was calculated for four locations: intraepithelial at 
the tumor center, intraepithelial at the invasive margin, intrastromal in the tumor center and 
intrastromal at the invasive margin. For statistical analysis values for CD8 were dichotomized 
using the median as a cut off.
The Cancer Genome Atlas (TCGA) RNAseq data
Details of the TCGA RNAseq analysis have been previously reported.1 Level 3 RSEM 
normalized RNA data profiled using the Illumina HiSeq RNAseq v2 were retrieved at the 
TCGA data portal. MSI events, differences in length of microsatellites, in 30 MSI EC patients 
were reported by Kim et al.4 In total, 25 MSI endometrial cancers with both RSEM normalized 
and DNA slippage event data were informative for analysis.
Statistical analysis
JAK1 mutation status was compared between cases with and without microsatellite instability 
using Chi-square tests. Similarly, Chi-square tests were used to detect differences in expression 
of LMP7, TAP1, HLA class I and number of CD8-positive T-cells below or above the median 
for cases with and without JAK1 mutation. The non-parametric Mann-Whitney test was used 







variables. RNAseq data was visualized by unsupervised clustering using RStudio.
To evaluate the impact of JAK1 mutation status on survival in MSI endometrial cancer patients 
that participated in the randomized PORTEC-1 and -2 clinical trials, time-to-event analyses 
were calculated from the date of randomization to date of recurrence (vaginal, pelvic and/or 
distant recurrence) or to date of death (overall survival); patients who were alive and without 
recurrence were censored at the date of last follow-up. Survival curves were calculated using 
the Kaplan–Meier method with log-rank test. Analyses were performed using SPSS (v20, IBM 
statistics, Chicago, IL, USA).
Results
Of the 181 endometrial cancers from the study cohort, MSI was detected in 62 (34%) cases, 
in nine cases MSI status remained unclear due to technical failure. Twenty-two (35%) MSI 
endometrial cancers had a JAK1 frameshift mutation, mainly at position K860, whereas only 
3 of 110 (3%) MSS endometrial cancers had a JAK1 mutation (P<0.001, Supplementary Table 
1). Two of these three JAK1 mutant MSS cases showed focal loss of MLH1 protein expression 
in part of the tumor as a result of MLH1 promoter hypermethylation. There were no significant 
differences in age, FIGO stage, differentiation grade or tumor type between JAK1 wildtype 
and mutant MSI endometrial cancers (Table 1). However, JAK1 mutations were associated 
with deeper myometrial invasion (P=0.030; odds ratio 3.500, 95%CI 1.102-11.116).
Table 1. Clinicopathological characteristics of 58 MSI endometrial cancers of the study cohort and 187 MSI 
endometrial cancers of the PORTEC cohort according to JAK1 mutation status.
  JAK1 wildtype n=36 (%) JAK1 mutation n=22 (%) P-value
Age      
<60 years 18 (50.0) 11 (50.0) 1.000>60 years 18 (50.0) 11 (50.0)
Tumor type    
Endometrioid 35 (97.2) 22 (100) 0.430Serous 1 (2.8) 0 (0.0)
FIGO (2009)*    
I 22 (61.1) 11 (52.4)  
II 3 (8.3) 4 (19.0) 0.650III 10 (27.8) 5 (23.8)
IV 1 (2.8) 1 (4.8)  
Grade    
1 13 (36.1) 7 (31.8)  
2 14 (38.9) 10 (45.5)  0.885 
3 9 (25.0) 5 (22.7)  
Myometrial invasion*  
<50% 21 (55.3) 6 (28.6) 0.030>50% 15 (41.7) 15 (71.4)
* 1 missing value    
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The functional implication of JAK1 in tumor immune evasion was analyzed by expression 
analysis of TAP1, LMP7, HLA class I and presence of CD8-positive T-cells in the MSI 
endometrial cancers (Table 2). Distribution of TAP1 expression was similar for both JAK1 
wildtype and mutant (P=0.151). Upregulation of LMP7 was impaired in JAK1 mutant tumors, 
although not statistically significant (P=0.074). Upregulation of HLA class I was significantly 
impaired in JAK1 mutant tumors (P<0.001). The expression of HLA class I was related to 
LMP7 expression in contrast to TAP1 (P=0.001 vs. P=0.381). Presence of CD8-positive 
T-cells was not related to JAK1 mutation (Figure 1). In order to validate these findings in 
an independent cohort, RNAseq data was used from 25 TCGA MSI endometrial cancers 
with analyzed DNA slippage events. The 13 JAK1 mutant endometrial cancers showed 
significantly lower expression of TAP1 (2.1-fold, P<0.001), LMP7 (3.0-fold, P<0.001), and 
HLA class I (2.5-fold, P<0.001) in comparison to JAK1 wildtype endometrial cancers (Figure 
2). Consistent with the results in our study cohort, JAK1 mutation status did not correlate 
with CD8 expression (P=0.112).
Table 2. Expression of antigen processing machinery components TAP1, LMP7 and HLA class I in JAK1 wildtype 
and mutant MSI endometrial cancers.
  JAK1 wildtype n=36 (%) JAK1 mutation n=22 (%) P-value
TAP1*     0.151
Impaired/Normal 24 (68.6) 18 (85.7)  
Upregulated 11 (31.4) 3 (14.3)  
LMP7*     0.074
Impaired/Normal 8 (22.9) 10 (45.5)  
Upregulated 27 (77.1) 12 (54.5)  
HLA class I     <0.001
Impaired 7 (19.4) 12 (54.5)  
Normal 3 (8.3) 6 (27.3)  
Upregulated 26 (72.2) 4 (18.2)  
* 1 missing value
Figure 1. Quantification of CD8-positive T-cells in intraepithelial and intrastromal components in the center of the 







Figure 2. Heatmap of RNA expression of genes encoding for antigen machinery components. Case numbers 1-12 
represent JAK1 wildtype and 13-25 JAK1 mutant MSI endometrial cancers. A broader analysis independent of MSI 
status was previously shown by Kim et al.
Two patient cohorts derived from the PORTEC-1 and -2 randomized trials with MSI early-stage 
endometrial cancers (n=198) with long-term mature follow-up data were used to investigate 
a possible prognostic effect of JAK1 frameshift mutations. In this independent cohort, fifty-
two (28%) of MSI endometrial cancers had a JAK1 mutation (Supplementary table 1). No 
significant differences were found between JAK1 mutation status and clinicopathological 
characteristics, and the association of JAK1 mutation and deep myometrial invasion could 
not be confirmed (Table 1). This discrepancy could be explained by the fact that this cohort 
consisted of significant more tumors with deep myometrial invasion compared to the study 
cohort (Supplementary Table 2). For JAK1 wildtype and mutant endometrial cancers, 10-year 
recurrence free rates were 84% versus 77%, respectively (P=0.301) and 10-year overall survival 
was 64.4% and 63.5% (P=0.716) (Figure 3). Neither did subanalysis (e.g. in grade 3 cancers, or 
when analyzing only pelvic and distant recurrences) show a significant difference in outcome 
between JAK1 wildtype and mutant endometrial cancer patients. Survival analysis within the 
TCGA microsatellite unstable endometrial cancers with known JAK1 mutation status (n=30) 
showed neither a survival benefit for JAK1 wildtype tumors (data not shown).
 
     Fold  
   change P-value
 
TAP1       2.1   <0.001  
LMP7       3.0   <0.001
JAK1       1.9     0.004
CD8       0.6     0.112
HLA class I     2.5   <0.001
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Figure 3. Clinical outcome of 198 MSI endometrial cancer stratified by JAK1 mutations status. A) Overall recurrence 
rate and B) Overall survival. WT= wildtype; MUT=mutant.
Discussion
This research shows that frameshift mutations in JAK1 frequently and almost exclusively occur 
in MSI endometrial cancers. JAK1 mutations were associated with impaired upregulation 
of antigen presenting machinery proteins LMP7 and HLA class I. The association of JAK1 
mutations with limited expression of the antigen presentation pathway was validated using 
RNAseq data of the TCGA MSI endometrial cancers. Impaired upregulation of HLA class 
I expression interferes with tumor lysis by cytotoxic T-cells, and therefore JAK1 mutations 
may facilitate an immune escape. However, no effect was observed of JAK1 mutation status 
on recurrence rate and overall survival in a large independent cohort of 198 MSI endometrial 
cancers. These findings suggest a functional role for JAK1, although with no prognostic value 
which suggests that JAK1 mutations are pivotal to cancer initiation and/or maintenance, in an 
intriguing tissue-specific manner. 
The overall JAK1 mutation frequency of 28% in our large series of MSI endometrial cancers 
is in line with findings from two recent smaller studies.4,5 Both studies also showed that JAK1 
frameshift mutations in MSI tumors are tissue specific and significantly less important in 
colorectal cancers as compared with endometrial cancers. Similarly, Ren et al. identified JAK1 
frameshift mutations mainly in gynecological cancers, primarily in endometrial and cervical 
cancer, when sequencing more than 3,000 tumors from various human tissues.10 Altogether, 
the occurrence of JAK1 mutation specifically in endometrial cancer is suggestive of a positive 
selection for this mutation in endometrial cancer. 







To date, there is very little evidence for the functionality of JAK1 frameshift mutations in 
endometrial cancer. An in vitro study with one endometrial cancer and two ovarian cancer 
cell lines harboring JAK1 frameshift mutations demonstrated that JAK1 mutations impede 
STAT1 posphorylation and upregulation of antigen presenting machinery components LMP2 
and TAP1.10 Kim et al. have shown that JAK1 mutations were associated with hampered JAK/
STAT signaling and lymphocyte activation.4 These findings suggest that JAK1 mutations 
have a negative effect on tumor immune surveillance. Our study now confirmed impaired 
upregulation of LMP7 and HLA class I with no effect on TAP1 expression and the number 
of CD8-positive T-cells in JAK1 mutant endometrial cancer tissue samples. The findings on 
protein expression were validated using RNAseq data of TCGA MSI endometrial cancers, 
except for TAP1. TAP1 gene expression may not be equal to its protein expression because of 
the small number of cases with RNAseq data (n=25) or due to the (post-)translational process 
into proteins. The lack of correlation between JAK1 mutations and CD8-positive T-cells might 
be explained by the fact that recruitment and migration of T-cells do not rely on recognition 
of peptides presented by HLA class I molecules. In addition, previous studies have also shown 
a high correlation between LMP7 expression and HLA class I expression, but not with LMP2 
or TAP1/2.24,25 This further strengthens the argument that JAK1 mutations favor immune 
escape via the JAK/STAT signaling, although, this study did not evaluate the activation status 
of the JAK/STAT signaling by phospho-STAT1 expression. 
The association of JAK1 mutations and lack of HLA class I upregulation in MSI endometrial 
cancers with no effect on clinical course was an unanticipated finding of our study. Bijen et 
al. and Yakabe et al. reported impaired upregulation of HLA class I as a prognostic marker 
for survival in endometrial cancer patients.13,15 Of note, a large proportion of HLA class I 
negative endometrial cancers are MSI14, therefore, separate analysis of MSI and MSS tumors 
would be of interest to determine the prognostic impact of HLA class I. This study indirectly 
showed no effect of HLA class I expression on survival via the JAK1 mutation status in a large 
cohort of MSI, early-stage endometrial cancers. HLA class I expression was not analyzed on 
the precious PORTEC tissue samples as this will only validate previous findings of Ren et al., 
the study and TCGA cohort and the fact that JAK1 mutations have no effect on survival will 
remain. However, the relatively good prognosis of this cohort of early-stage cancers needs 
to be taken into account. The previous studies were performed in heterogeneous groups of 
endometrial cancers consisting of different histologic subtypes and different FIGO stages.13-15 
Therefore, the prognostic role remains to be determined in higher risk endometrial cancers. 
These results, in contrast to the finding that JAK1 mutations favor immune evasion, may 
suggest a lack of negative selection of JAK1 mutations specifically in endometrial cancer. 
Considering the process of immune surveillance in cancer11,12, it is likely that JAK1 mutant 
tumors are still recognizable to cells of the innate immune system (natural killer cells) or 
that JAK1 wildtype tumors have encountered other mechanisms to evade immune-mediated 
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killing. However, low numbers of natural killer cells that lack an association with HLA class I 
expression were observed in endometrial cancer (unpublished data by Versluis et al.). On the 
contrary, IFNγ production might be responsible for a CD4-positive T-cell-mediated antitumor 
immunity.26 Furthermore, JAK1 wildtype tumors may not demonstrate a survival benefit 
because of other strategies to dampen immune response such as upregulation of anti-apoptotic 
molecules, expression of immune-inhibitory ligands or secretion of immunosuppressive 
cytokines. Nevertheless, our findings imply that JAK1 mutations may exert in part its 
oncogenic effects by immune escape, but we cannot exclude other contributions of JAK1 in 
the JAK/STAT signaling.7
Better understanding of the antigen-specific immune responses and tumor microenvironment 
may guide immunotherapy. Recently, immune checkpoint blockade were reported as promising 
therapies for tumors with a high mutational load, including mismatch repair deficient 
endometrial cancers, as a result of an increased neo-antigen specific T-cell response.17 JAK1 
mutations in MSI endometrial cancers may interfere with the T-cell response due to impaired 
HLA class I or PD-L1 expression.17,18 In melanoma, one patient without a clinical response 
to PD-1 blockade and increased T-cell response showed a loss of function JAK1 mutation 
that unables PD-L1 upregulation. All other fifteen melanoma patients did not show genetic 
alterations in the interferon receptor signaling pathway.18 These limited data suggest that 
JAK1 mutations may be used as negative selective predictive biomarker for immune blockade 
therapy. However, additional studies are required on the immune microenvironment of JAK1 
mutant endometrial cancers (e.g. PD-L1 expression).
We have identified a high frequency of JAK1 mutations in MSI endometrial cancers in two 
relatively large series of MSI endometrial cancers. In addition, JAK1 mutations may have a 
negative effect on tumor immune surveillance due to lack of HLA class I upregulation on 
the cell surface. It must be noted that it remains unclear why JAK1 mutations are limited 
to gynecological cancers and mainly to MSI endometrial cancer. However, B2M frameshift 
mutations, also leading to immune escape via loss of HLA class 1 expression, frequently 
occur in MSI colorectal cancer and are a rare phenomenon in MSI endometrial cancer.14,27 
In addition, Xiong et al. showed that JAK1 inhibition is associated with cell cycle arrest and 
apoptosis in colorectal cancer.28 No effect on cell viability upon IFNγ was found in JAK1 
mutant gynecological cell lines.10 In conclusion, we confirmed the remarkably high frequency 
of JAK1 mutations and associations with impaired upregulation of antigen presenting 
machinery components in MSI endometrial cancers, which suggest a functional role for JAK1 
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Supplementary files
Supplementary Table 1. JAK1 mutation frequency in 181 endometrial cancers and 198 MSI endometrial cancers.
n=181* MSI        
n=62 (%)
MSS      
n=110 (%) P-value
JAK1 mutation status   <0.001
Wildtype 40 (64.5) 107 (97.3)  
K142fs 1 (1.6) 1 (0.9)  
P430fs 8 (12.9) 0  
K860fs 11 (17.8) 2 (1.8)  
P430fs & k860fs 2 (3.2) 0  
n=198** MSI            
n=187 (%)    
JAK1 mutation status    
Wildtype 135 (72.2)    
K142fs 1 (0.5)    
P430fs 7 (3.7)    
K860fs 40 (21.4)    
K142fs & K860fs 1 (0.5)    
P430fs & k860fs 3 (1.6)    
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Discussion and future perspectives
In this thesis, results on molecular alterations in endometrial cancer and their prognostic 
significance are presented with the ultimate goal to refine indications for adjuvant therapy. In 
addition, an improved risk assessment to guide adjuvant therapy in early-stage endometrial 
cancer is presented in which the prognostic molecular markers DNA polymerase epsilon 
(POLE) mutations, mismatch repair (MMR)-deficiency, CTNNB1 (gene coding for β-catenin) 
mutations, L1 cell adhesion molecule (L1CAM) expression and tumor protein 53 (TP53) 
abnormalities are integrated with known clinicopathological risk factors. These promising 
markers, the current issues for their clinical implementation, and future perspectives in 
adjuvant treatment of endometrial cancer are discussed in this chapter. 
 
POLE exonuclease domain mutations
In endometrial cancer, somatic mutations in POLE exonuclease domain were first identified 
in 2013.1,2 POLE mutations were also identified in other cancer types, including melanoma, 
lung and colorectal cancer,3 but the highest frequency (7%) was observed in endometrial 
cancer.1,2 In addition, germline POLE mutations have been shown to predispose to colorectal 
and endometrial cancer, and other malignancies.4 A POLE mutation affects the DNA binding 
and/or exonuclease activity of DNA polymerase epsilon, leading to misincorporation of bases 
during DNA replication and an excess of substitution mutations.5,6 It is suggested that POLE 
mutations occur early during endometrial tumorigenesis, because of the minor overlap with 
other molecular markers of the genomic classification and its occurrence in endometrial 
precancerous lesions.2,7 Following the observation that POLE-mutant endometrial cancers 
have a favorable outcome in The Cancer Genome Atlas study,2 we and others have confirmed 
the prognostic impact of POLE mutations in higher quality clinical and/or independent 
cohorts.8-14 These studies have also shown that POLE mutations are more common (10-20%) 
and even predict a favorable prognosis in high-grade and high-risk endometrial cancers.8,9,12 
Few POLE-mutant endometrial cancer patients have been reported who experienced relapse 
after primary surgery. 
Studies to unravel the mechanism(s) by which these mutations lead to the excellent prognosis 
of these patients are limited. Several theories have been suggested. The first theory has been 
suggested because of the observation that the majority of endometrial cancer patients studied 
received adjuvant radiotherapy. An increased radiosensitivity of POLE-mutant tumors may 
explain their favorable outcome, however, limited available evidence points in the opposite 
direction. In two studies, locoregional recurrences were absent in patients with POLE-mutant 
endometrial cancers who received adjuvant radiotherapy as well as in those who received no 
additional treatment.9,13 Of note, the number of POLE-mutant cancers and number of events 
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in the wildtype subgroup were small. Therefore, additional studies, sufficiently powered, 
are required to provide evidence that POLE-mutant endometrial cancers do not require 
(more aggressively) adjuvant therapy. In addition, the association of POLE mutations with 
radiosensitivity may also be investigated using a preclinical model, POLE-mutant cell line. A 
recent preclinical study exclusively investigated the sensitivity to chemotherapeutic agents.15 
No significant differences in sensitivity to 5-fluorouracil and oxaliplatin were found between 
POLE-wildtype and -mutant colorectal cancer cell lines.
The favorable prognosis of POLE-mutant cancers may also be explained by the high 
mutational burden that causes an enrichment of neo-antigens, which in turn stimulates an 
anti-tumor T-cell response.16,17 This mechanism has been previously described to explain 
the good prognosis of mismatch repair-deficient colorectal cancers18 and recently also 
confirmed for POLE-mutant colorectal cancers.15 Tumor immune evasion by upregulation 
of immunosuppressive immune checkpoint molecules, including PD-1 and PD-L1, may 
explain the clinically detectable tumor mass and in some cases the lymphatic spread.16,17 
Upregulation of these immune checkpoints may suggest that the highly immunogenic POLE-
mutant cancers are also sensitive to immune checkpoint inhibitors, similar to mismatch 
repair-deficient cancers.19,20 Although recurrences rarely occur in POLE-mutant endometrial 
cancers, to date, two POLE -mutant endometrial cancer patients presenting with metastatic 
disease were treated with anti–PD-1 checkpoint inhibitors, and showed remarkable responses 
for over 7 and 14 months, respectively.21,22 These findings suggest that it may be worthwhile to 
set up clinical trials of immune checkpoint inhibitors for advanced or recurrent POLE-mutant 
cancers. Basket trials based on the premise that POLE mutations predict tumor response 
to immune checkpoint inhibitors independent of tumor histologic origin hold promise to 
further advance this field. 
Another explanation for the favorable prognosis of POLE-mutant cancers might be that the 
high mutational load exceeds an ‘error threshold’ leading to oncogenic stress and eventually 
apoptosis. Studies of mutant POLE in yeast have shown that the mutation rate can exceed the 
optimum for cell viability.23 DNA mismatch repair proteins activated upon base mismatches 
are needed for DNA repair and to ensure cell viability. This is supported by the finding that 
POLE-mutant endometrial cancers are in general microsatellite stable.2,10-12,24 Targeting the 
DNA repair pathway in advanced or recurrent POLE-mutant cancers may be considered 
to increase the mutational load to the ‘error threshold’ resulting in lethal mutagenesis and 
reduced viability. The emerging data on radiosensitivity, immune response and mutational 
burden may also demonstrate a combination of mechanisms responsible for the favorable 
prognosis of POLE-mutant cancers. For example, the effect of radiotherapy on promoting an 








The majority of MMR-deficient endometrial cancers are due to hypermethylation of the 
MLH1 gene promoter. This DNA promoter hypermethylation is strongly interrelated with 
histone lysine methylation mediating MLH1 gene silencing.26 MMR-deficient endometrial 
cancers are also associated with a genome-wide increase in DNA promoter CpG island 
hypermethylation.2 Similarly, the CpG Island Methylator Phenotype (CIMP) has been 
reported in colorectal cancers.27 The CIMP profile in colorectal cancer is strongly associated 
with MLH1 promoter hypermethylation and BRAF mutations. However, there is no conclusive 
functional evidence supporting the observation that a BRAF mutation induces MLH1 
promoter hypermethylation or is a causal event for CIMP.28,29 Interestingly, BRAF mutations 
are not involved in endometrial tumorigenesis.30,31 To date, the cause and relevance of genome-
wide DNA promoter hypermethylation in endometrial cancer, the link between specific 
molecular alterations, and similarities in the regulation of methylation across cancer types 
remains to be elucidated. In addition, reversal of DNA methylation and histone modifications 
could potentially be therapeutic, reactivating tumor suppressor genes, enhancing the anti-
proliferative effect of chemotherapy or upregulating immune signaling, but this requires 
further investigation.32-34 Promising preclinical data demonstrated the potential of DNA 
methyltransferase inhibitors and histone deacetylase inhibitors for tumor growth inhibition 
and apoptosis in endometrial cancer cell lines.35,36 However, a more comprehensive analysis on 
the sensitivity of endometrial cancer cell lines of different histologies and molecular subgroups 
to epigenetic agents is needed. Then, the efficacy of such agents needs to be evaluated in 
animal model systems. This can potentially be performed in a panel of patient-derived tumor 
xenograft models which have been established and molecularly characterized.37
MMR-deficiency leads to base pair mismatches, insertions and deletions in microsatellite 
coding and non-coding regions – a phenomenon named microsatellite instability (MSI). Most 
of these mutations within coding microsatellites remain without consequences (passenger 
mutations), while other mutations are relevant for tumorigenesis. Genes with mutations in 
microsatellite regions are classified as ‘true’ MSI target genes based on mutation frequency 
and functional studies. It has been shown that the MSI target genes differ between MMR-
deficient endometrial and colorectal cancers.38-40 In fact, in colorectal cancer, mutations in 
the growth factor receptor TGFBR2 and transcription factor TCF-4 have been frequently 
found, but these have been rarely found in endometrial cancers. We and others have shown 
that JAK1 inactivating mutations frequently and almost exclusively occur in MMR-deficient 
endometrial cancers.40-44 MMR-deficient endometrial cancers are also highly immunogenic 
due to the neo-antigens as a result of microsatellite instability. However, JAK1 mutations 
are associated with decreased expression of antigen presenting machinery proteins and 
may interfere with the T-cell response. Therefore, JAK1 mutations may be used as negative 
predictive biomarkers for immunotherapy. Immunotherapy agents have been suggested for 
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MMR-deficient endometrial cancers, as recent studies have shown that MMR-deficiency in 
colorectal and urothelial cancer is predictive of response to immune checkpoint blockade.19,20 
Mutation analysis of JAK1 in biopsies from patients with metastatic MMR-deficient cancers 
before and after treatment with immune checkpoint inhibitors will prove whether JAK1 
mutations are indicative for resistance to immunotherapy. Such a study in melanoma has 
described JAK1 mutations as a mechanism of acquired resistance to immunotherapy.45 
Further investigation into the MSI target genes driving the tumorigenic process may help to 
understand the differences between MMR-deficient cancers and may guide adjuvant therapy. 
Genes involved in double strand break repair by homologous recombination such as BRCA1/2, 
ATR, RAD50 and MRE11, have also been found with mutations in their microsatellite 
regions as a result of the MMR-deficiency in endometrial cancer.40,46-51 Although the gene 
mutation frequency varies between studies, e.g. 0-15% for BRCA1 and 15-30% for MRE11, it 
has been reported that most MSI events occur in the homologous recombination pathway.51 
Homozygous mutations in these genes are known to cause double strand break repair defects, 
while MSI-derived heterozygous mutations show reduced protein expression of affected 
genes and reduced double strand break repair.50-52 This suggests that DNA repair defects in 
addition to MMR-deficiency may be lethal, while a limited level of genetic instability may 
confer a growth advantage for tumor cells in carcinogenesis. Functional studies have shown 
that MMR-deficient cells with impaired DNA repair by homologous recombination may be 
sensitive to agents inducing double strand breaks, such as PARP inhibitors.50,51 Therefore, 
advanced or metastatic MMR-deficient endometrial cancer patients may potentially benefit 
from PARP inhibitors, which are already approved for BRCA-deficient recurrent epithelial 
ovarian and breast cancers.53
A small proportion of MMR-deficient endometrial cancers are due to germline mutations in 
the MMR genes and are Lynch syndrome-associated cancers. The cumulative lifetime risk of 
endometrial cancer for women with Lynch syndrome is 50-60%.54-56 These women are also 
at risk of colorectal cancer and a spectrum of other malignancies.54-56 Although women with 
a diagnosis of endometrial cancer have a ~3-5% risk of Lynch syndrome, there is currently 
no general agreement on screening endometrial cancer patients for Lynch syndrome. In 
contrast, for colorectal cancer, consensus guidelines for MMR-deficiency testing have been 
published.57 We and others have shown that an immunohistochemical approach is sufficient 
for determining MMR-deficiency in endometrial cancer.58-61 In addition, one study suggested 
that the POLE mutation status may have implications for Lynch syndrome screening.10 POLE 
mutations and MMR-deficiency rarely co-occur (~1%, Table 1),1,2,10-12,17,24,62-66 however, to date 
none of these cancers were Lynch-associated.10,66 Little is known about how Lynch syndrome-
associated endometrial cancer differs from sporadic MMR-deficient and -proficient cancers 
with respect to prognosis. Two studies showed no significant difference in survival rate 
between Lynch syndrome-associated and sporadic MMR-deficient endometrial cancers.67,68 
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In contrast, improved survival has been reported in Lynch syndrome-associated compared 
to sporadic colorectal cancer matched by stage.69,70 The survival benefit might be ascribed to 
the stronger immunogenic response in Lynch-associated colorectal cancer.71 This implies that 
genes affected by the MMR-deficiency cause differences in neo-antigen responses, tumor and 
clinical behavior between MMR-deficient cancers.
We and others have shown an association between MMR-deficiency and lymphovascular space 
invasion (the presence of tumor cells in either blood vessels, lymphatic vessels, or both).12,24,72-
78 On the other hand, five studies found no association.11,79-82 These conflicting findings may 
in part be explained by the lack of uniform scoring of lymphovascular space invasion. The 
mechanism underlying the correlation between MMR-deficiency and lymphovascular space 
invasion is unclear. Little is known about how tumor cells locate, migrate and intravasate into 
blood and lymphatic vessels. Mechanisms that have been described include tumor-induced 
or stromal microenvironment-induced (lymph-) angiogenesis, or endothelium releasing 
factors to recruit tumor cells.83 Microsatellite instability affected target genes may be involved 
in the tumor-induced (lymph-) angiogenesis. A 3D-model in which endometrial tumor 
cells are co-cultured or flowed over  endothelial cells may give more insight in the biological 
mechanism of lymphovascular space invasion. Lymphovascular space invasion is indicative of 
aggressive behavior,84-86 therefore, development of targeted therapies preventing or inhibiting 
lymphovascular space invasion is critical to improve patient outcomes. 
CTNNB1
CTNNB1 encodes for β-catenin which has two major roles in the cell. β-catenin forms a 
complex with the transmembrane protein E-cadherin at adherent junctions to play a role in 
cell-cell adhesion. In addition, free cytoplasmic β-catenin is immediately phosphorylated by 
the destruction complex containing AXIN1/2, APC, CSNK1A1 and GSK3β and subsequently 
degraded by the proteasome. Upon Wnt signaling, β-catenin stabilizes by the inactivation of 
the destruction complex and translocates to the nucleus to function as a transcriptional factor 
regulating expression of genes involved in proliferation and survival (e.g. CCND1 and MYC). 
Missense mutations in exon 3 of CTNNB1 were frequently identified within the copy-
number low group by The Cancer Genome Atlas, thereby contributing to refinement of 
the current molecular classification.2 The copy-number low group also presented with low 
number of mutations, and CTNNB1 mutations are detected as an early event in endometrial 
hyperplasia,87 therefore, it is currently believed that the tumorigenesis is driven by CTNNB1 
mutations. In accordance with previous studies, we showed that CTNNB1 mutations (~40%) 
characterized an aggressive subset within low-grade early-stage endometrial cancers.24,88,89 The 
clinical significance of CTNNB1 mutations, occurring less frequent (~10%)2,12 in endometrial 
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cancer patients with high-risk features, remains to be elucidated. The mutations hinder 
the phosphorylation of serine and threonine residues by GSK3β, which results in nuclear 
accumulation of β-catenin and constitutively active Wnt signaling.87,90,91 This is supported 
by the observation of increased expression of downstream targets of Wnt signaling, which 
were also associated with significantly poorer overall survival.88 Thus far, there is no evidence 
that CTNNB1 missense mutations, not identified in the β-catenin domain that interacts with 
E-cadherin, alter the interaction between β-catenin and E-cadherin. Accordingly, it has been 
suggested that nuclear β-catenin upon CTNNB1 mutations drives tumorigenesis by its role 
in Wnt signaling.
The strong correlation of CTNNB1 exon 3 mutations with β-catenin nuclear expression 
suggests the possibility to screen for alterations using an immunohistochemical approach.87,90,91 
However, we also observed that the β-catenin nuclear localization is not restricted to CTNNB1-
mutant endometrial cancers. Alterations in the destruction complex, such as APC and 
AXIN1 mutations, may also lead to stabilization and nuclear localization of β-catenin.92 Loss 
of heterozygosity and promoter hypermethylation of APC were not associated with nuclear 
β-catenin expression.93 Loss of E-cadherin expression, either due to CDH1 mutations or 
promoter hypermethylation, results in the disruption of cell–cell adhesion, but does not lead 
to nuclear localization of β-catenin, as the destruction complex immediately phosphorylates 
β-catenin for subsequent degradation. Estrogens may also play a role in β-catenin/Wnt 
signaling. The role of estrogen is suggested because β-catenin is detected in the nucleus in 
the proliferative phase of the menstrual cycle, and in the cytoplasm and at the membrane in 
the secretory phase. In addition, most of the CTNNB1-mutant tumors are estrogen-driven.
Not all CTNNB1-mutant endometrial cancers exhibit nuclear staining. It is hypothesized that 
the amount of nuclear β-catenin in these tumors is sufficient to activate Wnt signaling but is 
not enough to be detected by immunohistochemistry.91 Another hypothesis for endometrial 
cancers could be that the proteins responsible for the cytosol-nucleus transport of proteins 
without a nuclear localization sequence (such as β-catenin) are altered. The exact mechanisms 
controlling β-catenin nuclear localization are poorly understood, although many mechanisms 
have been reported.94 A final hypothesis could be that a chaperone protein with a nuclear 
export sequence rapidly exports β-catenin from the nucleus to the cytosol.
L1CAM 
L1CAM expression, in more than 10% of tumor cells, has been reported as a strong, 
independent prognostic factor for distant recurrences and overall survival in endometrial 
cancer.95-99 This is consistent with findings in several other malignancies, including colorectal, 
breast, pancreas, and ovarian cancer.100 It has been described that L1CAM downregulates 
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cadherins and interacts with molecules in the extracellular matrix, thereby enhancing cell 
motility and promoting invasiveness.101 In view of their inferior prognosis, adjuvant systemic 
treatment may be considered for patients with L1CAM expressing tumors. However, 
L1CAM has been proven to confer chemotherapy resistance in glioblastoma and pancreatic 
cancer.102,103 Antibody therapies targeting L1CAM have shown promising anti-tumor effects 
in preclinical models,104,105 and should be further explored in metastatic L1CAM-positive 
endometrial cancer. Furthermore, the mechanism underlying the expression of L1CAM 
remains to be elucidated in endometrial cancer in order to understand and improve the 
therapeutic implications of L1CAM expression.
Several mechanisms leading to L1CAM expression in cancer have been described. DNA 
methylation of the L1CAM promoter appears to play a role in the regulation of L1CAM 
expression.106-108 The L1CAM gene has two different promoter regions, among which promoter 
1 was found to be the core promoter.106,107 DNA hypomethylation at this promoter region 
correlated with L1CAM expression both in colorectal cancer and endometrial cancer.106-108 
In addition, the chromatin (DNA-protein complex) can also be modified and remodeled 
by histone acetyltransferases and histone methyltransferases. Endometrial cancer cell lines 
treated with an histone deacetylase inhibitor showed upregulation of L1CAM expression. 
Combination treatment with a DNA demethylating agent and histone deacetylase inhibitor 
showed even a stronger induction of L1CAM expression. Our preliminary observations 
also showed a correlation between L1CAM DNA promoter methylation status and L1CAM 
promoter histone methylation. Further studies on the interrelationships between DNA and 
histone modification will aid in the understanding of the epigenetic regulation.
Hypomethylation and changes in chromatin remodeling in the L1CAM promoter could 
influence the binding of transcription factors which regulate L1CAM expression. In 
colorectal cancer, it has been demonstrated that nuclear β-catenin activates L1CAM gene 
expression through binding to the L1CAM promoter region 2.109 Overexpression of mutant 
β-catenin was associated with increased L1CAM expression in endometrial cancer cell 
lines.110 However, no correlation between L1CAM and nuclear β-catenin expression was 
found in the molecular analysis of the PORTEC-1 and -2 study samples, in line with the 
finding that expression of L1CAM mostly depends on the core promoter region 1.106,107 
Another transcription factor implicated in L1CAM expression is SLUG, that functions 
upon transforming growth factor β1 (TGFβ1) induction.111 In vitro studies in endometrial 
cancer cell lines have shown that SLUG binds to the L1CAM promoter region 1 upon TGFβ1 
treatment or SLUG overexpression, thereby activating L1CAM expression.95,110 Snail, a family 
member of SLUG, is also upregulated upon TGFβ1 induction and can lead to downregulation 
of the estrogen receptor.112 Interestingly, similar to breast cancer studies, we found a strong 
inverse correlation between estrogen receptor and L1CAM expression, but not all L1CAM 
expressing cancers showed loss of the estrogen receptor.95,113 Further studies are necessary to 
identify if there is a cause-effect relationship.
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Several microRNAs (miRNAs) have also been shown to inhibit L1CAM expression. miR-
34a was identified as a binder to the L1CAM-3’UTR region in endometrial cancer which 
leads to inhibition of L1CAM expression.100 A functional link between wildtype p53 by 
upregulation of miR-34a and loss of L1CAM expression has been identified.114 A significant 
association was found between mutant p53 and L1CAM expression, but the majority of 
endometrial cancers with mutant p53 expression displayed low L1CAM expression.24,98,114 In 
early-stage endometrial cancer, we have shown that L1CAM is a strong prognostic marker, 
often coexisting with but independent from p53 expression.24 Another way to increase miR-
34a levels is by DNA demethylation.114 Treatment with demethylating agents in L1CAM 
expressing endometrial cancer cells leads to upregulation of miR-34a and decreased L1CAM 
expression. In conclusion, the (epi)genetic mechanisms leading to upregulation of L1CAM 
expression in cancer are complex. Non-endometrioid endometrial cancers are more frequently 
L1CAM positive than pure endometrioid cancers (43-100% vs. 6-33%).95-99,115,116 Therefore, it 
may be hypothesized that L1CAM expression is differently regulated in non-endometrioid 
histological subtypes.
p53
The gene TP53, encoding the protein p53, is frequently mutated in endometrial cancer. TP53 
mutations are mainly identified in non-endometrioid cancers (>90%) and in ~10-20% of 
endometrioid cancers (mainly grade 3).2 Therefore, TP53 mutations cannot be used as marker 
to reliably distinguish between histological subtypes. Further, TP53-mutant serous cancers 
frequently harbor PPP2R1a mutations, whereas PTEN mutations are frequently identified in 
TP53-mutant endometrioid endometrial cancers.117,118 The majority of TP53 mutated cancers 
are defective for apoptosis and cell cycle arrest upon stressed conditions, thereby contributing 
to tumor development. TP53 mutation is a strong predictor of an aggressive clinical course, 
even in a selected cohort of high-grade and high-risk endometrial cancers.2,12,119
We and others have suggested that routine evaluation of p53 abnormalities might refine 
prognostic risk assessment of endometrial cancers.11,24 p53 immunohistochemistry, which 
can be easily implemented in daily diagnostics, can be used as a surrogate marker for TP53 
mutations, but this requires correct interpretation of the staining. TP53 abnormalities 
correlate with certain p53 immunostaining patterns including diffuse intense nuclear staining 
and totally absent staining, whereas wildtype staining is focal, weak and heterogeneous.120,121 
Interestingly, in the PORTEC-1 and -2 molecular studies, 15% of p53-mutant endometrial 
cancers displayed subclonal p53-mutant expression. It remains to be determined whether 
subclonal p53-mutant expression has the same unfavorable prognostic impact as p53-
mutant expression in all tumor cells. In chronic lymphocytic leukemia it was found that p53 
abnormalities in a fraction or in all tumor cells have the same impact on clinical outcome.122 
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Furthermore, pathologists need to be aware of the rare cases (~1%, Table 2) that present with 
p53 abnormalities together with the favorable POLE mutation. Some studies have classified 
these tumors within the POLE-mutant subgroup, however, further analysis on a larger subset 
is required to determine the prognostic significance, mutational load and copy-number status 
of these rare cases with multiple classifiers.
Adjuvant chemotherapy may be considered for p53-mutant endometrial cancers, although 
the efficacy of adjuvant chemotherapy still needs to be proven for patients with endometrial 
cancer. However, TP53 mutations have been strongly associated with chemoresistance 
in several cancers.123,124 Since TP53 is frequently mutated in cancer, approaches have been 
undertaken to target p53 for the development of precision cancer medicine.125-127 Strategies 
that are currently being explored to target mutant TP53 include: promotion of mutant p53 
degradation, restoration of transcriptional activity of mutant p53, restoration of wildtype 
p53 and induction of synthetic lethality. Some drugs reactivating wildtype p53 or depleting 
mutant p53 are already in phase I/II clinical trials, including ovarian cancer (ClinicalTrials.
gov). However, several issues (e.g. unwanted side effects, acquired resistance after prolonged 
exposure) have been described that need to be resolved before the provision of p53 as targeted 
therapy.125
Current issues 
There are some challenges to overcome before an individual molecular profile predicting 
recurrence risk in patients with endometrial cancer can be clinically implemented. Ideally, a 
combination of clinicopathological risk factors and the above discussed molecular alterations 
should be used. Prognostic validation of the molecular integrated risk assessment is essential,11,12 
although the prognostic significance of the molecular alterations and classification have been 
previously reported. A randomized phase III trial, PORTEC-4a, has been initiated to assess if 
a molecular integrated risk assessment improves prognostication and recommendations for 
adjuvant radiotherapy for early-stage endometrial cancer.128 The molecular integrated risk 
profile guided recommendation for adjuvant treatment (favorable: observation; intermediate: 
vaginal brachytherapy; unfavorable: external beam radiotherapy) will be compared to standard 
postoperative vaginal brachytherapy based on high-intermediate risk factors. PORTEC-4a 
will mainly address the issue of overtreatment because the exclusion of serous cancers affect 
the number of p53-mutant endometrial cancers entering the trial. Still, some patients will 
receive external beam RT instead of brachytherapy in view of unfavorable risk features. The 
prognostic significance of the molecular classification in patients with clinicopathological 
high-risk features still needs to be confirmed. This can be analyzed in endometrial cancer 
tissue samples from patients who participated in the PORTEC-3 randomized phase III trial 
(see General Introduction Table 4 for details on PORTEC-3).129  
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The molecular risk assessment can be achieved using clinically applicable methods on 
formalin-fixed paraffin-embedded endometrial cancer samples. The feasibility of determining 
the molecular profile within tight time limits will also be prospectively established in the 
PORTEC-4a trial. If risk assessment and decision-making is desired before surgery, we and 
other have suggested the possibility to determine the molecular profile on endometrial biopsy 
or curettage specimens obtained at the time of diagnosis.130-132 The high concordance of 
molecular alterations between pre-operative and hysterectomy specimens also implies that 
intratumor heterogeneity is not a major issue for the molecular classifiers. This is supported 
by the finding that alterations in MMR and p53 protein expression are mostly seen in all 
tumor cells of the analyzed tumor tissue slide.61,133-137 Finally, this has also been confirmed 
in our follow-up study in which multiple tumor samples of one endometrial cancer were 
analyzed for molecular alterations.138 Analyzing one tumor sample was found to be sufficient 
in >90% of endometrial cancers to ensure correct molecular classification. 
The PORTEC-4a feasibility data will also focus on the practical issues such as the  logistics 
of specimen processing, molecular assessment and analysis of the results. The proportion 
of samples with successful molecular analysis will be determined. In case of quality issues, 
e.g. suboptimal tissue fixation, pathologists can rely on immunohistochemical analysis of the 
pre-operative endometrial cancer specimen. Another issue which has already been pointed 
out in the above sections is how to deal with the rare occurrence of double classifiers (e.g. co-
occurrence of POLE and TP53 mutation in one tumor). In view of the very small numbers 
of cases with double classifiers, (inter)national collaborations are essential to further study 
these uncommon cases and determine which molecular alteration has the strongest impact 
on outcome. 
The integrated risk assessment combining clinicopathological and molecular prognostic 
factors is mostly based on objective variables, such as mutational status of POLE. 
Immunohistochemical analyses tend to be less accurate and less objective than mutational 
analyses. However, training sessions for pathologists will improve the performance of 
interpretation of staining results. For the interpretation of MMR protein expression, there 
is knowledge and experience from the colorectal cancer diagnostic pathology. In addition, 
TP53 mutation analysis may be helpful in reaching correct assessment of p53 staining in 
ambiguous cases. A recent study showed a good agreement between the different pathologists’ 
interpretations on L1CAM protein expression (kappa of 0.82).99 Future studies need to prove 
whether the cut-off of 10% for L1CAM positivity also applies for high-risk endometrial 
cancers.98,99 In addition to the integration of molecular alterations in the clinicopathological 
risk assessment, quantitative grading (focal versus extensive) of lymphovascular space invasion 
further improves the prediction of patients’ recurrence risk.86 The prognostic significance of 
lymphovascular space invasion has been firmly established and is incorporated in clinical 
decision making by its implementation in the ESMO-ESTRO-ESGO guidelines for treatment 
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of endometrial cancer. Recent work established that pathologists can reliably distinguish 
lymphovascular space invasion from its mimics, but that training and experience are required 
to improve reproducibility of the quantification of lymphovascular space invasion.139
Future perspectives
The performance of the molecular integrated risk assessment is considered to be a good model 
(AUC >0.8), but not yet excellent.24 In addition, the largest subgroup of The Cancer Genome 
Atlas molecular classification, the copy-number low group, cannot be identified by a specific 
molecular classifier and is still a heterogeneous subgroup.2 Therefore, there is still room for 
improvement of the molecular classification and refinement of the molecular integrated 
risk model. The copy-number low, endometrioid endometrial cancers can be characterized 
by CTNNB1 mutations, chromosome 1q amplification, and increased hormone receptor 
expression. CTNNB1 mutations have already been included in the molecular integrated risk 
assessment, as CTNNB1 was found to be an independent risk factor for the copy-number low 
group of early-stage endometrial cancer. 
Amplifications of chromosome arm 1q were previously identified as prognostic factor in single 
biomarker studies.140,141 Analysis of 1q amplifications in the PORTEC-1 and -2 endometrial 
cancers have confirmed the prognostic significance of 1q. Although 1q amplifications have 
been frequently noted in cancer, the candidate genes on chromosome 1q that contribute to 
tumorigenesis remain to elucidated.142 More than 600 genes are located on the chromosome 
1q which may play a role in tumorigenesis, including genes involved in calcium-binding 
(S100-family), phosphoinositide signaling pathway (PI3KC2B, AKT3), chromatin modifying 
(SETDB1).142 MDM4, located on chromosome 1q32, may also be a candidate gene because of 
its role in p53 inactivation. However, we were unable to correlate MDM4 gene amplification 
with increased protein levels using immunohistochemistry. We observed that MDM4 gene 
amplification co-occurs with p53 mutant-like expression in endometrial cancer, although, an 
inverse correlation was observed in breast cancer.143 MDM4 oncogenic functions independent 
of p53 have also been described.144 Future studies may confirm this p53 independent 
tumorigenesis in endometrial cancer, which will make MDM4 a potential targetable alteration.
Patients with high-risk endometrial cancer have an inferior prognosis due to their higher 
risk of distant spread. Recently, studies investigating the efficacy of combined adjuvant 
chemotherapy and radiotherapy compared to radiotherapy or chemotherapy alone in 
these patients (PORTEC-3, GOG-258) have completed accrual and results are awaited. The 
identification of molecular subgroups with distinct clinical outcomes among the broad group 
of high-risk endometrial cancers would improve patient selection based on their molecular 
and immunological risk factors and enable tailored treatment. First findings require validation 
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in a larger series of high-risk endometrial cancers before they can be introduced in clinical 
decision making.2,12,145 In addition, the identification of molecular alterations predicting 
chemotherapy response or resistance is mandatory to reduce unnecessary exposure to toxic 
chemotherapeutic agents. Patients receiving combined chemotherapy and radiotherapy in the 
PORTEC-3 trial had significant more severe adverse events and reduced health-related quality 
of life during and after treatment compared with radiotherapy alone.146 More importantly, the 
identification of actionable molecular alterations may lead to tailored targeted therapies (e.g. 
checkpoint inhibitors, or drugs targeting p53) for endometrial cancer patients with high-risk 
features.
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Endometrial cancer is a cancer that arises from the inner lining of the uterus and is the 5th 
most common cancer in women worldwide. The incidence is increasing due to ageing of 
the population, increased life expectancy, increasing rates of obesity, and decreasing rate 
of hysterectomy for benign causes. Postmenopausal vaginal bleeding is the most common 
symptom, which often leads to diagnosis of endometrial cancer at an early stage before it 
has spread outside the uterus. The standard treatment consists of abdominal or laparoscopic 
hysterectomy with bilateral salpingo-oophorectomy, in case of risk factors followed by tailored 
adjuvant therapy.
Over the last two decades, the management of endometrial cancer has improved by refining 
indications for adjuvant therapy and introducing adjuvant treatment modalities with fewer 
side effects. Adjuvant therapy of early-stage endometrial cancer is tailored to the patient’s risk 
of disease recurrence, generally based on three risk groups using clinicopathological factors 
such as age, stage, histological subtype, tumor grade, and lymphovascular space invasion. 
The PORTEC-1 and -2 (Post Operative Radiation Therapy for Endometrial Cancer) clinical 
trials have contributed evidence that adjuvant radiotherapy can be safely omitted in patients 
with low- and intermediate-risk features, and that endometrial cancer patients with high-
intermediate risk features can effectively be treated with vaginal brachytherapy. Recently, 
two randomized trials, evaluating the role of adjuvant chemotherapy in combination with 
external beam radiotherapy for high-risk endometrial cancer (PORTEC-3 and GOG258) have 
completed accrual and results are awaited. Surgery followed by adjuvant treatment based on 
risk factors provides effective curative treatment for the majority of patients with endometrial 
cancer, but, considerable over- and undertreatment remains and patients could benefit from 
refinement of more individual risk assessment and tailored therapy.
Traditionally, endometrial cancer was classified into two subtypes based on epidemiology, 
histopathology and clinical behavior by the dualistic model of Bokhman. The histologic 
subtypes and molecular alterations expanded the dualistic model at a later stage – type I, 
mainly endometrioid, low grade, hormone receptor positive, prognostically favorable 
endometrial cancers and type II mainly non-endometrioid, high grade, receptor negative, 
unfavorable cancers. The Cancer Genome Atlas studies provided a molecular classification of 
endometrial cancers and identified four molecular subtypes based on comprehensive genomic, 
transcriptomic and proteomic analysis. These four molecular subgroups; polymerase-epsilon 
(POLE) ultramutated, microsatellite instability hypermutated, copy-number low with 
frequent CTNNB1 mutations, and copy-number high with frequent TP53 mutations, were 
associated with distinct clinical outcomes. Subsequent studies have shown that L1CAM is 
also an emerging prognostic marker, which has been confirmed in The Cancer Genome Atlas 
cohort using RNA expression data. These recent advances in the molecular understanding of 
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endometrial cancer may strongly improve the clinicopathological risk assessment. Moreover, 
new effective targeted drugs may be developed for patients with high-risk features or recurrent 
disease.
This thesis focuses on molecular alterations and their prognostic significance in endometrial 
cancer, investigated mainly in early-stage endometrial cancers with (high)-intermediate risk 
features, to refine clinicopathological risk assessment and direct adjuvant therapy. Chapter 2 
provides evidence that molecular alterations such as CTNNB1 mutations and microsatellite 
instability can be successfully evaluated in pre-operative endometrial curettage specimens using 
DNA-based and immunohistochemical techniques. The paired curettage and hysterectomy 
specimens of 48 endometrial cancers showed that pre-operative curettage samples can 
reliably predict the molecular alterations of the endometrial cancers as found in the definitive 
hysterectomy specimens. These findings may impact future studies that determine molecular 
alterations on hysterectomy specimens, as the results can safely be translated to diagnostic 
tissue samples and thus be used in pre-surgical clinical decision making. The prognostic value 
of POLE exonuclease domain mutations is described in Chapter 3. The Cancer Genome Atlas 
studies were the first to show the association of POLE exonuclease domain mutations with 
a high mutation burden and favorable clinical outcome. We confirmed the frequency and 
favorable prognosis of POLE exonuclease domain mutations in 788 early-stage endometrial 
cancer tissues from patients enrolled in the PORTEC-1 and -2 clinical trials and in 681 
patients from three additional endometrial cancer series. Although the POLE subgroup is 
relatively small (5-10%), the strong association of POLE exonuclease domain mutations with 
grade 3 tumors, and the highly favorable prognostic outcome of this subgroup suggests that 
strategies to minimize therapy in these patients are worthy of investigation.
Several other molecular alterations, such as loss of hormone receptor expression, CTNNB1 
and FGFR2 mutations, have been previously reported as having prognostic potential in 
single biomarker studies. Chapter 4  reports on an integrated analysis of molecular and 
clinicopathological prognostic factors in the PORTEC-1 and -2 tissue samples resulting in 
a comprehensive overview of the prognostic potential of these factors. The clinical outcome 
of (high)-intermediate risk endometrial cancer patients was very heterogeneous, and our 
study showed that approximately 15% of these patients had unfavorable prognostic features 
(substantial lymphovascular space invasion, p53-mutant, and/or >10% L1CAM expression), 
35% had intermediate features (microsatellite instability or CTNNB1-mutant) and 50% had 
favorable features (POLE-mutant, CTNNB1-wildtype and remaining tumors). This integrated 
risk model combining molecular and clinicopathological risk factors clearly improved 
risk prognostication. Cases with unfavorable prognostic features may need more intensive 
treatment to improve their prognosis, while overtreatment and unnecessary exposure to 
potential toxic treatment might be avoided in cases with favorable prognostic features. 
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Summary
In Chapter 5, a series of 116 endometrial cancers with high-risk features was molecularly 
analyzed to explore whether high-risk endometrial cancers can also be classified in molecular 
prognostic subgroups. Our findings indicate that molecular analysis can discriminate high-
risk patients with a favorable (POLE-mutant, or microsatellite instability) and unfavorable 
(p53-mutant and remaining tumors with no specific molecular classifier) clinical outcome. 
Moreover, within the latter group of truly high-risk patients, targetable alterations were 
identified which may serve as targets for individualized treatment. The identified mutations 
in the PI3K-AKT pathway, mutations in FBXW7 and FGFR2 and hormone receptor 
positivity are potentially targetable with PI3K-AKT-mTOR inhibitors, HDAC inhibitors, 
FGFR inhibitors or hormonal therapies. To conclude, our findings emphasize that molecular 
classification does not replace but clearly improves the clinicopathological risk assessment by 
refining the prediction of tumor behavior and identifying targets for therapy.
DNA mismatch repair-deficiency, characteristic of one of the prognostic molecular subgroups, 
was detected by microsatellite instability testing in our studies, while others analyzed the 
protein expression of typically four mismatch repair proteins. Chapter 6 focuses on the 
optimal approach for mismatch repair-deficiency testing in endometrial cancer. Microsatellite 
instability analysis and mismatch repair protein expression analysis using a two- (PMS2 and 
MSH6) or four-antibody immunohistochemical approach were highly concordant, also in 
<3% of the cases with subclonal loss of mismatch repair protein expression. These findings, 
based on comprehensive analysis of 696 endometrial cancers, provide sufficient evidence that 
a two-antibody immunohistochemical approach is both practical and feasible for mismatch 
repair-deficiency testing in routine clinical pathology. The mismatch repair-deficiency affects 
microsatellites in genes causing frameshift mutations and functional inactivation of affected 
proteins, thereby promoting (driver mutation) or not promoting (passenger mutation) 
tumor survival. Chapter 7 describes the high frequency of JAK1 frameshift mutations in 
endometrial cancers with microsatellite instability and its possible mechanism contributing 
to tumorigenesis. JAK1 frameshift mutations were not associated with survival, but showed an 
association with impaired upregulation of LMP7 and HLA class I. This impaired upregulation 
may interfere with tumor lysis by cytotoxic T-cells, and therefore JAK1 frameshift mutations 
may facilitate immune escape.
Taken together, better understanding of the molecular profiles in endometrial cancer may 
greatly improve the clinical decision-making for endometrial cancer patients, reducing 
over- and undertreatment by integrating clinicopathological and molecular risk factors 
to direct adjuvant therapy. Chapter 8 describes current issues for clinical implementation, 
highlights remaining questions about the established molecular markers and discusses future 
perspectives. Th e clinical utility for tailoring adjuvant therapy and the feasibility of determining 
the molecular integrated profile within tight time limits needs to be prospectively established. 
In addition, better understanding of the molecular mechanisms is needed to improve 
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therapeutic outcome. For instance, POLE mutations may guide alternative management and 
surveillance choices for endometrial cancer patients; however, the mechanism(s) by which 
these mutations lead to the excellent prognosis of these patients is unknown. Endometrial 
cancers with microsatellite instability are associated with genome-wide DNA promoter 
hypermethylation, which makes epigenetic therapy an attractive approach for cancer 
treatment. However, the cause and relevance of epigenetics in endometrial cancer remains to 
be elucidated. L1CAM might be a target for antibody-therapy, but the mechanism underlying 
the expression of L1CAM are not clearly established. Finally, the performance of the molecular 
integrated risk assessment is considered to be a good model, but may be further refined to an 
excellent model. The identification of actionable molecular alterations may provide an even 




Baarmoederkanker, ofwel endometriumcarcinoom, is een kwaadaardig gezwel dat ontstaat 
in het slijmvlies dat de binnenkant van de baarmoeder bekleed. Het is wereldwijd de vijfde 
meest voorkomende kankersoort bij vrouwen. De incidentie van endometriumcarcinoom 
neemt toe als gevolg van de vergrijzing van de bevolking, verlengde levensverwachting, 
obesitas, en het minder vaak verwijderen van de baarmoeder bij goedaardige aandoeningen. 
Het meest voorkomende symptoom van endometriumcarcinoom is het optreden van 
postmenopauzaal vaginaal bloedverlies, waardoor de aandoening veelal in een vroeg 
stadium wordt ontdekt waarin de tumor beperkt is tot de baarmoeder. De eerst aangewezen 
behandeling van het endometriumcarcinoom is een operatie, waarbij de baarmoeder wordt 
verwijderd (hysterectomie) en doorgaans ook de eierstokken en eileiders, eventueel gevolgd 
door aanvullende behandeling afhankelijk van risicofactoren.
De afgelopen jaren hebben verbeteringen plaatsgevonden in de behandeling van 
endometriumcarcinoom, door betere mogelijkheden in het voorspellen van een recidief 
en door nieuwe behandelopties met minder bijwerkingen. De noodzaak tot aanvullende 
behandeling met inwendige of uitwendige radiotherapie bij patiënten met vroeg stadium 
endometriumcarcinoom is afhankelijk van de recidiefkans die bepaald wordt door een 
combinatie van de volgende klinische en pathologische risicofactoren: leeftijd, FIGO-stadium, 
histologisch type, differentiatiegraad, en aanwezigheid van tumorgroei in lymfevaten. Op 
basis van deze risicofactoren kunnen patiënten worden ingedeeld in drie risicogroepen. De 
PORTEC-1 en -2 (Post Operatieve RadioTherapie bij EndometriumCarcinoom) klinische 
studies toonden dat de patiënten met een laag en intermediair risicoprofiel geen aanvullende 
behandeling nodig hebben, en dat bij patiënten met een hoog-intermediair risicoprofiel 
maximale locoregionale controle met zo min mogelijk bijwerkingen wordt bereikt met een 
korte behandeling van 3 inwendige bestralingen, ook wel vaginale brachytherapie genoemd. In 
de recentelijk gesloten PORTEC-3 en GOG258 klinische trials, waarvan de resultaten worden 
afgewacht, is bij de meer zeldzame patiëntengroep met hoog-risico endometriumcarcinoom 
gekeken naar het effect van de combinatie van uitwendige radiotherapie met aanvullende 
chemotherapie, vergeleken met radiotherapie of chemotherapie alleen. 
Operatie met eventueel aanvullende radiotherapie en/of chemotherapie is in de meeste 
gevallen een curatieve behandeling, maar ondanks het gebruik van de klinische en 
pathologische risicobepaling is er nog altijd sprake van overbehandeling van patiënten met 
een goede prognose die geen extra behandeling nodig hebben, en onderbehandeling van 
patiënten waarvan de tumor een slechtere prognose heeft dan ogenschijnlijk lijkt. Een meer 
geïndividualiseerde risicobepaling kan patiënten gerichter behandelen.
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Van oudsher wordt endometriumcarcinoom onderverdeeld in twee type maligniteiten 
gebaseerd op klinische en pathologische kenmerken, zoals beschreven in het dualistische 
model van Bokhman. De histologische subtypes en moleculaire afwijkingen werden later ook 
ondergebracht in deze tweedeling – het type 1 carcinoom, endometrioid histologisch subtype, 
laaggradig, hormoon receptor-positief en met een gunstig klinisch beloop en het type 2 
carcinoom, non-endometrioid histologisch subtype, hooggradig, hormoon receptor-negatief 
en met een ongunstig klinisch beloop. Uitgebreid genomisch onderzoek van de “The Cancer 
Genome Atlas” studies heeft vier moleculaire subgroepen binnen het endometriumcarcinoom 
onderscheiden, waardoor de klassieke tweedeling verder wordt aangescherpt en opgedeeld. 
De vier moleculaire subgroepen; (1) polymerase epsilon (POLE)-gemuteerd met extreem 
veel mutaties, (2) microsatelliet instabiel met veel mutaties, (3) weinig copynumbervariaties 
(deletie of duplicatie van bepaalde stukken DNA op een chromosoom) en frequent CTNNB1 
mutaties, en (4) veel copynumbervariaties en frequent TP53 mutaties, presenteerden zich 
met ieder een eigen prognose. Andere onderzoeken toonden dat L1CAM expressie in het 
endometriumcarcinoom ook een belangrijke prognostische factor is. Deze bevinding werd 
gevalideerd in de “The Cancer Genome Atlas” studies met behulp van de L1CAM RNA 
expressie gegevens. De toegenomen kennis betreffende de moleculaire veranderingen in het 
endometriumcarcinoom draagt mogelijk bij aan een verbetering van de risico-inschatting van 
het biologisch gedrag van endometriumcarcinoom. Bovendien kan de nieuwe kennis worden 
gebruikt om doelgerichte, geïndividualiseerde therapieën te ontwikkelen voor patiënten met 
hoog risicofactoren of recidiverende ziekte.
Het onderzoek in dit proefschrift richt zich op moleculaire afwijkingen in voornamelijk 
patiënten met vroeg stadium endometriumcarcinoom en (hoog)-intermediaire risicofactoren, 
die het klinisch beloop met betrekking tot locoregionaal terugkeren of metastasering van de 
kankercellen en overleving van de patiënt kunnen voorspellen. Het doel is om de huidige 
risico-inschatting op basis van klinische en pathologische kenmerken en indicatiestelling voor 
aanvullende behandeling te verbeteren. In Hoofdstuk 2 wordt beschreven dat moleculaire 
afwijkingen, zoals CTNNB1 mutaties en microsatelliet instabiliteit, met behulp van DNA- 
en immunohistochemische technieken al in het preoperatieve curettageweefsel kan worden 
bepaald. De 48 gepaarde preoperatieve curettage- en hysterectomieweefsels toonden 
dat moleculair onderzoek in het preoperatieve weefsel betrouwbaar de afwijkingen kan 
voorspellen in het hysterectomieweefsel van het endometriumcarcinoom. Deze studie laat 
hiermee zien dat moleculaire afwijkingen in het hysterectomieweefsel direct vertaald kunnen 
worden naar preoperatief weefsel en kunnen helpen bij de besluitvorming van (aanvullende) 
behandeling. In Hoofdstuk 3 wordt de prognostische waarde van POLE proofreading domein 
mutaties beschreven, die door “The Cancer Genome Atlas” studies voor het eerst werden 
geassocieerd met extreem veel mutaties en een gunstige prognose. De frequentie van POLE 
proofreading domein mutaties en de relatie met een gunstig ziektebeloop werd bevestigd 
in 788 patiënten met vroeg stadium endometriumcarcinoom, die geparticipeerd hebben 
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in die PORTEC-1 en -2 klinische studies en in drie onafhankelijke cohorten van samen 
681 patiënten met endometriumcarcinoom. POLE proofreading domein mutaties komen 
frequenter voor in patiënten met hooggradig endometriumcarcinoom en voorspellen ook in 
deze patiënten een gunstig klinisch beloop. Deze bevinding suggereert dat patiënten met een 
POLE-gemuteerde endometriumcarcinoom in de huidige situatie overbehandeld worden en 
vervolgstudies nodig zijn om te onderzoeken of voor deze patiënten aanvullende behandeling 
met de daarmee gepaard gaande bijwerkingen weggelaten kan worden. 
Andere moleculaire afwijkingen zoals verlies van hormoon receptor expressie, CTNNB1 
en FGFR2 mutaties zijn ook eerder beschreven als prognostische factoren in studies, 
waarin maar naar één specifiek biologisch kenmerk (biomarker) is gekeken. Hoofdstuk 4 
beschrijft een geïntegreerde analyse van moleculaire afwijkingen, klinische en pathologische 
factoren die is uitgevoerd op endometrium-carcinoomweefsel van patiënten, die hebben 
geparticipeerd in de PORTEC-1 en -2 klinische studies. Het klinisch beloop van patiënten 
met endometriumcarcinoom en (hoog)-intermediaire risicofactoren was heterogeen; ~15% 
toonde ongunstige prognostische factoren (uitgebreide aanwezigheid van tumorgroei 
in lymfevaten, p53-mutante expressie, en/of >10% L1CAM expressie), 35% toonde een 
gemiddeld risico (microsatelliet instabiliteit of CTNNB1-gemuteerd), en 50% toonde gunstige 
factoren (POLE-gemuteerd, CTNNB1-wildtype en resterende tumoren zonder specifieke 
moleculaire classifier). Dit geïntegreerde model van moleculaire afwijkingen, klinische 
en pathologische factoren verbeterde sterk de risico-inschatting van het biologisch gedrag 
van het endometriumcarcinoom. Patiënten met endometriumcarcinoom en ongunstige 
prognostische factoren zouden mogelijk geïntensiveerde nabehandeling moeten krijgen 
om hun klinische uitkomst te verbeteren, terwijl overbehandeling en onnodige toxiciteit 
waarschijnlijk vermeden kunnen worden in patiënten met gunstige prognostische factoren. 
In Hoofdstuk 5 wordt de prognostische waarde van onder andere de vier moleculaire 
subgroepen beschreven in een meer zeldzame groep van 116 patiënten met 
endometriumcarcinoom en hoog risicofactoren. Een populatie van patiënten met hoog 
risicofactoren bleek ook onderverdeeld te kunnen worden aan de hand van moleculaire 
afwijkingen in een gunstig (POLE-gemuteerd of microsatelliet instabiel) en ongunstig (p53-
mutante expressie en resterende tumoren zonder specifieke moleculaire classifier) klinisch 
beloop. Bovendien werden bij de patiënten met een ongunstig klinisch beloop moleculaire 
afwijkingen gevonden, waarvoor in de toekomst doelgerichte therapie gegeven kan worden. 
De gevonden mutaties in de PI3K-AKT signaleringsroute, mutaties in FBXW7 en FGFR2, 
en de expressie van hormoon receptoren komen mogelijk in aanmerking voor doelgerichte 
therapie met PI3K-AKT-mTOR, HDAC of FGFR--remmers of hormonale therapie. Onze 
bevindingen benadrukken dat de moleculaire classificatie niet de huidige risicobepaling 
vervangt, maar dat juist de combinatie van klinisch-pathologische en moleculaire factoren de 
risico-inschatting van het biologisch gedrag van het endometriumcarcinoom sterk verbetert 
en factoren identificeert voor doelgerichte therapie.
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DNA mismatch repair deficiëntie, karakteristiek van één van de prognostische 
moleculaire subgroepen, werd in onze studies vastgesteld met behulp van de microsatelliet 
instabiliteitsanalyse, maar kan ook worden vastgesteld door immunohistochemische analyse 
van vier mismatch repair eiwitten. De optimale bepaling voor het vaststellen van mismatch 
repair deficiëntie is beschreven in Hoofdstuk 6. De uitkomsten van de microsatelliet 
instabiliteitsanalyse kwamen sterk overeen met de immunohistochemische analyse van zowel 
twee (PMS2 en MSH6) als alle vier de mismatch repair eiwitten. Dit was ook het geval in de 
<3% van de tumoren met verlies van mismatch repair eiwitexpressie in een deel van de tumor. 
Deze bevindingen, gebaseerd op een uitgebreide analyse van 696 baarmoedertumoren, tonen 
voldoende bewijs dat immunohistochemische kleuringen van ten minste de twee mismatch 
repair eiwitten PMS2 en MSH6 praktisch en haalbaar is voor het vaststellen van DNA mismatch 
repair deficiëntie in de dagelijkse pathologische diagnostiek. Een defect DNA mismatch 
repair systeem leidt tot frameshiftmutaties (insertie of deletie van nucleotiden) in repeterende 
sequenties, die in een coderende sequentie van een gen kan leiden tot een functioneel inactief 
eiwit. De frameshift mutaties kunnen worden onderscheiden in mutaties die de tumor een 
selectieve voorsprong geven (driver-mutaties), en mutaties die niet betrokken zijn bij het 
ontstaan van de tumor (passenger-mutaties). Hoofdstuk 7 beschrijft de frequentie en de 
mogelijke bijdrage aan tumorprogressie van frameshift mutaties in het JAK1 gen in patiënten 
met een microsatelliet instabiel endometriumcarcinoom. JAK1 frameshift mutaties hadden 
geen effect op de overleving, maar toonden wel een verband met verminderde opregulatie 
van LMP7 en HLA-klasse I. Deze deregulatie verstoord de celdoding van tumor cellen door 
cytotoxische T-cellen, waardoor de tumor mogelijk kan ontsnappen aan het immuunsysteem. 
Samenvattend kan de kennis over moleculaire veranderingen in het endometriumcarcinoom 
de klinische besluitvorming voor aanvullende behandeling verbeteren en hiermee over- en 
onderbehandeling verminderen. Hoofdstuk 8 beschrijft de huidige kwesties die van belang 
zijn voor klinische implementatie, de openstaande vragen betreffende de prognostische 
moleculaire afwijkingen en bespreekt de toekomstperspectieven. Allereerst moet de klinische 
toepasbaarheid van de moleculair geïntegreerde risico-inschatting voor aanvullende 
therapie worden gevalideerd in een prospectieve klinische studie, en moet de bepaling van 
het moleculaire profiel hiervoor in een kort tijdsbestek kunnen plaatsvinden. Verder is een 
beter begrip van de moleculaire mechanismen van de prognostische moleculaire afwijkingen 
nodig voor een betere therapeutische benadering. Bijvoorbeeld: de aanwezigheid van POLE 
mutaties kunnen een indicatie zijn voor het onthouden van aanvullende behandeling: het 
is echter onbekend via welke mechanismen POLE mutaties aanleiding geven tot een goede 
prognose. De associatie tussen microsatelliet instabiliteit en genoombrede toename van DNA 
methylering in promoter-regio’s van genen in het endometriumcarcinoom suggereert dat 
DNA methylering een aantrekkelijke kandidaat is voor epigenetische therapieën. De oorzaak 
en relevantie van de epigenetische veranderingen in het endometriumcarcinoom moeten 
echter nog worden onderzocht. L1CAM expressie is mogelijk een doelwit voor doelgerichte 
171
Nederlandse samenvatting
therapie, maar het mechanisme, dat leidt tot de expressie van L1CAM is nog niet geheel 
opgehelderd. Tenslotte: het moleculair geïntegreerde model heeft een goede voorspellende 
waarde voor het klinisch beloop bij een patiënt, maar er is nog ruimte voor verbetering naar 
een uitstekend model. Uiteindelijk zal de ontwikkeling van doelgerichte, geïndividualiseerde 
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